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Abstract 
α-Actinin-3 (ACTN3) is an actin binding protein that is specifically expressed at the Z-line in fast-
twitch muscle fibres. Homozygosity for a nonsense polymorphism (577XX) in ACTN3 occurs in ~16% of 
the global population resulting in complete deficiency of α-actinin-3. ACTN3 genotype significantly 
influences muscle performance in elite athletes and the general population; in both cases the α-actinin-
3 deficient (XX) genotype is detrimental to sprint and power performance but advantageous to 
endurance activity. These associations have been replicated in the Actn3 KO mouse which shows a shift 
towards a slow-twitch muscle phenotype including reduced fast fibre diameter, decreased force 
generation and increased recovery from fatigue. An alteration in metabolic profile appears to underlie 
this shift in contractile properties, as KO muscle shows a reduction in glycolysis and increased 
mitochondrial oxidation, characteristic properties of slow fibre types. 
Quantitative assessments of muscle function in human populations have shown a pattern of gene 
dosage, where the RX genotype lies in between RR and XX. We investigated this phenomenon, by 
analysing the phenotype of Actn3+/- mice in relation to both wild-type and Actn3 KO. Here we show that 
heterozygous mice show an intermediate phenotype in muscle mass, fast fibre size and endurance 
capacity. A 50% reduction in Actn3 transcript was seen in heterozygous muscle, which results in a 
reduction in α-actinin-3 expression. As a result, we show a dose-dependent remodelling of the 
sarcomere which underpins the altered contractile properties in heterozygous muscle. 
There is considerable inter-patient variability in Duchenne muscular dystrophy (DMD), some of 
which is caused by the modifying effects of genes independent of the causative mutation in dystrophin. 
Given that α-actinin-3 deficiency significantly affects muscle function in both elite athletes and the 
general population, we tested ACTN3 as a genetic modifier of DMD. Here we show that α-actinin-3 
deficiency significantly reduces muscle strength in both mdx mice and XX patients, providing strong 
evidence for ACTN3 as a genetic modifier of DMD. 
We also show that α-actinin-3 deficiency protects against stretch-induced damage and slows the 
accumulation of branched fibres in aged mdx muscle, suggesting an amelioration of disease progression. 
Slow muscle fibres are known to be relatively spared from the pathogenesis of DMD, and we 
demonstrate a shift towards a slow twitch muscle phenotype in Actn3 KO mdx muscle. In particular the 
shift towards aerobic metabolism, caused by increased activity of calcineurin and AMP-activated protein 
 vii 
 
kinase, protects α-actinin-3 deficient muscle against the progression of dystrophic pathology in mdx 
mice. 
Overall, this project demonstrates the tight regulation that exists between the highly homologous α-
actinin-2 and -3 isoforms and highlights the influence that sarcomeric protein composition has on 
muscle function. We show that ACTN3 genotype is associated with strength in DMD, and provide a 
convincing argument that this should be considered in the analysis of clinical trial outcomes. Finally, we 
suggest that the oxidative metabolic profile of slow fibres is the basis of their protection against the 
dystrophic pathology, highlighting this pathway as a promising avenue for therapeutic development.  
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 Chapter 1: Literature Review 
1.1 The Sarcomeric α-Actinins 
1.1.1 Introduction 
The α-actinins are a family of actin-binding proteins belonging to the spectrin protein superfamily, 
which includes the spectrins and dystrophin (Blanchard et al., 1989). α-Actinin isoforms have been 
identified and characterised in a number of taxa, including protists (Noegel et al., 1987), invertebrates 
(Fyrberg et al., 1990, Barstead et al., 1991), birds (Youssoufian et al., 1990) and mammals (Beggs et al., 
1992). 
Mammals possess four separate α-actinin-encoding genes (ACTN1 - ACTN4) which code for up to six 
different protein products, and these can be classified into two groups according to tissue expression, 
biochemistry and subcellular localization (MacArthur and North, 2004). α-Actinin-1 and -4 are non-
muscle, cytoskeletal, calcium sensitive proteins, whereas the α-actinin-2 and -3 isoforms are calcium 
insensitive and their expression is restricted to muscle sarcomeres. It is the sarcomeric α-actinins that 
are the focus of this manuscript. 
In skeletal muscle, sarcomeric α-actinins are the predominant protein component of the Z-line, 
where they form antiparallel dimers, which cross-link the actin thin filaments, forming a lattice structure 
to stabilise the muscle contractile apparatus (Squire, 1997). In addition to this structural role, the 
sarcomeric α-actinins interact with a number of different proteins to influence cellular signalling and 
metabolism. α-Actinin-2 is the principal isoform in cardiac and oxidative skeletal muscle fibres, whereas 
α-actinin-3 expression is restricted to fast glycolytic skeletal muscle fibres (Mills et al., 2001). The 
sarcomeric α-actinin isoforms are highly conserved - they share 90% protein similarity and have 80% 
identical gene sequences (Beggs et al., 1992). 
1.1.2 Domain Structure 
α-Actinin family members share a characteristic protein domain structure (Fig. 1.1). All α-actinins 
feature an N-terminal actin-binding domain (ABD), a central rod domain containing four spectrin-like 
repeats (SLRs) and a C-terminal region that contains two EF-hand calcium binding motifs (Baron et al., 
1987).  
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The ABDs are highly homologous across all α-actinin isoforms, which reflects both the high 
evolutionary conservation of actin (Sheterline et al., 1999) and the importance of actin-binding to α-
actinin function. The central rod domain shows a higher degree of evolutionary divergence. All 
vertebrate α-actinins feature four SLRs in the rod domain, the primary function of which appears to be 
protein-protein interactions, both for dimerisation and interactions with other structural and metabolic 
proteins (Djinovic-Carugo et al., 2002).  
The α-actinin C-terminal region, which contains two EF hand domains, is the best-characterised site 
of functional divergence between α-actinins. In cytoskeletal (non-muscle) isoforms the EF hand domains 
bind Ca2+, which regulates actin-binding kinetics (Tang et al., 2001). In contrast, the sarcomeric isoforms 
contain a five amino acid deletion and several substitutions which eliminate their ability to bind calcium 
(Noegel et al., 1987). Like the SLRs, the EF hand region of the α-actinins plays additional roles in 
interactions with various proteins, such as titin (Ohtsuka et al., 1997). 
 
Figure 1.1: Z-line localization and domain structure of sarcomeric α-actinins. A) The sarcomeric α-actinins localise 
to the sarcomeric Z line, where they cross-link actin thin filaments from adjacent sarcomeres. B) The sarcomeric α-
actinins contain an N-terminal actin-binding domain (ABD), four spectrin-like repeats (R1-R4) and a C-terminal EF-
hand region (EF), and form homo- and heterodimers in a head-to-tail fashion (MacArthur and North, 2004). 
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1.1.3 Protein Interactions 
The contractile properties of skeletal muscle are maintained through a complex array of protein-
protein interactions.  The skeletal muscle contractile apparatus (myofiber) is composed of sarcomeres 
(repeating units) which contain actin thin filaments and myosin thick filaments.  The Z-line is an electron 
dense band at the junction between adjacent sarcomeres, running perpendicular to the myofibrils which 
anchor the actin-containing thin filaments (Fig 1.1A). Stable anchorage of these actin thin filaments at 
the Z-line is required for the transmission of mechanical strain along the serially arranged sarcomeres, 
and ultimately along the length of the muscle. 
The sarcomeric α-actinins are the predominant protein present at the Z-line where they play an 
important role in maintaining the structural integrity of the sarcomere. In order to perform this function, 
α-actinins form head-to-tail dimers (Blanchard et al., 1989) through interactions between their spectrin-
like repeats (Flood et al., 1997), creating a molecule with an actin-binding domain at either end. These 
α-actinin-2 and -3 homo- and hetero-dimers crosslink overlapping actin thin filaments from adjacent 
sarcomeres, forming a lattice structure (Luther, 1991), which maintains the structural integrity of the 
contractile apparatus and allows transmission of force between sarcomeres and along the entire muscle 
fibre (Fig. 1.1B). 
In addition to their obvious role in actin-binding, sarcomeric α-actinins also interact with a vast array of 
proteins within the muscle fibre (Fig. 1.2). Muscle α-actinins have been shown to bind a number of 
structural proteins at the sarcomere, including the actin cross-linking protein myotilin (Salmikangas et 
al., 1999), the ‘sarcomeric ruler’ proteins titin (Ohtsuka et al., 1997) and nebulin (Nave et al., 1990) and 
the actin thin filament capping protein CapZ (Papa et al., 1999). Based on the complex network of 
interactions with the major sarcomeric scaffolding proteins, it is apparent that the sarcomeric α-actinins 
play an integral role in the structure of the contractile apparatus at the Z-line. 
 The sarcomeric α-actinins are also thought to have some structural function at the sarcolemma. 
Interactions have been demonstrated between α-actinin and dystrophin (Hance et al., 1999), which links 
the sarcomere to the dystrophin glycoprotein complex at the membrane and integrin (Otey, 1990) a 
transmembrane protein important in cell-to-cell adhesion. In this case sarcomeric α-actinins appear to 
be involved in linking sarcomeric structures to the muscle membrane. 
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Figure 1.2: Summary of α-actinin protein interactions. Protein-protein interactions reported in the literature, 
identified using either yeast two-hybrid analysis or co-immunoprecipitation, shown as black lines. Proteins are 
categorised by sub-cellular localisation as Z line (red), sarcomeric ruler proteins spanning the Z line (purple), thin 
filament (pink), intermediate filament (dark blue), sarcolemma (muscle membrane; green), extracellular matrix 
(brown) and soluble signalling proteins or metabolic enzymes (orange). See text for references. Figure created by 
DG MacArthur. 
The sarcomeric α-actinins also interact with a vast array of signalling proteins, including the PDZ-LIM 
domain-containing proteins ZASP (Zhou et al., 1999), hCLIM (Kotaka et al., 2000) and MLP (Mohapatra et 
al., 2003) which play a role in responding to physiological stimuli to maintain structural integrity of the 
muscle fibre(Arber et al., 1997, Zhou et al., 2001). Also significant is the direct interaction between the 
α-actinins and the calsarcins (Faulkner et al., 2000, Takada et al., 2001); the calsarcins regulate 
calcineurin activity, which is responsible for muscle remodelling (Olson and Williams, 2000) and fibre 
type switching (Chin et al., 1998). 
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Finally, the sarcomeric α-actinins interact with metabolic enzymes, including the glycogenolytic 
enzyme glycogen phosphorylase (Chowrashi et al., 2002) , and (as a ternary complex) the enzymes fruc-
tose-1,6-bisphosphatase and aldolase (Rakus et al., 2003). The functional significance of these inter-
actions is unclear. However, the binding of metabolic enzymes to cytoskeletal proteins is a common 
mechanism of enzyme regulation (Masters, 1984), and it is possible that the tethering of these enzymes 
at the sarcomeric Z line by α-actinin contributes to the local availability of metabolites for energy 
generation. 
Interestingly, the vast majority of these interactions are mediated by the SLRs that make up the rod 
domain of α-actinin, which is the where the majority of sequence differences occur between α-actinin-2 
and -3 (Virel and Backman, 2007). Taken together, these data suggest there are likely binding partners 
which have a higher affinity to α-actinin-2 than -3 and vice versa and these preferential interactions are 
likely to underpin the functional differences between the two isoforms (Lek et al., 2010). 
1.2 α-Actinin-3 Deficiency 
1.2.1 The R577X Polymorphism 
The ACTN3 gene is interesting in that it harbors a common null polymorphism. Discovered in 1999, a 
single nucleotide polymorphism (SNP) results in the typical arginine residue at position 577 being 
substituted with a premature stop (X) codon (North et al., 1999). This X allele codes for an unstable N-
terminal protein fragment which appears to be rapidly degraded (MacArthur and North, 2004). Hence, 
homozygosity for the X allele results in complete deficiency of α-actinin-3. The ACTN3 577XX genotype 
associated with α-actinin-3 deficiency occurs at varying frequencies in all ethnic groups; it is most 
common in Asians (~25%) and Caucasians (~18%) and much less frequent in African (<1%) populations. 
An estimated 1.5 billion healthy individuals worldwide are deficient in α-actinin-3 (North et al., 1999, 
Mills et al., 2001). 
With such a high frequency, it is apparent that the absence of α-actinin-3 is not detrimental to the 
normal development and function of skeletal muscle. This suggests that α-actinin-3 has some degree of 
functional redundancy, with the highly homologous isoform, α-actinin-2, the most likely protein to 
compensate for its absence (North et al., 1999, Mills et al., 2001). However, both the highly conserved 
nature of the ACTN3 sequence during evolution and the differences between α-actinin-2 and -3 in key 
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functional domains suggests that α-actinin-2 may not be able to completely compensate and hence 
there are likely some functional consequences of α-actinin-3 deficiency. 
1.2.2 ACTN3 Genotype and Athletic Performance 
It has long been suggested that athletes are born and not made (Bouchard and Malina, 1983); a 
recent genome-wide linkage analysis estimates the heritability of athlete status as 66% (De Moor et al., 
2007). Based on this data, it is apparent that athletic performance is genetically predetermined to a 
large extent, and supplemented by training and nutritional regimes (MacArthur and North, 2005). 
ACTN3 genotype has been shown to be associated with elite athletic performance, suggesting α-
actinin-3 has a significant functional role in skeletal muscle. Initially this association was demonstrated in 
a cohort of elite Australian athletes; in this cohort the XX genotype frequency was significantly reduced 
in elite sprint and power athletes when compared to controls, whereas endurance athletes showed a 
trend for over-representation of XX individuals  (Yang et al., 2003). This association has since been 
replicated in numerous athlete cohorts across the world including elite Finnish (Niemi and Majamaa, 
2005), American (Roth et al., 2007), Russian (Druzhevskaya et al., 2008), Greek (Papadimitriou et al., 
2008) and Israeli athletes (Eynon et al., 2009). In all of these studies ACTN3 genotype was strongly 
associated with sprint and power performance, while the association with endurance performance was 
less clear. From this data we can confidently say that α-actinin-3 deficiency is detrimental to sprint and 
power performance in elite athletes; to date no single Olympic sprinter has been found to have the XX 
genotype.  
1.2.3 Influence on Normal Muscle Function 
While the athlete association studies provide strong evidence that α-actinin-3 plays a significant role 
in muscle function, it should be noted that elite athletes represent the absolute extreme end of the 
muscle performance spectrum and hence tell us little about the role α-actinin-3 plays in day-to-day 
muscle function. As such, a number of studies have sought to examine the influence of ACTN3 genotype 
on muscle performance in non-athletes. 
A study in adolescent Greek subjects showed an association between ACTN3 genotype and 40m 
sprint time, with the R allele linked to faster times in an additive fashion (Moran et al., 2006). However, 
the same study found no association with other measures of power performance (grip strength, vertical 
leap) or with endurance capacity using VO2 max. α-Actinin-3 deficiency was also associated with reduced 
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elbow flexor (Clarkson et al., 2005) and knee extensor (Walsh et al., 2008) strength in adult women. 
Taken together, these data mirror the associations seen in athletes, where α-actinin-3 deficiency is 
detrimental to power performance. However, a further study demonstrated the opposite effect; 
increased power output in the quadriceps of XX women (Delmonico et al., 2007), which may suggest 
that the effects of α-actinin-3 deficiency are less evident in the general population than elite athletes. 
ACTN3 genotype also influences muscle mass and fibre type. The XX genotype is associated with lower 
thigh cross-sectional area (Zempo et al., 2010) and a reduction in fast, glycolytic type 2x muscle fibres 
(Vincent et al., 2007). mRNA analysis suggests that α-actinin-2 may be upregulated to compensate for 
the absence of α-actinin-3 in XX individuals (Norman et al., 2009) 
Interestingly, two separate studies showed an increase in strength gain following resistance training 
associated with the XX genotype (Clarkson et al., 2005, Delmonico et al., 2007), suggesting α-actinin-3 
deficiency improves the skeletal muscle response to training. This ‘training effect’ may explain the trend 
for the XX genotype being advantageous to endurance performance. 
Overall, the association seen in these studies is weaker than observed in the elite athlete cohorts 
presented in the previous section. This is likely a reflection of the relatively subtle effect of α-actinin-3 
deficiency on skeletal muscle – it’s absence does not cause disease, but appears to alter the properties 
of healthy muscle. Hence, the ACTN3 genotype effect is more evident in athletes which represent the 
extreme end of the muscle performance spectrum rather than in ‘healthy individuals’ a population 
which features significant variation in muscle properties. 
1.3 Actn3 Knock-Out Mouse 
Whilst the above human studies suggest an association between ACTN3 genotype and muscle 
performance, they shed very little light on the functional changes which occur in muscle as a result of α-
actinin-3 deficiency.  The major issue is the significant variation that exists in muscle characteristics 
between individuals due to genetic variance and environmental factors such as diet and exercise levels, 
making subtle differences in function very difficult to detect. 
In order to overcome these problems and accurately evaluate the effect of α-actinin-3 deficiency on 
muscle function, an Actn3 knockout (KO) mouse was developed in this laboratory (MacArthur et al., 
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2007). These mice are physically indistinguishable from their wild-type (WT) littermates, but carry a 
deletion of exons 2-7 in Actn3 and cannot produce α-actinin-3, mirroring XX humans. 
1.3.1 Baseline Phenotypes 
Initial studies show that KO mice have significantly increased endurance capacity, as they run 33% 
further before reaching exhaustion on a treadmill (MacArthur et al., 2007). These KO mice also 
demonstrate significantly reduced forelimb grip strength (MacArthur et al., 2008a), suggesting a 
reduction in force-producing capacity in KO muscle. This data agrees with the most prominent 
associations seen in human studies reviewed in the previous section, confirming the Actn3 KO mouse as 
an excellent model for α-actinin-3 deficiency seen in XX humans. 
Actn3 KO mice also display slightly reduced overall body mass, a product of a reduction in lean mass 
(MacArthur et al., 2008a). The isolated wet weight of a number of skeletal muscles are also reduced in 
KO mice, the lone exception being the soleus which does not express α-actinin-3, suggesting the 
observed reduction in lean mass is a result of alterations in skeletal muscle in response to α-actinin-3 
deficiency. A reduction in the diameter of fast, myosin heavy chain (MyHC) 2b expressing fibres was also 
observed in muscle from Actn3 KO mice (MacArthur et al., 2008a). These fibres would usually express α-
actinin-3, and their reduction in size underlies the reduction in mass of isolated muscles from these 
mice. 
1.3.2 Contractile Properties 
The extensor digitorum longus (EDL), a muscle from the lower hindlimb of the mouse, provides a 
great tool in dissecting the function of α-actinin-3. The EDL is comprised solely of ‘fast-twitch’ muscle 
fibres –responsible for rapid, powerful contractions, but are particularly susceptible to fatigue as they 
rely primarily on anaerobic metabolism.  In WT mice all EDL fibres express Actn3, compared to KO 
muscle where there is none. 
Isolated EDLs from KO mice demonstrate lower maximum specific force (force per cross-sectional 
area), but increased recovery from fatigue when compared to their WT littermates (Chan et al., 2008). 
Again this agrees with previous data from both human association studies and whole body mouse 
function experiments. Because the muscles in this preparation are devoid of any nervous or vascular 
input, these experiments demonstrate that the ‘detrimental to sprint, beneficial to endurance’ 
phenotype resulting from α-actinin-3 deficiency arises directly from skeletal muscle. 
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The isolated EDLs from Actn3 KO mice also showed longer relaxation times from the twitch evoked 
by a single action potential (MacArthur et al., 2008a). The relaxation process is dependent on the 
dissociation of Ca2+ from the contractile apparatus and being pumped back into its intracellular store, 
the sarcoplasmic reticulum (SR). The speed of this process is determined by the metabolic profile of the 
muscle fibre; fast muscle fibres rely on anaerobic metabolism to contract and relax quickly, but are 
susceptible to fatigue, whereas slow fibres contract and relax more slowly and are resistant to fatigue 
due to their reliance on aerobic metabolism. Isolated single fibres from KO mice pump Ca2+ more slowly 
back into the SR following contraction (Chan et al., 2011) , a finding which both explains the longer 
twitch relaxation times and suggests that α-actinin-3 deficiency directly alters the metabolic profile of 
individual fibres. 
1.3.3 Influence on Metabolism 
Initial analysis of Actn3 KO muscle showed appreciable increases in staining for both succinate 
dehydrogenase (SDH) and nicotinamide adenine dinucleotide tetrazolium reductase (NADH-TR) 
(MacArthur et al., 2007), enzymes which feature in oxidative metabolism. Interestingly, the difference 
was particularly evident in 2b fibres. In addition, protein expression of porin, a mitochondrial membrane 
protein, and cytochrome c oxidase (COX), a complex in the electron transport chain, was significantly 
increased in KO muscle (MacArthur et al., 2007). These findings suggest a shift towards oxidative 
metabolism in α-actinin-3 deficient muscle, consistent with the contractile properties discussed above. 
Profiling the metabolic enzyme activity in the whole quadriceps muscle from Actn3 WT and KO mice 
revealed a change in the fate of the key energy molecule pyruvate. KO muscle showed a decrease in 
lactate dehydrogenase (LDH), an important enzyme in anaerobic metabolism. Correspondingly, 
increases were observed in the activity of citrate synthase (CS), SDH and cytochrome c oxidase; enzymes 
involved in the oxidative metabolism of glucose (MacArthur et al., 2008a). Increases in fatty acid 
oxidation (BHAD and MCAD) enzymes were also seen in KO muscle, providing further evidence for a shift 
towards oxidative metabolism as a result of α-actinin-3 deficiency.  
No change was observed in mitochondrial DNA copy number (MacArthur et al., 2008a), which 
implies that these changes are not a result of mitochondria proliferation in KO muscle, just a shift in 
their metabolic properties. However, more recent research suggests that mitochondrial DNA copy 
number is a poor marker of mitochondrial content in skeletal muscle (Larsen et al., 2012), and that 
citrate synthase is a much better marker (which would suggest increased mitochondrial content in KO 
Chapter 1: Literature Review 
10 
 
muscle). Hence, while it is clear that α-actinin-3 deficiency causes an increase in oxidative 
phosphorylation, the precise mechanisms which underlie this change remain unclear. 
1.4 The Slow Myogenic Program 
The diversity of skeletal muscle was recognized as early as 1873 when Ranvier categorised muscles 
as ‘red’ with slow muscle contraction and ‘white’ muscles having fast contractile properties (Ranvier, 
1873). Fast-forward to the current day, and muscle fibres are largely classified according to the MyHC 
isoform they express, as it correlates to the myosin ATPase activity and speed of contraction. 
Table 1.1: Summary of mouse skeletal muscle fibre properties by fibre type 
MyHC Isoform Type 1 Type 2a Type 2x Type 2b 
Contractile Speed Slow-twitch Fast-twitch Fast-twitch Fast-twitch 
Metabolism Oxidative Oxidative Glycolytic Glycolytic 
FIbre CSA Small Medium Large Large 
 
The properties of skeletal muscle are determined by the proportions of fibres expressing individual 
MyHC isoforms. It is important to note that this system is plastic – activation of particular signalling 
pathways can induce a shift in fibre type according to the functional demands of the muscle. 
Transcriptional analysis of rat skeletal muscle reveals fibres can switch along a continuum, ie Type 1↔ 
2a ↔ 2x ↔ 2b, confirmed by the existence of transitional or hybrid fibres which express both of the 
neighboring MyHC isoforms as the fibre switches (DeNardi et al., 1993). 
1.4.1 Calcineurin 
The mechanisms which underlie fibre type transition are complex, and hence a complete list of the 
signalling factors involved is currently impossible to construct. However the calcium-sensitive, serine-
threonine phosphatase calcineurin has been identified as a key player in the induction of the slow 
myogenic program, promoting a shift towards slow fibre types. 
Calcineurin is an enzyme complex comprised of a calcineurin A (CnA) catalytic subunit, calcineurin B 
(CnB) regulatory subunit and the calcium-binding protein calmodulin (Schulz and Yutzey, 2004).  Widely 
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distributed through the body, calcineurin signalling has been implicated in T-lympocyte activation, 
vascular, neuronal and cardiac development and growth (Crabtree, 2001). 
In skeletal muscle, calcineurin responds to a sustained increase in intracellular Ca2+ from both 
extracellular entry and release from the sarcoplasmic reticulum (SR). The free Ca2+ binds to both the CnB 
regulatory subunit and calmodulin. Calcium bound calmodulin changes the conformation of the complex 
and allows for the catalytic activity of the CnA subunit. Activated calcineurin then dephosphorylates the 
nuclear factor of activated T-cells (NFAT) and myocyte enhancer factor-2 (MEF2), transcription factors 
which translocate to the nucleus to alter gene expression (Fig. 1.3). 
 
Figure 1.3: Calcineurin signalling pathway in skeletal muscle remodelling. Sustained elevation of intracellular 
calcium, from sarcoplasmic reticulum calcium store and from extracellular entry, leads to calcium binding to 
calmodulin (CaM) and CnB. The association of calcium-CaM with the CnA–CnB dimer displaces the CnA 
autoinhibitory domain from its catalytic site, forming an activated phosphatase complex. Activated calcineurin 
targets substrates, such as NFAT and MEF2 transcription factors, for dephosphorylation activation and mediates 
induction of the slow gene expression program (Mallinson et al., 2009).  
SR 
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1.4.2 Activation of the Slow Myogenic Program by Calcineurin 
The intracellular [Ca2+] of slow fibres oscillates between 100 – 300 nM (Chin and Allen, 1996), a 
concentration range known to activate calcineurin in T-cells (Dolmetsch et al., 1997). In comparison fast 
fibres have a low resting [Ca2+] of just 50nM, with transient high amplitudes during contraction 
(Westerblad and Allen, 1991), a profile that calcineurin is unresponsive to. 
The above data suggests that, based on findings in T lymphocytes, calcineurin is more likely to be 
activated by intracellular Ca2+ levels in slow fibres rather than fast. This hypothesis was confirmed by 
demonstrating that stimulation of cultured muscle cells with activity patterns mimicking slow fibre 
activity resulted in NFAT translocation to the nucleus, indicating calcineurin activation (Liu et al., 2001). 
Inhibiting calcineurin signalling by administering cyclosporine A (CsA) has the opposite effect, as CsA 
injection results in a significant increase in fast MyHC-expressing fibres in the soleus muscle of a rat 
(Chin et al., 1998). 
Transfection of adult skeletal muscle fibres with constitutively active NFAT results in the up 
regulation of the slow type 1 and the inhibition of type 2b MyHC isoforms (McCullagh et al., 2004). 
Similarly, mice deficient in calsarcin-2 (a negative regulator of calcineurin) show a switch towards slow-
twitch, oxidative skeletal muscle fibres (Frey et al., 2008). It is clear from these results that calcineurin 
activation favors a switch towards slow MyHC isoforms. Calcineurin is also able to induce expression of 
other genes known to be important in the characteristics of slow fibres, including myoglobin and 
troponin I (Chin et al., 1998).  
However the story is not that simple. While transgenic mice overexpressing a constitutively active 
CnA transgene show a substantial slow fibre type switch, the effect is only seen in a subset of muscles 
(Naya et al., 2000). The usually fast plantaris muscle contains about 6%  type 1 fibres with CnA 
overexpression (Talmadge et al., 2004), which is a similar proportion expressed in the developing 
neonatal muscle. It appears that calcineurin alone cannot induce large fibre type shifts, suggesting the 
involvement of other signalling factors. 
1.4.3 Other Players in the Slow Myogenic Program 
Whilst the properties of muscle fibres are typically defined according to the MyHC expression 
profile, there are a number of other characteristics which combine to give rise to the slow fibre 
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phenotype. Most obvious is the proliferation of mitochondria and a shift in metabolism towards 
oxidation. These processes are controlled independently of the contractile apparatus. 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a transcriptional 
regulator involved in energy metabolism, in particular controlling mitochondrial biogenesis (Wu et al., 
1999). In skeletal muscle, PGC-1α is enriched in type 1 fibres where it drives oxidative metabolism. 
Transgenic mice overexpressing PGC-1α show a comparable increase in slow fibres to that of CnA 
overexpressors, with up regulation of myoglobin and TnI (Lin et al., 2002). PGC-1α is thought to induce 
MEF2 in this process, suggesting it may share a similar signal transduction pathway to calcineurin in 
inducing a shift towards slow fibres. 
The calcium-calmodulin kinases (CaMKs) also play an apparent role in fibre type specification. 
CaMKII is highly enriched in the nuclei of skeletal muscle fibres and is activated by elevated intracellular 
Ca2+ in a similar fashion to calcineurin. In particular CaMKII is strongly upregulated following endurance 
training, with a corresponding increase in oxidative metabolism (Rose et al., 2007). Inhibition of CaMKII 
in cultured adult muscle fibres also results in a shift towards a faster MyHC expression profile (Mu et al., 
2007). Taken together, these data suggest that CaMKII is capable of upregulating slow gene expression 
and downregulates slow gene expression to mediate a fast-to-slow fibre type transition. 
As a key regulator of cellular energy homeostasis, AMP-activated protein kinase (AMPK) has some 
influence in determining the properties of skeletal muscle. AMPK signals for increased glucose transport 
(Fujii et al., 2006) and fatty acid oxidation (Lee et al., 2006) to maintain ATP levels during exercise. In 
doing so, AMPK shifts cellular metabolism towards that of a slow fibre, increasing muscular endurance.  
Mice deficient in AMPK show an impaired shift towards slow fibre types in response to exercise training, 
suggesting that AMPK plays a role in fast-to-slow fibre type conversion. Stimulation of AMPK signalling 
with the drug AICAR also induces mitochondrial biogenesis and oxidative metabolism in skeletal muscle, 
possibly via activation of PGC-1α (Winder et al., 2000). 
Muscle fibre type specification is a complex combination of contractile properties, sarcomeric 
protein isoform expression and cellular metabolism. Despite the plasticity of the system, it is clear that a 
single factor is unlikely to control fast-to-slow fibre type transition. The signalling molecules presented 
above all appear to control certain aspects of the transition process, and the cross-talk between their 
respective signalling pathways suggests they may act in concert to control fibre type conversion. 
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1.4.4 Actinin-3 Deficiency and the Slow Myogenic Program 
The above discussion of fast-to-slow fibre type conversion is important in the context of α-actinin-3 
deficiency as muscle from both XX individuals and Actn3 KO mice shows a shift towards ‘slow’ 
properties; reduced force producing capacity, increased recovery from fatigue and a shift towards 
oxidative metabolism (discussed in sections 1.2 and 1.3). In Actn3 KO mice, at baseline, these changes 
occur without a shift in fibre type, however a reduction in the size of 2b fibres is observed, such that 
these fibres become a similar size to their slower 2x or 2a counterparts (MacArthur et al., 2008a). 
The ‘slower’ properties suggest that the slow myogenic program may be more active in α-actinin-3 
deficient muscle. Indeed, Actn3 KO muscle has higher calcineurin activity than wild-type (WT) 
littermates and has a lower threshold for a fast-to-slow fibre type switch in response to exercise training 
(Seto et al., 2013). This is due to the fact that α-actinin-2 binds the calcineurin regulator calsarcin-2 more 
strongly than α-actinin-3. Hence in KO muscle where only Actn2 is expressed, a higher ratio of calsarcin-
2 is bound, resulting in a larger pool of free calcineurin and greater induction of the slow myogenic 
program of genes. 
1.5 Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is an X-linked, lethal childhood genetic muscular disease, 
characterized by progressive muscle weakness. Affecting 1 in 3500 male births (Emery, 1991), DMD is 
caused by mutations in the dystrophin gene, resulting in absence of dystrophin protein from the 
sarcolemma of muscle fibres (Hoffman et al., 1987). The onset of skeletal muscle weakness is typically 
observed between 3 to 6 years of age with symptoms being difficulty with running or climbing stairs, 
contractures and toe walking (Engel and Ozawa, 2004). Serum creatine kinase levels are significantly 
elevated in DMD patients and are used clinically in the diagnosis of DMD. The Gower’s sign (Fig. 1.3), 
where the patient uses their hands to ‘walk’ up their body when raising from a sitting position, indicates 
significant weakness of the hip and leg muscles is another clinical hallmark of DMD. 
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Figure 1.3: Illustrating the Gower’s maneuver. Original drawings from Gower WR: A Manual of Diseases of the 
Nervous System, Vol. 1, London, Churchill, 1886. Adapted from Engel & Ozawa (2004). 
DMD patients are typically wheelchair-bound by age 12. After loss of ambulation, weakening of the 
paraspinal muscles can cause scoliosis which may require corrective surgery. The respiratory muscles 
are also affected and respiratory failure is a common cause of mortality in patients in their late teens or 
early twenties (Emery, 1993). Improved standards of care, including the use of nocturnal ventilation 
devices, have increased the life-expectancy for DMD patients in the past decade (Eagle et al., 2002). 
However, DMD sufferers still rarely live past 30 years of age. 
Histologically, the skeletal muscle of DMD patients displays characteristic ‘dystrophic’ changes which 
reflect the progressive muscle decline associated with the disease. These changes include significant 
variation in muscle fibre size, fibre necrosis, centralisation of nuclei, inflammatory infiltrate and the 
proliferation of connective tissue leading to extensive fibrosis. 
1.6 Dystrophin 
1.6.1 The Dystrophin Gene 
Dystrophin is a 427-kDa cytoskeletal protein which is primarily expressed in skeletal and cardiac 
muscle, with lower expression levels also seen in the brain (Monaco et al., 1986). The identification of 
the DMD gene on the X chromosome was the first major triumph of positional cloning (Hoffman et al., 
1987). The gene is one of the largest discovered in humans, comprising 79 exons and covering ~2.5 Mb 
of genomic sequence at locus Xp21 (Monaco et al., 1992).  
The brain (B), muscle (M) and Purkinje (P) promoters drive the expression of the full-length 14 kb 
transcript which consists of a unique first exon spliced to a common set of 78 exons (Fig. 1.4). The 
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product of the M promoter is predominantly expressed in skeletal and cardiac muscle, with low levels 
observed in the glial cells of the brain. The B promoter drives expression in the cortical neurons of the 
hippocampus, while the P promoter is expressed in the cerebellar Purkinje cells. The gene also has 4 
internal promoters which control the expression of 4 short isoforms, which are expressed in skeletal 
muscle. Based on their molecular weight these short form dystrophins have been designated Dp71, 
Dp116, Dp140 and Dp260. These isoforms still contain the COOH-terminus and hence can presumably 
still interact with dystrophin’s numerous binding partners, however no cellular function has been 
elucidated for them to date. 
 
 
 
 
 
 
 
 
 
Figure 1.4:  A: Genomic organisation of the dystrophin gene, located in Xp21. The black vertical lines represent 
the 79 exons of the dystrophin gene distributed over about 2·5 million bases. The arrows indicate the various 
promoters: in particular are brain (B), muscle (M), and Purkinje (P) promoters. B: The domain composition of the 
various dystrophin proteins is indicated. The amino-terminal domain is followed by the spectrin like domain, the 
cysteine rich, and the carboxy-terminal domain (Muntoni et al., 2003). 
1.6.2 The Dystrophin Protein 
Like α-actinin, dystrophin is a member of the spectrin protein superfamily and hence features the N-
terminal actin binding domain and central rod domain characteristic of this protein family. The NH2 
terminus binds directly to, but does not cross-link cytoskeletal actin (Rybakova et al., 1996). The central 
Chapter 1: Literature Review 
17 
 
rod domain is composed of 24 spectrin-like repeats which are thought to give the protein a flexible 
structure similar to that of β-spectrin. These repeating units are interrupted by four proline-rich hinge 
regions which confer additional flexibility (Koenig and Kunkel, 1990). The WW domain immediately 
follows the 4th hinge and separates the rod domain from the cysteine-rich and COOH-terminal domains 
which are important for dystrophin’s vast array of protein-protein interactions. 
While the N-terminal binds actin, the C-terminus of dystrophin binds a network of plasma 
membrane structural proteins known as the dystrophin-associated protein complex (DAPC, Fig. 1.5).  
The DAPC includes the dystroglycans (α and β), sarcoglycans (α, β, γ and δ), sarcospan, α-dystrobrevin 
and syntrophin (Blake et al., 2002). Within the DAPC, α-dystroglycan interacts directly with laminin α2 of 
the basal lamina. Hence, via it’s interactions with actin (N-terminus) and the DAPC (C-terminus), 
dystrophin provides a link between the internal cytoskeleton of the muscle fibre to the extracellular 
matrix. Interestingly, mutations in the genes coding for other members of the DAPC can result in other 
forms of muscular dystrophy (Lapidos et al., 2004), highlighting the importance of the complex to 
muscle function. 
Figure 1.5: Dystrophin binds to the DAPC at the sarcolemma. The DAPC is composed of sarcoplasmic proteins (α-
dystrobrevin, syntrophins and nNOS) and transmembrane proteins (β-dystroglycan, the sarcoglycans, caveolin-3 
and sarcospan), many of which have been individually associated with alternate forms of muscular dystrophy 
(Davies and Nowak, 2006).  
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1.6.3 Mutations in the Dystrophin Gene 
The most common changes in dystrophin are intragenic deletions which account for approximately 
65% of all mutations (Muntoni et al., 2003). Deletions and, to a lesser extent, insertions can occur 
almost anywhere in the dystrophin coding sequence, however two hotspots of high deletion frequency 
are known; the most common is in the central part of the gene and includes exons 44 – 55 and the other 
occurs at the 5’ end, affecting exons 2 – 19. 
It is important to note that not all mutations in dystrophin cause DMD – in cases where a partially 
functional or truncated protein is transcribed the result is a much less severe dystrophy, referred to 
clinically as Becker muscular dystrophy (BMD). It appears that the central and distal parts of the rod 
domain are almost dispensable functionally, with mutation in these areas causing very minor 
phenotypes. As a general rule, mutations which disrupt the reading frame tend to result in non-sense 
mediated mRNA decay and DMD, while in-frame deletions result in a truncated protein being produced 
and a BMD phenotype. This phenomenon becomes important when we consider the prospect of gene 
therapies later in the chapter. 
1.7 Animal Models of Duchenne Muscular Dystrophy 
The discovery of dystrophin allowed the identification of other animals with mutations in their 
orthologous genes. Spontaneous changes in dystrophin have been observed in mice, cats and dogs while 
targeted disruption of the gene in nematodes (Bessou et al., 1998) and the zebra fish (Bassett et al., 
2003) has led to dystrophin deficiency in these animals. Because the structure and function of 
dystrophin is highly conserved, these animals develop a dystrophic phenotype with varying similarity to 
that of DMD patients. Hence, they provide functional models of DMD and allow investigation of the 
pathophysiological processes at work and initial screening of putative therapeutic interventions. 
1.7.1 The mdx Mouse Model 
The mdx mouse was initially identified from the raised serum creatine kinase levels and observable 
muscle pathology (Bulfield et al., 1984). The mouse lacks dystrophin (Hoffman et al., 1987) due to a 
spontaneous point mutation in exon 23 of the DMD gene, which results in a premature stop codon 
(Sicinski et al., 1989). The position of the point mutation means that mdx mice retain some of the COOH-
terminal isoforms of dystrophin, however deletion of these isoforms does not perceptibly alter the 
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phenotype (Cox et al., 1993), suggesting that full length dystrophin is the functionally significant isoform 
in skeletal muscle. 
Mdx mice do not suffer from a grossly reduced lifespan like DMD patients (Pastoret and Sebille, 
1995). As a result it has been argued that mdx mice are an inappropriate model for DMD. However, 
more careful analysis reveals significant muscle dysfunction in these mice. In particular mdx mice show 
marked hypertrophy and reduced normalised force and power output (Lynch et al., 2001). Muscle fibre 
necrosis is evident in the hindlimb at 3 – 4 weeks of age (Tanabe et al., 1986) and almost 100% of fibres 
express the neonatal MyHC isoform and display centralisation of myonuclei, both key indicators of 
muscle regeneration (Coulton et al., 1988). Interestingly, this extensive regeneration does not persist 
past 4 weeks as only 10% of fibres stain for neonatal MyHC at 10 weeks and less than 1% at one year of 
age (DiMario et al., 1991). 
Body weight and muscle mass of these mice declines rapidly after 12 months of age, with an 
appreciable difference in muscle fibre size, the accumulation of fibrosis and adipose tissue infiltration 
(Pastoret and Sebille, 1995) – all key indicators of the dystrophic process in DMD patient biopsies. 
Pragmatically, what this suggests is that the time of the analysis is key, depending on the intervention 
one wishes to evaluate. The initial phase of necrosis and regeneration at 4 weeks allows insights into the 
functional consequences of dystrophin deficiency – the primary driver of DMD pathology, whereas the 
aged mdx mouse seems to more closely model the progressive muscle wasting associated with the 
disease.  
As opposed to the limb muscles, the mdx diaphragm displays a pattern of degeneration, fibrosis and 
progressive weakness comparable to that of DMD limb muscle (Stedman et al., 1991). As such the 
diaphragm is a commonly used model in the evaluation of therapeutic interventions (Gehrig et al., 2012, 
Percival et al., 2012). However, unlike DMD patients, mdx mice do not display respiratory dysfunction 
despite the obvious diaphragm pathology. This highlights further that the mdx mouse, whilst not a 
perfect model, provides valuable insights into the pathogenesis of DMD and that care should always be 
taken in the extrapolation of mouse-model results to human patients.  
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1.7.2 Dystrophin-Deficient Dogs 
Spontaneous mutations leading to dystrophin-deficiency have been identified in a number of 
different dog breeds (Kornegay et al., 2012). The most commonly used clinically is the Golden Retriever 
model (GRMD) because it displays a severe dystrophic phenotype, resulting in premature death (Cooper 
et al., 1988). A single nucleotide change results in aberrant splicing of dystrophin in the GRMD, resulting 
in a shift in the reading frame and a severely truncated protein product (Sharp et al., 1992). The 
dystrophic phenotype is evident soon after birth as the pup has trouble feeding, but is obvious at 6 
weeks of age as the pelvic limbs are shifted forward and the angle of the tibiotarsal joint is significantly 
reduced (Fig. 1.6).  
 
Figure 1.6: Characteristic stance of the GRMD dog at 6 months of age. The pelvic limbs are shifted forwards and 
the angle of the tibiotarsal joint indicated in black is reduced to approximately 110° versus 140° in healthy animals 
(Kornegay et al., 2012). 
The GRMD model is used in the validation of putative therapeutic agents before they are tested in human 
clinical trials. However, there is marked variation in the dystrophic phenotype observed in the model, such that 
some dogs suffer extremely severe complications and die soon after birth, while others display a remarkably mild 
phenotype and little reduction in lifespan despite not producing any dystrophin (Ambrósio et al., 2008). This 
inter-individual variation makes it both time-consuming and expensive to conduct preclinical trials as large 
numbers of dogs need to be used. 
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1.7.3 Zebrafish Models 
Zebrafish have emerged as a popular model for human disease as they are relatively easy to 
generate and have strong similarity to the human genome (Woods et al., 2000). In 1996, a large-scale 
screen of mutant zebrafish families yielded a number which suffered motility impairment (Haffter et al., 
1996). From this screen, the sapje mutant was later identified as having a nonsense mutation in exon 4 
of the zebrafish dystrophin gene (Bassett et al., 2003). The sapje fish show progressive muscle 
degeneration in a similar fashion to DMD (Fig. 1.7). 
Figure 1.7: The dystophin-null Sapje zebrafish. Sapje mutant zebrafish show patchy muscle birefringence, an 
indication of muscle fibre damage and disorganisation. Birefringence is assayed by placing zebrafish between 2 
polarising filters rotated 90° to each other and measuring the light rotated by the muscle (Guyon et al., 2007). 
The sapje mutant has become an important model in drug discovery as the zebrafish are small and reproduce 
in large numbers, allowing for high throughput analysis of pharmaceutical compounds by simply adding them to 
the water. Traditionally compounds are screened in cell culture models, but this is a highly artificial in vitro 
environment which bears little direct resemblance to human biology in vivo. Many drugs have comparable effects 
in zebrafish and humans (Zon and Peterson, 2005), providing further evidence for the use of the sapje model as 
a screen for putative DMD therapeutic agents. 
However, the model is not perfect - because zebrafish are more distant evolutionarily from humans than 
mammalian DMD models, findings from fish experiments will still likely need to be replicated in mammals before 
being extrapolated to humans. 
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1.8 The Pathophysiology of DMD: Primary Mechanisms 
While the gene responsible for DMD and its protein product have been characterised for well over 
20 years, the primary molecular mechanisms responsible for DMD pathogenesis are still unclear. The 
mdx mouse has been used extensively as a tool to investigate the direct consequences of dystrophin 
deficiency and the hypotheses arising from these studies are presented below. 
1.8.1 Mechanical Hypothesis 
The absence of dystrophin results in reduced expression of its associated proteins and their de-
localisation from the plasma membrane (Ervasti and Campbell, 1991), where the primary function of the 
DAPC is thought to be maintaining the structural integrity of the sarcolemma and cell adhesion to the 
extracellular matrix. A key pathological phenotype is an increase in serum creatine kinase (CK) levels. 
Because CK is a cytosolic enzyme, its presence in the serum of DMD patients has long been interpreted 
as a reflection of membrane fragility such that the enzyme could leak out of the cell (Mokri and Engel, 
1998). The reverse is also true, as membrane-impermeable Evans blue dye (EBD) is able to enter the 
muscle fibres of mdx mice following systemic administration (Straub et al., 1997) or by incubation of 
isolated muscles in a physiological bath containing the dye . 
Dystrophin deficient muscle is particularly susceptible to stretch-induced damage after a series of 
lengthening (eccentric) contractions (Head et al., 1992, Moens et al., 1993, Petrof et al., 1993) or if mdx 
mice are run downhill on a treadmill (Whitehead et al., 2006b). Importantly, re-introduction of 
shortened dystrophin protein significantly ameliorates the phenotype (Deconinck et al., 1996), 
suggesting that dystrophin deficiency is directly responsible for the increased susceptibility to stretch-
induced damage in dystrophic muscle.  
The mechanism which underpins the force deficit following eccentric contraction in dystrophin 
deficient muscle is unclear. Because the absence of the DAPC from the sarcolemma results in membrane 
fragility, it has been proposed that stretching of the fibre may result in membrane tears and allow 
cytosolic enzymes like CK to leak out (Davies and Nowak, 2006). Exercising the mdx mouse increases the 
amount of serum EBD which is able to enter the muscle fibres (Whitehead et al., 2006b), suggesting that 
this theory has merit. In theory, the small membrane tears would cause and allow calcium influx, 
triggering proteolytic pathways and resulting in necrosis of the fibre. 
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1.8.2 The Calcium Hypothesis 
An elevation in intracellular calcium is observed in isolated fibres from mdx mice (Turner et al., 
1988). However when these fibres were stretched, a gradual influx of calcium occurred over a 60 minute 
time period (Yeung et al., 2005), rather than a rapid influx immediately following the contraction which 
would be expected if the ‘membrane tears’ hypothesis held true. Imaging the fibre reveals a global 
increase in intracellular calcium (Balnave et al., 1997) rather than near-membrane focal points which 
might be expected if the calcium entered via sarcolemmal tears, arguing against the existence of these 
tears. 
So, if the calcium does not enter via tears in the membrane, how does the intracellular calcium 
concentration rise following eccentric contraction in isolated mdx fibres? Blocking stretch-activated 
calcium channels with streptomycin prevents the rise in intracellular calcium following eccentric 
contraction (Whitehead et al., 2006a), suggesting this may be the mechanism of entry. However, while 
these channels can explain the calcium influx, they will not allow entry of large molecules like the Evans 
blue dye known to accumulate in dystrophic muscle fibres. 
Over expression of TRP calcium channels in mice significantly increases calcium influx and results in a 
phenotype similar to mdx, confirming the pathogenicity of deregulated calcium influx to skeletal muscle 
(Millay et al., 2009). A sustained increase in cytosolic calcium concentration will activate proteases, 
particularly calpains, resulting in destruction of the sarcomere and reduce the force production of the 
fibre. In addition, degradation of the DAPC and other membrane-associated proteins will likely 
destabilise the sarcolemma and, in combination with calcium-induced phospholipase activation, 
significantly increase the membrane permeability and allowing further calcium influx. Indeed, following 
eccentric contraction, the membrane permeability of mdx fibres does increase gradually over a two hour 
timeframe (Allen et al., 2005), which fits with calcium-induced activation of phospholipases and 
calpains. 
The increase in cytosolic calcium concentration will also have a negative effect on mitochondrial 
function, causing an increase in the production of reactive oxygen species (ROS) (Brookes et al., 2004). 
Consistent with this, mitochondrial oxidative phosphorylation is impaired in mdx muscle and this was 
postulated to be a result of mitochondrial calcium overload (Kuznetsov et al., 1998). ROS can reduce the 
calcium-sensitivity of the contractile apparatus and impair force production (Moopanar and Allen, 2005) 
Incubation with hydrogen peroxide, a common ROS, also causes an influx of intracellular calcium in 
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isolated mdx fibres via the stretch-activated channels (Gervásio et al., 2008) and this may be a further 
mechanism for calcium entry in dystrophic muscle following mitochondrial dysfunction. 
Taken together, the above data forms an elegant hypothesis explaining the mechanisms behind the 
susceptibility of dystrophin-deficient muscle to stretch-induced damage (Fig 1.8). However, the story is 
not quite this simple. Trials of the calcium channel blocker diltiazem have shown almost no clinical 
benefit in DMD patients (Bertorini et al., 1988, Pernice et al., 1988), suggesting that while calcium influx 
is an important pathological mechanism, it is  not the primary driver of pathogenesis in DMD.  
 
Figure 1.8: Possible intracellular pathways by which stretched contractions cause reduced force production and 
increased membrane permeability. Dashed box indicates hypothetical mechanisms which may be involved in 
activating channels for Ca
2+
 entry. Dashed arrow indicates positive feedback pathway that would occur when 
increased membrane permeability causes elevated [Ca2+]i. (Allen et al., 2005). 
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 1.8.3 Nitric Oxide and Local Ischemia 
Because necrotic fibres typically occurred in clusters in biopsies from DMD patients, early 
hypotheses proposed a role of the muscle vasculature in pathogenesis. However, early structural studies 
revealed no blood vessel abnormalities (Fidziaoska et al., 1987, Koeher, 1977). More recently, nitric 
oxide (NO) has been shown to have a role as a local vasodilator in skeletal muscle (Thomas et al., 1998), 
which has implications in the pathophysiology of DMD. 
NO is synthesised in skeletal muscle by neuronal nitric oxide synthase mu and beta (nNOSµ and 
nNOSβ), which are normally localised to the sarcolemma via association with the DAPC members, 
dystrobrevin and syntrophin. In the absence of dystrophin, the DAPC is significantly disrupted and an 
80% reduction is observed in nNOS mRNA and protein levels (Brenman et al., 1995, Chang et al., 1996). 
Importantly, transgenic overexpression of nNOSµ in mdx mice ameliorates the dystrophic phenotype 
(Wehling et al., 2001), suggesting it plays a role in the pathogenesis of DMD.  
In active muscle, disruption of contraction-coupled nNOSµ signalling impairs muscle perfusion, 
resulting in ischemic muscle damage and greatly exaggerated inactivity following mild exercise 
(Kobayashi et al., 2008). In dystrophin-deficient muscle, the influence of nNOS mislocalisation is twofold; 
the absence of nNOS from the sarcolemma causes local ischemia following contraction and exacerbates 
the contraction-induced damage phenotype, and the accumulation of cytosolic nNOSµ causes 
nitrosylation of the ryanodine receptor causing leakage of calcium from the sarcoplasmic reticulum back 
into the cytosol, further contributing to the raised intracellular calcium phenotype discussed in the 
previous section (Bellinger et al., 2009). 
Because of the nature of NO as a diffusible gas, it is not plausible for use as a therapeutic agent. 
However, a major function of nNOS-derived NO is the stimulation of cyclic guanosine monophosphate 
(cGMP) production, which can be mimicked pharmacologically via the use of phosphodiesterase 5 
inhibitors, like sildenafil (Viagra®). Treatment of mdx mice with sildenafil slows the accumulation of 
fibrosis and increases force production in the diaphragm (Percival et al., 2012). Sildenafil also reduced 
EBD accumulation in fibres, suggesting improved membrane integrity in these mice. However sildenafil 
did not improve fatigue resistance nor correct the mitochondrial defects observed as a result of 
increased intracellular calcium seen in mdx mice (Percival et al., 2013). Again, this work highlights that 
while NO signalling pathways play a role in the pathogenesis of DMD, they cannot be considered the 
primary mechanism at play. 
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1.9 The Pathophysiology of DMD: Secondary Mechanisms 
The hypotheses presented above all deal with the direct consequences of the absence of dystrophin 
and hence can be considered primary disease mechanisms. However, given the progressive muscle 
weakness associated with DMD, it is clear that secondary mechanisms exist to perpetuate the initial 
degenerative process, such that muscle damage accumulates over time. These secondary mechanisms 
may be of great importance in determining the severity of the disease, potentially providing 
symptomatic treatments as an adjunct to targeting primary mechanisms. 
1.9.1 Chronic Inflammation 
The infiltration of inflammatory cells is a significant histological feature in the biopsies of DMD 
patients, particularly as the disease progresses (Engel, 1986). Gene expression profiling from mdx mice 
reveals the coordinated up regulation of numerous components of a chronic inflammatory response 
(Porter et al., 2002). Consistent with this, muscle lesions in mdx mice are filled with invading cells from 
the immune system, including T cells (Spencer et al., 2001), macrophages (Wehling et al., 2001) and 
neutrophils (Radley et al., 2008). 
Interestingly, the expression of osteopontin (Spp1) is also upregulated in mdx muscle.  Spp1 released 
by invading immune cells promotes fibrosis in dystrophic muscle (Vetrone et al., 2009), providing a 
direct link between inflammation and the fibrotic changes that hinder muscle function and interfere 
with muscle regeneration. 
Because the chronic inflammation evident in dystrophic muscle appears to be directly tied to the 
progression of DMD, it has become a popular target for therapeutic intervention. A number of studies 
have shown that depletion of various subsets of immune cells including; CD8+ T cells (Spencer et al., 
1997), CD4+ T cells (Spencer et al., 2001), macrophages (Wehling et al., 2001), neutrophils (Hodgetts et 
al., 2006) and tumor necrosis factor alpha (Radley et al., 2008), in vivo can improve the pathogenic 
features of mdx mice. Immunosuppression via corticosteroids significantly ameliorates the dystrophic 
phenotype in mdx mice (Wehling-Henricks et al., 2004) and has become the ‘gold standard’ for the 
symptomatic treatment of DMD patients. While the dramatic effects in mdx mice have not directly 
translated to humans, prednisolone does delay disease progression in DMD patients, prolonging 
ambulation and preventing the development of scoliosis (Merlini et al., 2003, Yılmaz et al., 2004). 
However corticosteroid treatment cannot reverse the dystrophic phenotype; typically stabilisation is 
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observed for 2 years following treatment, followed by a decline which may be slower than untreated 
patients (Manzur et al., 2008). 
1.9.2 Muscle Regeneration 
Skeletal muscle harbors considerable regenerative capacity due to the presence of adult muscle 
stem cells, known as satellite cells, which play a major role in postnatal muscle growth and repair 
(Tedesco et al., 2010). In DMD, the greater propensity for myofibre damage means a constant need for 
regeneration. As such, satellite cell populations isolated from DMD patients show impaired replicative 
potential (Decary et al., 2000) and a limited ability to regenerate muscle tissue when transplanted 
(Mouly et al., 2005). This gradual depletion of the muscle regenerative capacity coincides with the 
accumulation of fibrosis, presumably as the extracellular matrix is expanded to support the improperly 
repaired myofibres. 
Satellite cell-based regeneration also explains the milder phenotype of the mdx mouse when 
compared with human patients (Partridge, 2013). Humans have relatively short telomeres of ~5-15 Kb, 
whereas in-bred strains of laboratory mice have telomeres which are typically >40 Kb (Kipling and 
Cooke, 1990). Hence, satellite cells in mice have significantly greater proliferative potential, giving mdx 
mice a longer window before their regenerative capacity is exhausted and progressive muscle damage 
ensues. Indeed, shortening the telomeres in satellite cells of mdx mice accelerates the dystrophic 
phenotype significantly, resulting in a progressive pathology which more closely models that of DMD 
patients (Sacco et al., 2010). 
1.9.3 Branched Fibre Accumulation 
In addition to being gradually depleted, the skeletal muscle regeneration process itself may also 
contribute to the progression of DMD. Malformed or “branched’ fibres are a feature of regenerating 
muscle following injury (Sadeh et al., 1985). Fibre branches appear to originate directly from myogenic 
precursor cells (Blaveri et al., 1999), suggesting the branching is most likely a result of imperfect fusion 
of satellite cells as they attempt to regenerate a damaged fibre. The association of fibre branching is 
further evidenced by the frequent occurrence of centrally located nuclei at branch points (Ontell et al., 
1982), a characteristic feature of regenerating muscle. 
Importantly, these fibre branches are found in muscle biopsies from DMD patients (Bell and Conen, 
1968, Schmalbruch, 1984) and in the muscles of mdx mice (Head et al., 1992). The fibre branches 
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accumulate as the pathology advances in the mdx mice; less than 20% of EDL fibres are branched in 
mice under 2 months old, but up to 90% of fibres contain a branch by the time the animal is 6 months 
old (Chan et al., 2007). In comparison, branched fibres are rarely observed in healthy, dystrophin-
positive control mice (Chan et al., 2007, Lovering et al., 2009). Isolated fibres will break at the branch 
point when submaximally activated, suggesting they are associated with mechanical weakening of the 
sarcolemma (Head, 2010). As a result, aged mdx muscles (containing ~90% branched fibres) are 
considerably more susceptible to stretch-induced damage than their adolescent counterparts (less than 
20%) (Chan and Head, 2011).  
While not a primary driver of pathology, these studies demonstrate the central role that the skeletal 
muscle regeneration process plays in the progression of DMD. The gradual depletion of satellite cells 
and their imperfect fusion with damaged fibres to produce branching combine in perpetuating the 
damage process in a cyclical fashion, where the muscle gets progressively weaker over time. 
 1.10 Gene Therapies: Replacing Dystrophin 
As illustrated in the section above, the pathological mechanisms responsible for the progressive 
muscle weakness associated with DMD are complex. To date, targeting these individual pathways has 
provided modest therapeutic benefit. The most obvious case for therapeutic intervention is the re-
introduction of full-length dystrophin to the muscle fibres to correct their susceptibility to damage and 
halt disease progression. This strategy is currently being developed using a number of different delivery 
methods as outlined below. 
1.10.1 Cell Therapies 
The theory behind the use of stem cells in the treatment of DMD is twofold; they could theoretically 
replace the depleted satellite cell pool and prolong muscle regeneration in patients and, because when 
myoblasts fuse with a muscle fibre their nucleus is incorporated in the fibre, healthy stem cell fusion 
would introduce a functional copy of the dystrophin gene to that fibre. 
From a clinical point of view, a candidate stem cell must possess a high rate of proliferation and 
remain capable of efficient myoblast conversion (Mendell et al., 1995). Other than isolated satellite 
cells, alternative adult multilineage progenitor cell populations retain myogenic potential, including 
muscle-derived stem cells (Sarig et al., 2006), mesangioblasts (Cossu and Bianco, 2003), mesenchymal 
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stem cells (Pittenger et al., 1999) and PW1 interstitial cells (Mitchell et al., 2010). Such cell populations 
have been trialled as potential DMD therapies (Meregalli et al., 2013), but the most significant issue 
hampering progress is the survival and subsequent migration of the cells from the site of injection to the 
compromised muscles of the body. Although promising results have been obtained, the prospect of cell-
based therapies for DMD will likely take a number of years before becoming a reality (Tedesco and 
Cossu, 2012). 
1.10.2 Viral Vector Therapies 
Direct replacement of dystrophin can also be achieved using adeno-associated virus (AAV) as a 
vector for gene delivery. AAV vectors are used as they are non-pathogenic in humans (Carter, 2004) and 
are capable of driving stable gene expression in muscle (Manno et al., 2003). The challenges associated 
with this technique have largely revolved around the large size of full-length dystrophin mRNA (14kB) 
compared to the limited capacity of the vector (4.7kB). 
In order to overcome this problem, truncated mini- or micro- genes have been developed based on 
observations of BMD, where large deletions in the rod domain produce relatively mild muscle 
phenotypes (England et al., 1990, Passos-Bueno et al., 1994). In comparison, the C-terminal domain is 
known to be essential to dystrophin function (Hoffman et al., 1991). A number of truncated dystrophin 
constructs have been tested in mdx mice, leading to the identification of a micro-dystrophin with a rod 
domain truncation which restored the force producing capacity of the transduced muscle to wild-type 
levels (Scott et al., 2002). Modification of this mini-gene to include the nNOS binding site in the rod 
domain improves the observed therapeutic effect, highlighting the importance of NO signalling to the 
pathogenesis of DMD. 
When administered systemically, AAV vectors are capable of widespread transduction of both 
skeletal and cardiac muscle, resulting in robust dystrophin expression which persists for at least 6 weeks 
following treatment (Gregorevic et al., 2004). This is a critical step, as any putative intervention must be 
capable of affecting the global musculature of a patient in order to have genuine therapeutic benefit. 
The AAV vector is capable of restoring dystrophin expression in canine DMD models (Wang et al., 2007), 
suggesting it has promise as a therapy, but the most recent clinical trial showed a failure to establish 
long-term expression in the biceps of human patients (Mendell et al., 2012). 
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1.10.3 Modifying Transcription or Translation of Dystrophin 
It may also be possible to restore the expression of functional dystrophin protein by modifying either 
the transcription or translation of the defective gene. Several different approaches have been 
investigated, depending on the nature of the pathogenic mutation carried by the patient.  
Nonsense mutations result in the creation of a premature stop codon in the gene, and as a result the 
transcribed mRNA is often targeted for nonsense mutation-mediated decay (Mendell and Dietz, 2001). 
During translation of the mRNA, the nonsense mutation causes the ribosome to prematurely release the 
protein, which is often non-functional and degraded. Read-through strategies involve using small 
molecules which invoke a conformational change in the mRNA, allowing the ribosome to insert an 
amino acid in place of the premature stop codon (Manuvakhova et al., 2000). One such molecule 
PTC124 (Ataluren®) was shown to induce full-length dystrophin expression in the mdx mouse (Welch et 
al., 2007), highlighting its potential application in DMD. However a phase II clinical trial of PTC124 was 
halted prematurely in 2010 as the drug did not cause a significant improvement in the 6 min walk test 
(PTC Therapeutics). 
As noted in the previous section, truncated forms of dystrophin result in BMD and a mild muscle 
phenotype. Hence, the specific exons carrying mutations could be skipped during translation to produce 
a truncated, but functional protein. Oligonucleotides targeted at splice sites around the mutation-
carrying exon 23 are capable of restoring dystrophin expression and ameliorating the phenotype of mdx 
mice (Lu et al., 2003, Mann et al., 2001). These results have been replicated in dystrophin-deficient dogs 
(Yokota et al., 2009a), but a recent phase II clinical trial showed only a modest increase in dystrophin 
expression in treated patients (Cirak et al., 2011).  
However, the applicability of these approaches is highly dependent on the mutation a patient 
carries; stop codon read-through is theoretically possible in only ~13% of patients (Dent et al., 2005) and 
while exon-skipping could be used in up to 50%, it would require the generation and testing of a 
comprehensive library of oligonucleotides to suit the various DMD mutations (Yokota et al., 2009b). 
Hence, while these strategies are promising, it is clear that alternative approaches must be explored if 
only to ‘fill in the gaps’ where either exon-skipping or stop codon read-through cannot be applied. 
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1.10.4 Gene Modifiers 
Genetic manipulation of the mdx mouse has revealed a number of genes, independent of 
dystrophin, which are capable of influencing the phenotype. These modifiers both offer insight into the 
molecular pathogenesis and present intriguing possibilities for therapeutic intervention. A summary of 
gene manipulation in mdx mice is presented in Table 1.2 and two specific modifiers with great relevance 
to this study, utrophin and calcineurin are discussed in detail in this section. 
Table 1.2 Summary of identified genetic modifiers in mdx mice 
Function Gene Mouse Data Reference 
Structural Utrophin Co-deletion exacerbates phenotype 
Overexpression ameliorates pathology 
(Deconinck et al., 1997b) 
(Tinsley et al., 1998) 
 Integrin α7 Co-deletion exacerbates phenotype 
Overexpression ameliorates pathology 
(Rooney et al., 2006) 
(Burkin et al., 2001a) 
 δ-sarcoglycan Co-deletion exacerbates phenotype (Li et al., 2009) 
Signalling Calcineurin Overexpression ameliorates pathology (Chakkalakal et al., 2004)  
(Stupka et al., 2008) 
 HSP71 Overexpression ameliorates pathology (Gehrig et al., 2012) 
 IGF-1 Muscle specific expression ameliorates 
pathology 
(Barton et al., 2002) 
 Myostatin Co-deletion ameliorates pathology 
Inhibition by transgenic follostatin 
overexpression ameliorates pathology 
(Wagner et al., 2002) 
(Nakatani et al., 2008) 
 nNOSµ Co-deletion increases muscle strength 
Overexpression ameliorates pathology 
(Li et al., 2011) 
(Wehling et al., 2001) 
 VEGF Overexpression ameliorates pathology (Messina et al., 2007) 
Inflammation Osteopontin Co-deletion reduces fibrosis and 
ameliorates functional defecits 
(Vetrone et al., 2009) 
 TNFα Co-deletion exacerbates phenotype (Spencer et al., 2000) 
1.10.3.1 Utrophin 
Utrophin is a ubiquitously expressed protein, which shares considerable homology to dystrophin. In 
healthy muscle, utrophin is expressed at the neuromuscular junction, where it plays an important role in 
the clustering of acetylcholine receptors (Campanelll et al., 1994). However in dystrophin deficient 
muscle, utrophin displays a sarcolemmal expression pattern similar to dystrophin in healthy muscle 
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(Khurana et al., 1991). Because utrophin has a high degree of similarity to dystrophin in the important 
functional domains (Tinsley et al., 1992) and is capable of interacting with members of the DAPC 
(Matsumura et al., 1992), it is possible that utrophin may be able to compensate for the loss of 
dystrophin. 
Consistent with this hypothesis, overexpression of utrophin in the mdx mouse significantly 
amelorates the dystrophic phenotype (Tinsley et al., 1996). Conversely, deletion of the Utrn gene in this 
model increases the muscle pathology significantly, reducing the lifespan to approximately 20 weeks 
(Deconinck et al., 1997b). From these studies it is apparent that utrophin is capable of significantly 
influencing dystrophic pathology in mdx mice, presumably via its ability to substitute for dystrophin and 
restore localisation of DAPC members to the sarcolemma. 
 In humans the influence of utrophin is less clear. UTRN expression is not altered in muscle biopsies 
taken from DMD patients compared to controls (Chen et al., 2000, Gramolini et al., 1999) and mRNA 
levels do not correlate with disease severity amongst patients (Kyriakides et al., 2011). However, 
utrophin protein expression is increased in DMD patient muscle and the expression level appears to 
correlate with the age at loss of ambulation (Kleopa et al., 2006). Overall, the low numbers of patients 
used in expression studies to date have made it difficult to determine the impact that utrophin 
expression is capable of exerting in DMD muscle. Nevertheless, a drug which transcriptionally 
upregulates utrophin expression has produced promising results in phase I clinical trials and may provide 
a potential therapy for DMD (Tinsley et al., 2011). 
1.10.3.2 Calcineurin 
As discussed in Section 1.4, calcineurin is a calcium sensitive phosphatase which regulates fast-to-
slow muscle fibre type conversion. Interestingly, fast fibres appear preferentially affected in DMD as 
extensive fast fibre degeneration and regeneration is observed before slow fibres show any signs of 
damage (Webster et al., 1988). It has been suggested that this may be purely a reflection of their smaller 
diameter and therefore reduced strain on the plasma membrane during contraction (Karpati et al., 
1988). However, because slow fibres differ from fast in both their metabolic profile and sarcomeric 
composition, it is possible that a number of factors unique to slow fibres contribute to their reduced 
susceptibility to damage. 
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Transgenically enhancing muscle calcineurin activity in mdx mice produces a shift towards a slow 
fibre type and significantly ameliorates the histological signs of the dystrophic pathology (Chakkalakal et 
al., 2004). Isolated muscles from CnA* mdx mice show reduced force production and an increased 
recovery from fatigue, which are characteristic properties of slow fibres and reflect the significant shift 
towards type 1 and type 2a fibres (Stupka et al., 2006). CnA* expression also reduces membrane 
permeablity and protects against stretch induced damage in the model, highlighting the functional 
benefits of a fast-to-slow fibre type conversion in dystrophic muscle. 
Unfortunately, the precise mechanisms behind the functional benefits are difficult to isolate. As 
mentioned previously, slow fibres are smaller in diamater and also express greater levels of utrophin 
(Gramolini et al., 2001), both of which could conceivably explain the reduced susceptibility to damage in 
CnA* mdx mice. Oxidative metabolism, a feature of slow fibres, is also impaired in dystrophic muscle 
(Even et al., 1994, Kuznetsov et al., 1998) and results in energy deficits. It is therefore possible that a 
shift towards the slow fibre phenotype boosts oxidative metabolism and ameliorates this deficit, 
producing a functional benefit. Consistent with this hypothesis, enhancing oxidative metabolism via the 
AMPK activator AICAR ameliorates the dystrophic phenotype in mdx mice (Jahnke et al., 2012, Ljubicic et 
al., 2011). 
Although the exact mechanism by which calcineurin overexpression ameliorates the dystrophic 
pathology is unclear, it does seem as though the intrinsic properties of slow fibres protect them from 
muscle damage and hence methods of inducing a fast-to-slow fibre type transformation have significant 
therapeutic potential. These lessons are being transferred to our care of human patients as it has been 
shown that regular low intensity exercise aimed at increasing muscle endurance capacity may benefit 
patients with DMD (Bushby et al., 2010a). 
1.11 Genetic Modifiers 
There is considerable inter-patient variability associated with disease onset and progression 
amongst DMD patients (Desguerre et al., 2009) and their response to corticosteroid therapies (Fenichel 
et al., 1991) This not only presents a significant challenge to clinicians in providing accurate counseling 
to patients and their families, but also threatens to mask the potential beneficial effects of novel 
therapies in clinical trials. To illustrate this issue, a recent trial of Ataluren (formerly PTC124) in DMD 
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patients was hampered by inter-patient variability and hence delivered inconclusive results (Pichavant 
et al., 2011). 
While environmental factors almost certainly play a role, it has long been hypothesised that genetic 
variation at loci independent from dystrophin (i.e. disease modifiers) underpin this unexplained 
variability in the progression of muscle weakness and response to therapies in patients with DMD. The 
concept of genetic modifiers is not without experimental precedent – as detailed in the section above, 
studies in the mdx mouse demonstrate that altered expression of a number of muscle genes is capable 
of significantly influencing the muscle pathology. It should be noted however, that these studies utilise 
extreme changes in gene expression; deletion or gross over-expression, which are likely to produce 
much greater effects than the relatively subtle genetic variations which exist between individuals. 
Perhaps stronger evidence for the existence of genetic modifiers is the observation that the genetic 
background significantly influences the pathology in mdx mice (Fukada et al., 2010), as the 
heterogeneity between mouse strains more closely reflects inter-patient genetic variation. 
1.11.1 SPP1 
The first disease modifying gene to be identified in humans with DMD, osteopontin (SPP1), was 
reported in early 2011 (Pegoraro et al., 2011). A single nucleotide polymorphism in SPP1, resulting in 
reduced expression, was associated with greater muscle weakness and earlier loss of ambulation in two 
separate cohorts. The mechanism for this association has not been explored, but osteopontin 
expression is known to affect muscle regeneration (Uaesoontrachoon et al., 2008), and is upregulated in 
DMD patients (Chen et al., 2000). Unfortunately, further analysis revealed that the SPP1 polymorphism 
had no appreciable effect on osteopontin mRNA or protein levels in DMD patients despite being 
associated with disease severity (Piva et al., 2012), which casts some doubt on the ability of SPP1 to act 
as a genetic modifier in DMD.  
Despite these issues, when segregating cohorts based on SPP1 genotype the number of patients 
required to detect a significant difference in a clinical trial setting is reduced by roughly 75% (number of 
subjects needed to achieve adequate power when all patients with DMD included n = 424; Number of 
subjects needed when only patients with the risk allele included n =106)(Pegoraro et al., 2011). So while 
we are unable to infer anything from the association of SPP1 and disease severity to the pathological 
mechanisms of DMD, it does provide proof of the importance of genetic modifiers in cohort 
stratification by genotype to increase the power of clinical trials. Overall the influence of SPP1 genotype 
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in DMD pathogenesis is unclear, but the studies to date do highlight the usefulness of understanding 
genetic modifiers to stratify cohorts and their potential to shed light on the molecular mechanisms 
behind disease pathology.  
1.11.2 LTBP4 
A second genetic modifier was identified recently, as a series of 4 SNPs in LTBP4 influenced the age 
at loss of ambulation in a cohort of DMD patients (Flanigan et al., 2013). The permutations associated 
with the SNPs give rise to a number of possible protein haplotypes in latent TGF-β binding protein 4 
which alter its regulation of transforming growth factor (TGF) β signalling. DMD muscle shows elevated 
TGF-β (Bernasconi et al., 1995), and inhibiting TGF-β signalling produces functional improvements in 
mdx mice (Nelson et al., 2011b). As a result, it is thought that LTBP4 may influence the progression of 
DMD via modulation of TGF-β, although this is yet to be demonstrated conclusively. 
Although there is still some degree of uncertainty regarding the genetic modification of DMD by 
both SPP1 and LTBP4, the studies presented above highlight the usefulness of genetic modifiers in both 
the stratification of clinical trials and improving the prediction of disease outcomes for patients. In time, 
the hope is that genetic modifiers will highlight the cellular pathways crucial to the pathogenesis of 
DMD, delivering novel therapeutic targets in the process. As such, the continued identification of these 
genes is crucial to the field of DMD research as we inch our way towards greater understanding and 
effective treatment. 
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1.12 Overall Project Aims 
ACTN3 genotype has a significant influence on muscle function in both elite athletes and the general 
population. Specifically, α-actinin-3 deficiency results in a shift in muscle properties towards what are 
classically considered slow fibre phenotypes; reduced strength and enhanced endurance performance. 
This shift in contractile properties is underpinned by alterations in the overall metabolic profile, as α-
actinin-3 deficient muscle displays enhanced aerobic metabolism - again a feature of slow fibres. 
α-Actinin-3 was initially thought to be primarily a structural protein due to its actin binding 
properties. Although the cross-linking of actin thin filaments at the Z-line is undoubtedly its most 
important function, α-actinin-3 has been demonstrated more recently to interact with a number of 
signalling and metabolic proteins, suggesting it plays a broader role in skeletal muscle than first thought. 
In particular, its interaction with calsarcin-2 results in increased calcineurin signalling in α-actinin-3 
deficient muscle, which is the basis of the observed shift towards slow fibre properties. 
Overall, this project aimed to further our understanding of ACTN3’s influence on muscle function, 
both at a molecular level in healthy muscle and in the context of muscle disease, where it had not been 
previously explored. We entered the project with 3 major hypotheses: 
1. That α-actinin-3 deficiency influences muscle function in a dose-dependent fashion. We 
have shown that differences in the binding properties of α-actinin-2 and α-actinin-3 are 
responsible for the phenotype observed in α-actinin-3 deficient muscle.  This implies that 
the ratio of these isoforms is important in determining muscle properties. To test this we 
have analysed the muscle structure and function of Actn3+/- mice. These results are 
presented in Chapter 3. 
 
2. That ACTN3 modifies muscle function in DMD. There is wide inter-patient variation in the 
clinical features of DMD, which may be explained to some degree by the presence of 
modifying genes. Because ACTN3 genotype significantly influences muscle function in both 
elite athletes and the general population, we hypothesise that it has a similar effect in DMD 
patients. As such, we analysed a cohort of DMD patients and generated an Actn3-/- mdx 
mouse model to determine the impact of α-actinin-3 deficiency on the dystrophic pathology. 
These results are presented in Chapter 4. 
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3. That α-actinin-3 deficiency ameliorates the progression of DMD. Slow fibres are known to be 
relatively spared from degeneration in DMD and induction of a fast-to-slow fibre type shift 
ameliorates the pathology of mdx mice. Because α-actinin-3 deficiency results in a shift 
towards slow muscle properties, we believe this may have a protective effect against the 
progression of DMD. This study is presented in Chapter 5. 
 
 
 
 
  
 
  
 Chapter 2: Methodology 
This chapter deals with the experimental protocols which are common to chapters 3, 4 and 5. 
Methods which are unique are detailed in the relevant chapter. 
2.1 Ethical Approvals 
Importation of mice was in accordance with the guidelines set out by our Institutional Biosafety 
Committee and the Office of the Gene Technology Regulator. All studies were approved by our local 
Animal Care and Ethics Committee. Mice had ad libitum access to food and water and were maintained 
on a 12h:12h light and dark cycle. 
2.2 Actn3 KO Mouse Colony 
The Actn3 KO mouse line was created in this laboratory with the insertion of a neo cassette in place 
of exons 2-7 in Actn3, which completely abolishes α-actinin-3 protein expression (MacArthur et al., 
2007). This original mouse model was created on the R129 genetic background. For the purposes of this 
project we required the Actn3 deletion to be transferred to the C57BL/10ScSnJ genetic background (The 
Jackson Laboratory, Bar Harbor, ME, USA). The breeding strategy implemented is detailed below. 
2.2.1 Backcrossing to C57Bl10 Genetic Background 
R129 Actn3-/- mice were crossed with C57BL/10ScSnJ to transfer the gene deletion, giving rise to the 
F1 generation. The F1 progeny, which are all heterozygous for the Actn3 deletion, are then backcrossed 
with the C57BL/10ScSnJ line to give the N2 generation. Animals heterozygous for the Actn3 deletion are 
selected from the N2 progeny (50% odds ratio) and crossed again with the C57BL/10ScSnJ line to give N3 
generation. This process is repeated until generation N10 is reached (Fig. 2.1); at this point the C57Bl/10 
Actn3-/- mice are 99.9% genetically identical to the C57BL/10ScSnJ strain and are considered fully 
congenic. This genetic homogeneity is important, as the C57BL/10ScSnJ line can now be used as WT 
controls for C57Bl/10 Actn3-/- mice. 
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Figure 2.1: Backcrossing the R129 Actn3 KO mouse line onto the C57Bl/10ScSnJ genetic background. R129 Actn3
-
/-
 mice were crossed with the C57Bl/10 strain, the progeny from this cross were again bred with C57Bl/10 mice. The 
generation and genetic similarity to the C57Bl/10 strain are displayed on the right. This process was repeated for 10 
generations to ensure homogeneity.   
2.2.2 Actn3 Genotyping 
Genomic DNA was extracted from earclips via an overnight digest at 55°C with proteinase K. 
Following this the DNA was precipitated with isopropanol and washed with ethanol before being re-
suspended in 10mM Tris buffer. This purified DNA was used for polymerase chain reaction (PCR) using 
the following primers:  
Forward :   GGGCCATTTCTCTTTTCTCC 
WT Reverse: CCACCATTCCCATAGGTCTC 
KO Reverse:  TAAAGCGCATGCTCCAGAC  
The PCR product was loaded onto a 2% agrose gel and separated by electrophoresis. The primers 
used produce a 381bp product for WT samples and a 309bp product for KO samples. Heterozygous 
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samples are identified by the presence of both bands. Known WT and KO samples and a no template 
control are included in each PCR to ensure a lack of contamination and accuracy of the resulting 
genotypes.  
2.3 Creation of Actn3 KO x mdx Mouse Model 
C57BL/10ScSn-Dmdmdx/J mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). 
These mice carry a C to T change at position 3185 within exon 23 of the Duchenne muscular dystrophy 
gene (Dmd) on the X chromosome, resulting in a premature stop codon and no expression of 
dystrophin. These mice, referred to as mdx, are the most commonly used animal model of DMD. For the 
entirety of this study, only male mdx mice are used as these bear the most direct relevance to DMD 
patients. 
The mdx mouse line is on the same genetic background as our recently generated C57/Bl10 Actn3 
KO mouse colony, hence these two can be crossed to produce Actn3 KO / mdx mice or mice lacking both 
α-actinin-3 and dystrophin. The breeding strategy employed to produce these double KO mice is 
detailed below (for the sake of simplicity, unused genotypes have been omitted).  
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Figure 2.2: Generation of Actn3-/- mdx mice. C57Bl/10 Actn3
-/-
 males were crossed with mdx females to produce 
female F1 mice heterozygous for both alleles. These F1 females were crossed with Actn3
-/-
 males to give Actn3
-/- 
mdx experimental animals. X
m
 denotes the mdx mutation contained on the X allele. 
The F1 intercross between these lines produces females which are heterozygous for both alleles (Fig. 
2.2). The F1 females are then mated with C57BL/10 Actn3 KO males to produce an F2 litter which 
includes Actn3-/- mdx XmY (KO mdx) mice at an expected frequency of 12.5%. Also included in the 
progeny are KO males which serve as controls for the experiments.  
Due to the number of mice required and the complexity of crossing two lines carrying gene 
deletions, mdx controls were generated from a separate cross. Rather than simply take mice from the 
C57BL/10ScSn-Dmdmdx/J colony and compare these to KO mdx mice during experiments, we bred 
females from the mdx colony with wild-type Actn3 C57BL/10 males (Fig. 2.3). This removes the 
possibility, albeit highly unlikely, that the KO mdx and mdx mice being compared experimentally are 
genetically distinct by being maintained in separate colonies. 
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Figure 2.3: Generation of mdx controls. mdx Females were crossed with WT males from the C57Bl/10 Actn3 colony 
to produce mdx males which are as close to littermate controls as possible for comparison with the Actn3
-/-
 mice 
detailed in Fig 2.2. 
We do recognise that this strategy is not perfect; ideally we would have liked to use heterozygous 
Actn3 / mdx breeding pairs, which would give us the 4 experimental genotypes (WT, KO, mdx and KO 
mdx) as littermates. However adopting this strategy was not possible; given the odds ratio of obtaining 
male mice with each of these genotypes is 1 in 16 we would require an excessive number of breeding 
pairs to generate experimental cohorts of animals which was deemed ethically unsuitable. 
2.3.1 Genotyping 
The genotyping process for the Actn3 / mdx colony is slightly more complex. Genomic DNA was 
extracted from earclips and screened for the Actn3 deletion as described above. Genotyping for the mdx 
mutation is more difficult however, as it is a single base change (C to T at position 3185). A method has 
been published using a primer set, where the last base of the reverse primer is the site of the point 
mutation (Bellinger et al., 2009). The authors reported that by mis-matching the primer to the base 
adjacent to the C to T change, they could create a mutant primer which would only bind to the mutant 
sequence and vice versa. Unfortunately, we found this technique to be unsuitable for genotyping our 
mice as, in our hands, the PCR did not produce clean enough bands for us to call genotypes with 
confidence. 
 
 
 
 
 
 
 
  Chapter 2: Methodology 
43 
 
TTGTTTAGATCTCTAAATTACATAAACTTTTATTTACCTTCTTCTTGATATGAATGAAAC 
                                                        >>>>          
TCATCAAATATGCGTGTTAGTGTAAATGAACTTCTATTTAATTTTGAGGCTCTGCAAAGT 
>>>>>>>>>>>>>>>>>>>>>> 
TCTTTGAAAGAGCAACAAAATGGCTTCAACTATCTGAGTGACACTGTGAAGGAGATGGCC  
               * 
AAGAAAGCACCTTCAGAAATATGCCAGAAATATCTGTCAGAATTTGAAGAGATTGAGGGG   
                                                                 
CACTGGAAGAAACTTTCCTCCCAGTTGGTGGAAAGCTGCCAAAAGCTAGAAGAACATATG   
                                                                 
AATAAACTTCGAAAATTTCAGGTAAGCCGAGGTTTGGCCTTTAAACTATATTTTTTCACA 
                <<<<<<<<<<<<<<<<<<<<                 
 
Figure 2.4: Illustration of primer binding in exon 23 of the dystrophin sequence. A 279bp fragment was amplified 
flanking the mdx point mutation and sequenced to determine the genotype.  
We settled on amplifying a 279bp fragment from exon 23 of the dystrophin gene which contained 
the mdx mutation using the following primers: 
Forward:  AACTCATCAAATATGCGTGTTAGTG 
Reverse: CAAACCTCGGCTTACCTGAA 
 Sanger sequencing was performed by the Australian Genome Research Facility and the base at 
position 3185 was analysed (C for WT, T for mdx) to determine the genotype. Genotypes were 
confirmed in experimental mice via testing for both α-actinin-3 and dystrophin protein expression by 
western blot. 
2.4 In Vivo Mouse Phenotyping 
2.4.1 Endurance Capacity 
The exercise capacity of the mice was tested using a modified version of a previously described 
protocol (Koch and Britton, 2001), using an AccuPacer mouse treadmill (AccuScan Instruments).   Mice 
were placed on the treadmill at a speed of 10m/min and an incline of 15°. A negative stimulus (electrical 
shock of 0.5mA) was placed at the rear of the treadmill, and the front of the treadmill housed a 
darkened box as positive reinforcement to encourage running. The speed of the treadmill was increased 
by 1m/min every 2min until the mice were exhausted (defined as the point where mice are unable to 
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extricate themselves from the negative stimulus without assistance inside 3s). The speed and time to 
exhaustion were recorded, and the total distance run calculated.  
2.4.2 Forelimb Grip Strength 
Mouse forelimbgrip strength was tested using a grip strength meter (Columbus Instruments). Mice 
were lifted by the base of the tail and allowed to grasp the trapeze with their front paws. Once the mice 
had established an overhand grip with both paws, they were pulled perpendicularly from the meter 
while keeping the body parallel to the floor.  The maximum force applied to the bar by the mouse was 
recorded in Newtons (N). Each mouse was trialed 15 times.  Occasionally the mouse failed to properly 
grasp the trapeze during the test, or relinquished its hold before any force was applied, resulting in 
readings which were inaccurate representations of the mouse’s grip strength. For this reason, the lowest 
reading was not included in the final analysis of the data. The highest reading was likewise excluded to 
control for operator error, since higher readings can be erroneously obtained if the experimenter does 
not pull the tail evenly and parallel to the ground. All operators were blinded to genotype during testing. 
2.5 Ex Vivo Muscle Physiology 
These studies were performed under the guidance of Dr Stewart Head in his laboratory at the 
University of New South Wales, with assistance from Dr Stephen Chan. 
2.5.1 Isolated Muscle Preparation 
The extensor digitorum longus (EDL) was carefully dissected from the lower hindlimb and tied by its 
tendons to a force transducer (Fort 10, World Precision Instruments) at one end, and a linear tissue 
puller (University of New South Wales) at the other using silk suture (Deknatel 6.0). The isolated muscle 
was placed in a bath continuously perfused with Krebs solution, composed of (in mM) 4.75 KCl, 118 
NaCl, 1.18 KH2PO4, 1.18 MgSO4, 24.8 NaHCO3, 2.5 CaCl2 and 10 glucose with 0.1% fetal calf serum, and 
was continuously bubbled with carbogen (95%O2, 5%CO2) to maintain pH at 7.4. 
  Chapter 2: Methodology 
45 
 
 
Figure 2.5: Top-down schematic representation of the ex vivo muscle physiology set-up. Isolated EDLs were tied 
by their tendons between a length controller and a force transducer and placed in a bath of Krebs buffer. Platinum 
electrodes were used to stimulate the muscle to contract, and the resulting force was measured.   
The muscle was stimulated by delivering a supramaximal current between two parallel electrodes in 
the bath using an electrical pulse generator (A-M Systems). The optimal length (LO) was determined as 
the muscle length at which maximum twitch force was generated prior to experimentation and set as 
the baseline. 
2.5.2 Force Frequency Curve 
A force frequency curve was obtained by delivering 500ms stimuli of different frequencies (2, 15, 25, 
25, 37.5, 50, 75, 100, 125 and 150 Hz) and measuring the force produced during each stimulation. A 30s 
rest was allowed between each to mitigate the effects of fatigue. A curve relating to the muscle force 
and stimulation frequency was fitted to the data with the following equation: 
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The values of r2 for the fitting procedure were never lower than 99.3%. From the fitted parameters 
of the curve, the following contractile properties were obtained: maximum force (Pmax), half-frequency 
(Kf), Hill coefficient (h) and twitch-to-tetanus ratio (Pmin/Pmax).  
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2.5.3 Twitch Kinetics 
The muscle was stimulated with a supramaximal pulse of 1-ms duration, and the resulting twitch 
was recorded. The twitch data were smoothed by averaging the raw data over 2.5-ms intervals, and 
from the resulting smoothed data the time to reach peak force and half-relaxation time (time taken to 
relax to half of peak twitch force) was obtained. 
2.5.4 Eccentric Contraction 
Following generation of the force frequency curve, the muscle was subjected to a series of 
lengthening (eccentric) contractions. The muscle was stimulated for 5s at 100Hz, and at t=250ms when 
the maximum isometric force was reached, was stretched to different parameters depending on the age 
of the mice being tested. Muscles from 8 week old mice were stretched to 20% longer than LO at a 
constant speed of 5mm/s, while those from 11 month old mice were stretched to 15% longer than LO at 
2mm/s. The muscle was then held at the extended length for 2s before being returned to LO. 
This process was repeated a series of times (6 times in 8 week muscle, 3 times in 11 month muscle), 
and the muscle was allowed to recover for 10min before a second force frequency curve was generated. 
The Pmax following the eccentric contractions was obtained from this and subtracted from the original 
Pmax to give the raw force deficit. Finally, the raw force deficit was expressed as a percentage of the pre-
stretch Pmax for analysis. 
2.5.5 Fatigue Recovery 
A separate set of muscles were used to analyse the recovery from fatigue. Following generation of a 
force frequency curve, muscles were subjected to the following fatigue protocol; repeated 1s tetani at 
100Hz every 2s for a period of 30s. To track the recovery, the force produced by short (250ms) 100Hz 
tetani was recorded at 30s, 1, 2, 3, 5 and 10min post fatigue.  
The force produced during each of the 100Hz tetani during the fatigue protocol and subsequent 
recovery was recorded and expressed as a percentage of the pre-fatigue force. 
2.5.6 Mass and Cross-Sectional Area 
At the end of the whole muscle experiment, the muscle was removed from the bath. The tendons 
were trimmed, and the muscle was lightly blotted on filter paper and weighed. An estimate of the cross-
sectional area was obtained by dividing the muscle's mass by the product of its Lo and the density of 
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mammalian muscle (1.06 mg/mm3). This estimate is subsequently used for the calculation of specific 
forces (force per cross-sectional area) to remove the individual effects of muscle size in the analysis. 
2.6 In Vitro Analyses 
2.6.1 Tissue Collection 
Mice were euthanized via cervical dislocation. The skin was removed from the hindlimb and 
individual muscles were dissected out, with overlying fascia and adipose tissue discarded. The wet 
weight of the isolated muscles was recorded immediately upon excision to minimise the effect of 
evaporation on measurement. Following this, the individual muscles were covered in a cryo-
preservation medium (TissueTek) and frozen in liquid nitrogen-cooled isopentane. Tissue was stored at -
80° until use. 
2.6.2 Myosin Heavy Chain Immunohistochemistry 
Transverse 8um sections were cut from the midpoint of the quadriceps muscle. These sections were 
blocked with 2% BSA for 10 min before being incubated overnight at 4°C with an antibody against 
myosin heavy chain 2B (BF-F3, 1:10 dilution) and Alexa488-conjugated wheat germ agglutinin (Life 
Technologies). Following primary incubation sections were washed three times with PBS and re-blocked 
with 2% BSA for 10 min.  
Secondary antibodies, Alexa555 goat anti-mouse IgM (Molecular Probes) and Alexa 488 goat anti-
rabbit IgG (Molecular Probes) were then applied for 2 hours at room temperature. Sections were 
washed three times in PBS and blocked with AffiniPure fab fragment goat anti-mouse IgG (Jackson 
ImmunoResearch) for 1 hour. Immediately following this, sections were incubated with antibodies 
against slow myosin (Millipore, diluted 1:100) and myosin heavy chain 2A (BF-F3, neat) covalently 
labelled with Alexa 488 and Alexa 350 respectively, with a Zenon labelling kit (Invitrogen) for 2hrs at 
room temperature. Finally sections were washed three times in PBS to remove any unbound antibody, 
fixed with 4% paraformaldehyde for 10 min and coverslips were mounted. 
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2.6.3 Fibre Size Analysis 
The labeled sections from above were imaged at 4x using ProgRes camera and software (SciTech). 
Corresponding sections from the red (555nm), green (488) and blue (350) channels were merged to give 
a composite image and sequential images were stitched together using Photoshop CS2 software (Adobe 
Inc.) to give a single image of the entire quadriceps muscle in cross-section. The fibre diameter and 
number was analysed using MetaMorph software (Molecular Devices) according to protocols previously 
developed in this laboratory (Garton et al., 2010). 
2.6.4 Protein Expression 
The snap frozen quadriceps from each of the mice were ground using a liquid nitrogen-cooled 
mortar and pestle. Approximately 2 mg of the ground tissue was solubilised in 500 µl 4% SDS buffer 
containing 50mM Tris, 10% glycerol, 50mM DTT, bromophenol blue and protease inhibitor cocktail 
(Sigma Aldridge). The concentration of total protein in each sample was assessed using a BCA protein 
assay kit (Thermo Fisher). 
20 µg of this protein lysate was loaded onto 4-12% Bis-Tris precast minigels (Life Technologies), 
separated by SDS-PAGE and transferred onto to polyvinylidene fluoride membranes (Millipore). The 
membranes were incubated with relevant primary antibodies (Table 2.1), including anti-α sarcomeric 
actin (5C5) as a loading control. Corresponding secondary antibodies conjugated to horseradish 
peroxidase were added and the membranes were developed using ECL chemiluminescent reagents 
(Amersham Biosciences). After developing, the PVDF membranes were stained with Coomassie 
BlueBrilliant (Sigma-Aldrich), and the expression of myosin was used as an additional loading control. 
Films were scanned using an Epson scanner, and the optical density of bands was computed using 
ImageJ software (NIH) and expressed relative to α sarcomeric actin for analysis. 
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Table 2.1: Primary antibodies used for western blot analysis. 
Antigen Antibody Manufacturer Working Dilution 
α-Sarcomeric Actin 5C5 Sigma-Aldridge 1:2000 
α-Actinin-2 4B3 Gift from Dr Alan Beggs 1:50,000 
α-Actinin-3 5A2 Gift from Dr Alan Beggs 1:1500 
AMPKα AMPK Cell Signalling 1:1000 
Cytochrome c Oxidase COX IV Molecular Probes 1:1000 
Desmin NCL-DES-DERII Novocastra 1:1500 
Dystrophin NCL-DYS1 Novocastra 1:200 
Myotilin NCL-MYOT Novocastra 1:2000 
Porin VDAC1 Abcam 1:1000 
RCAN 1.4 DSCR1 Sigma-Aldridge 1:1000 
Utrophin NCL-DRP2 Novocastra 1:60 
 
2.7 Statistics 
All comparisons reported in this study involved small sample sizes to which standard tests for 
normality could not be applied. As such, all pair-wise were performed using the non-parametric Mann-
Whitney U test and considered significant at P <0.05 (*P<0.05, **P<0.01, ***P<0.001). Statistics were 
performed using Prism 6 (GraphPad Software). All histograms show mean values, with error bars 
indicating standard error of the mean (SEM) unless otherwise stated. 
 
 
 
 
 
 
 Chapter 3: α-Actinin-3 Dosage: Implications 
of the Heterozygous Genotype 
3.1 Introduction 
In skeletal muscle, the sarcomeric α-actinins are a major component of the Z-line where they bind 
and crosslink the actin thin filaments. α-Actinin-2 is expressed in all muscle fibres, but the highly 
homologous α-actinin-3 isoform is expressed only in fast, glycolytic fibre types. Importantly, a common 
null polymorphism (R577X) occurs in the gene coding for α-actinin-3 (ACTN3) resulting in its complete 
absence in homozygous individuals (North et al., 1999). α-Actinin-3 deficiency is detrimental to sprint 
and power performance in both elite athletes (Eynon et al., 2013, Yang et al., 2003) and the general 
population (Clarkson et al., 2005, Moran et al., 2006, Walsh et al., 2008). Conversely, α-actinin-3 
deficiency appears to be associated with enhanced  endurance performance (Eynon et al., 2009, Yang et 
al., 2003) and improved response to resistance training (Clarkson et al., 2005).  Actn3 KO mice mimic the 
phenotype seen in α-actinin-3 deficient humans; Actn3 KO mice display reduced muscle mass and 
strength (MacArthur et al., 2008a), but display increased endurance capacity, improved recovery from 
fatigue (MacArthur et al., 2007) and enhanced response to training (Seto et al, JCI).  
Actn3 KO mice do not exhibit a change in fibre type distribution at baseline, but the fast 2B fibres, 
which would usually express α-actinin-3, display a shift towards the properties classically associated with 
slower fibre types including reduction in fibre diameter (MacArthur et al., 2008a), an increase in 
oxidative metabolism (MacArthur et al., 2007, MacArthur et al., 2008a, Quinlan et al., 2010), slowed 
relaxation from contraction (Chan et al., 2011) and an increased recovery from fatigue (Chan et al., 
2008).  
In Actn3 KO mice, α-actinin-2 is upregulated to compensate for the loss of α-actinin-3 (MacArthur et 
al., 2007). However, the loss of α-actinin-3 and up-regulation of α-actinin-2 does not change the total 
pool of sarcomeric α-actinin (Seto et al., 2011), suggesting that the phenotype in α-actinin-3 deficient 
muscle may result from differences in function and/or protein interactions between α-actinin-2 and α-
actinin-3.  For example, the Z-line associated proteins, ZASP, titin and vinculin preferentially bind to α-
actinin-2 over α-actinin-3 (Seto et al., 2013).. In addition, α-actinin-2 has increased  binding affinity for 
calsarcin-2, a negative regulator of calcineurin activity (Seto et al., 2013).In the absence of α-actinin-3, 
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up regulation of α-actinin-2 result in increased binding of calsarcin-2 and increased calcineurin activity. 
This, in turn, leads to the shift in metabolism towards the slow oxidative phenotype.  Thus, the 
substitution of α-actinin-2 for α-actinin-3 in Actn3 KO muscle changes the overall protein composition of 
fast fiber sarcomeres, altering the contractile and metabolic properties of the fibre. 
In combination, these data suggest that α-actinin-3 may influence muscle function in a dose-
dependent fashion; as the ratio of α-actinin-2 to α-actinin-3 in the sarcomeric pool exerts some 
influence on the overall properties of skeletal muscle. Consistent with this hypothesis, studies that 
involve quantitative analysis of muscle function reveal a dosage-effect pattern in which the RX genotype 
lies between the RR and XX genotypes. Specifically, in a study examining the muscle performance of 
healthy Greek adolescents, RX individuals showed a trend for a reduced 40 metre sprint time when 
compared to RR. The magnitude of this trend was approximately half the difference between RR and XX 
which proved statistically significant in this study (Moran et al., 2006). Similar trends were observed 
when examining the response to strength training in adult women (Clarkson et al., 2005) and the elderly 
(Delmonico et al., 2007). In both cases RX individuals demonstrated a trend towards increased strength 
gains compared to RR, with the magnitude approximately half of the significant increase in response to 
training attributable to the XX genotype. 
However, other studies have not shown any evidence of a dosage effect associated with ACTN3 
genotype (Norman et al., 2009, Walsh et al., 2008). The discrepancy in these studies may be attributable 
to confounding factors such as age, lifestyle and genetic background but the influence of α-actinin-3 
expression levels remains unclear. In order to remove these confounding factors, we examined 
heterozygous Actn3 mice and compared them to their wild-type and knockout littermates to rigorously 
test the possibility of a dosage effect associated with α-actinin-3 expression level. 
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3.2 Methods 
3.2.1 α-Actinin Gene Expression Analysis by qPCR 
3.2.1.1 Total RNA isolation  
Total RNA was extracted from ~100 mg of Actn3 wild-type, heterozygous and KO mouse quadriceps, 
lysed with 2 ml of Tri-Reagent (Molecular Research Center) as per manufacturer’s conditions. Briefly, the 
lysates were transferred to a 2 ml Eppendorf tube and 0.2 ml of chloroform was added. The 
homogenate was vortexed for 1 min and then centrifuged at 12,000 g for 15 min at 2-8°C. The upper 
aqueous solution was transferred to a fresh tube, and total RNA was precipitated with 0.5 ml of 
isopropyl alcohol per 1 ml of Tri-Reagent used in the initial lysate. The RNA was pelleted by 
centrifugation at 12,000 g for 10 min and washed with 1 ml of 70% ethanol, the RNA pellet was 
dissolved in 0.35 ml of RLT buffer from RNeasy Mini Kit (Qiagen). Further purification of total RNA was 
achieved using the RNeasy Mini Kit (Qiagen) following the manufacturer’s instruction. Total RNA quality 
was analysed using the Bioanalyser 6000 RNA kit (Agilent Technologies) according to the manufacturer’s 
protocol.  
3.2.1.2 Quantitative real-time PCR (qPCR)  
For quantitative real-time PCR (qPCR), cDNA was synthesised from 2 µg of Total RNA using Super-
ScriptTM III reverse transcriptase (Invitrogen) and random oligos (dN6, Roche), as per manufacturer’s 
instructions. cDNA were diluted 1/10 in DECP treated water (Bioline) prior to qPCR. Taqman probes 
(Applied Biosystems) for Actn2 (assay ID Mm00473657_m1), Actn3 (Mm00496495_m1) and the 
reference gene, Rer (Mm00471267_m1) were used to quantitate expression levels in Actn3 WT (n = 4), 
heterozygous (n = 4) and KO (n = 2) muscle. Standard curves were performed in each analysis and 
consisted of a serial (1/10) dilution of total cDNA from a WT sample. All samples were analysed in 
triplicate using the TaqMan assay master mix (1X) and selected probes (1X) with 2 µl of cDNA per 
reaction in a final volume of 10 µl; under the following conditions; 50oC for 2 min, followed by 40 cycles 
at 95oC for 15 sec and 60oC for 1 min. A melt curve analysis was performed following amplification which 
consisted of a 1oC/sec increase in temperature (68 – 90oC).  The amplification and melt analyses were 
performed using a Rotor-Gene 6000 (Qiagen) machine.  
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Rer was used as a reference gene as it was identified through microarray to be stably expressed 
between WT & KO at a level similar to the studied genes, and subsequently confirmed by qPCR in 3 
different mouse strains {Thomas, 2014 #443}. A standard curve was generated using amplified cDNA 
from a WT mouse. PCR was performed to generate gene specific products for RER and the genes of 
interest (ACTN2 and ACTN3). The concentration and molecular weight were determined and the number 
of cDNA copies/ul was calculated using the following equation: 
Copies/uL = (6.02x10^23copies/mol) x (concentration in g/uL) 
MW in g/mol 
 
The relative expression of each gene (Actn2 and Actn3) compared to the reference (Rer) were then 
determined and statistical analyses were performed using the non-parametric Mann-Whitney U test. 
3.2.2 Sarcomeric Protein Quantification 
3.2.2.1 Protein Expression and Purification 
The inserts for full-length α-actinin-2 and α-actinin-3 were subcloned into the pGEX-2T vector from 
the pGBT9 construct. Expression of soluble GST-tagged recombinant protein was then induced in E. 
coli BL21 (GE Healthcare) using 0.1 mM isopropyl-β-D-thiogalactopyranoside (Sigma). The purification 
was carried using a Glutathione Sepharose 4B microspin column (GE Healthcare) with thrombin to 
cleave recombinant proteins from the column. Protein purity was assessed on a Gelcode (GE Healthcare) 
stained SDS–PAGE gel. Protein concentration was quantified using NanoOrange protein quantification 
kit as per manufacturer's instructions (Invitrogen). 
3.2.2.2 Sarcomeric α-Actinin Protein Quantification 
A purified protein standard curve of known concentration was generated from the above 
recombinant α-actinin-2 and α-actinin-3 proteins. Equal amounts of total muscle protein (2.5 µg) from  
the quadriceps of WT, HET and KO mice were loaded onto  4-12% Bis-Tris pre-cast minigels (Life 
Technilogies) and western blotting was carried out as described in Chapter 2. Protein expression of α-
actinin-2 and α-actinin-3 in WT, HET and KO was quantified by densitometry using ImageJ software (NIH) 
and the purified protein standard curves were used to determine the level of sarcomeric α-actinin 
relative to total muscle protein. 
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3.3 Results 
All studies were performed on 8 ± 2 week old mice from the C57Bl/10 Actn3 KO colony detailed in 
Chapter 2. Normality cannot be assumed based on the numbers of mice used, so unless stated, the non-
parametric Mann-Whitney U test was used to perform pairwise comparisons between genotypes. For 
simplicity’s sake, genotypes in this chapter are annotated as follows wild-type (WT), Actn3+/- (HET) and 
Actn3-/- (KO). 
 
3.3.1 Gross Phenotyping 
Extensive phenotyping has been performed on Actn3 KO mice as detailed in the introduction. To 
date this work has been exclusively performed in the R129 mouse line, so in this study we aimed to 
investigate both the phenotype of heterozygous mice and replicate our previous findings on a different 
genetic background (C57Bl/10). 
3.3.1.1 Endurance Capacity 
α-Actinin-3 deficiency is associated with increased endurance performance in both mice (MacArthur 
et al., 2007) and humans (Yang et al., 2003). As in previous studies, we examined the endurance capacity 
of the mice, by forcing them to run to exhaustion on a motorised treadmill (Columbus Instruments). In 8 
week old C57Bl/10 mice, we again saw that KO mice run significantly further than their WT littermates 
before reaching exhaustion. Interestingly, HET mice show an intermediate phenotype, as they run 
further than WT, but had reduced endurance capacity compared to KO (Fig 3.1).  
The large sample size (WT & KO n = 16, HET n = 22) used in this experiment allowed us to perform a 
Kruskal-Wallis test across the three groups, which showed a significant effect of Actn3 genotype on 
endurance capacity (p > 0.05). To analyse this relationship further we performed a Dunn’s multiple 
comparisons test, which showed that KO mice run significantly further than WT (p < 0.001), but despite 
showing a trend for increased endurance capacity there was no statistical significance between WT and 
HET (p = 0.1). 
3.3.1.2 Grip Strength 
We also examined the forelimb grip strength of the mice, as reduced muscle strength has previously 
been observed in XX humans (Vincent et al., 2007) and Actn3 KO mice (MacArthur et al., 2008a). Again 
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we observed a significant reduction in the grip strength of KO when compared to WT, but saw no 
difference between WT and HET mice (Fig. 3.2). A Kruskal-Wallis test showed a significant effect of 
Actn3 genotype on grip strength (p < 0.05) which is a product of the difference between WT and KO (p < 
0.05) as the WT and HET groups demonstrated no significant difference. 
 
Figure 3.1: Intrinsic exercise capacity in C57Bl/10 mice. Mice were forced to run until exhaustion on a 
motorised treadmill (Columbus Instruments) and their total running distance was recorded. KO mice ran 
significantly further than WT (WT mean: 729 m, KO: 945 m, p < 0.001). HET mice showed a trend for increased 
endurance capacity compared to WT, which was not statistically significant (WT: 729 m, HET: 835, p = 0.1). Mean ± 
SEM (WT & KO n = 16, HET n = 22). 
 
Figure 3.2: Grip strength in C57Bl/10 mice. Mice were allowed to hang onto a horizontal bar with their 
forelimbs and pulled gently backwards by the base of their tail, the maximum grip force before they released the 
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bar was recorded by a force transducer. KO mice showed significantly reduced grip strength compared to WT (WT 
mean: 1.14 N, KO: 1.01 N, p < 0.05), but no difference was observed between the WT and HET groups (WT: 1.14 N, 
HET: 1.13 N). Mean ± SEM (WT & KO n = 16, HET n = 22). 
 
3.3.1.3 Body weight 
To further analyse the phenotype of our C57Bl/10 Actn3 KO model, we looked at the gross 
morphology of the mice. In the R129 strain, KO mice have reduced body weight compared to WT 
(MacArthur et al., 2008a). In C57Bl/10, while we observed a slight reduction in the body weight of KO 
mice compared to WT, however the different was modest and not statistically significant (Fig. 3.3). HET 
mice showed a similar small, but not statistically significant reduction in body weight when compared to 
WT.  
 
Figure 3.3: Body weight of 8 week old C57/Bl10 mice. No significant differences were observed, although both 
HET (22.7 g) and KO (23.1 g) did show a small trend for reduced body weight compared to WT (23.9 g). Mean ± 
SEM (WT & KO n = 10, HET n = 12). 
3.3.1.4 Isolated Muscle Mass 
Muscle strength is correlated with muscle size. α-Actinin-3 deficiency reduces muscle mass in both 
humans (Zempo et al., 2010) and mice (MacArthur et al., 2008a), which may underlie the reduced 
strength seen in these individuals. We isolated the individual skeletal muscles of the hindlimb and spine 
to assess the influence of Actn3 genotype on mass in the C57/Bl10 model. The small size of both the 
extensor digitorum longus (EDL) and soleus made differences difficult to detect, although we did 
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observe trends for decreased EDL weight, but increased soleus mass in KO compared to WT (Fig 3.4a) 
which is consistent with what has previously been published for the R129 strain (MacArthur et al. 2008).  
In the larger hindlimb muscles, KO mice showed a significant reduction in the mass of both the 
gastrocnemius and quadriceps compared to WT (Fig 3.4b). The spinalis, a postural muscle which runs 
along the dorsal aspect of the vertebrae, was also significantly smaller in KO mice. Interestingly, HET 
mice showed an intermediate muscle mass, and both the quadriceps and spinalis were significantly 
reduced compared to WT. 
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Figure 3.4: Isolated muscle mass. The major muscles of the hindlimb and spine were dissected and their wet 
weight was recorded. A) No significant differences were observed across the three genotypes in the wet weight of 
either the EDL or soleus (SOL). B) Significant reductions were observed in the mass of the gastrocnemius (GST), 
quadriceps (QUAD) and spinalis (SPN) from KO mice, but not the tibialis anterior (TA). Both the quadriceps and 
spinalis were also significantly reduced in HET compared to WT. Mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001 
(WT & KO n = 10, HET n = 12). 
3.3.2 Ex Vivo Muscle Physiology 
The above techniques are useful in determining the gross phenotype of our mouse model, but offer 
only imprecise measures of muscle function. To more accurately define the effect of α-actinin-3 
deficiency, we employed an ex vivo technique to investigate the contractile properties of isolated EDL 
muscles. The EDL is composed of mostly fast muscle fibres, and α-actinin-3 deficiency has a significant 
influence on muscle function in this model (Chan et al., 2011). This work was performed in collaboration 
with Dr. Stewart Head at the University of New South Wales. 
3.3.2.1 Maximum Force 
We tested the maximum force by stimulating the isolated EDLs with platinum electrodes at 
increasing frequencies to determine the maximum force-producing capacity of the muscle. Consistent 
with previous findings (Chan et al., 2011), KO muscles produced significantly less (~25%) force than WT 
(Fig. 3.5). However, muscles from HET mice produced significantly more force than WT, which was 
unexpected given the grip strength results in Fig. 3.2. 
However, as demonstrated in Fig 3.4, there are differences in EDL mass associated with Actn3 
genotype. When corrected for cross-sectional area, we observed no significant difference in the 
maximum specific force across the three genotypes, although KO did still show a trend for reduced 
maximum specific force compared to WT (Fig. 3.6). 
3.3.2.2 Twitch Kinetics 
In addition to the maximum force measurements, we also analysed the kinetics of a single twitch to 
further dissect the influence of Actn3 genotype on the contractile properties of skeletal muscle. The 
isolated EDLs were subjected to a single 250ms pulse, simulating a single action potential activating each 
fibre. We measured the time taken to reach peak force, and the first half of the relaxation phase. KO 
muscles took significantly longer than WT to reach peak force (Fig. 3.7) and showed a trend for longer 
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half-twitch relaxation times (Fig. 3.8). HET muscles did not show any difference to WT in either of these 
analyses. 
 
Figure 3.5: Maximum force produced by isolated EDLs. The maximum force generated by KO muscles was 
significantly less than WT (WT mean: 201 mN, KO: 159 mN, p < 0.001). Conversely HET muscles produced 
significantly more force than WT (HET mean: 214 mN, p < 0.05). Mean ± SEM (WT & KO n = 10, HET n = 8). 
 
 
 
Figure 3.6: Maximum specific force from isolated EDLs. To mitigate the effects of muscle size, the maximum 
force data from Fig. 3.5 was normalised by the cross-sectional area of each muscle to give the specific force. After 
this correction, no significant differences were seen in the maximum specific force across the three genotypes. 
Mean ± SEM (WT & KO n = 10, HET n = 8). 
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Figure 3.7: Twitch time to peak. The time to reach maximum force following a single 250 ms stimulus was 
calculated. KO muscles showed significantly reduced time to peak force when compared to WT (WT mean: 21.3 ms, 
KO: 19.3 ms, p < 0.05). No difference was observed between WT and HET muscles. Mean ± SEM (WT & KO n = 10, 
HET n = 8). 
 
 
Figure 3.8:Half-twitch relaxation time. Following excitation by a single 250 ms stimulus, the time taken for the 
muscle to relax from maximal activation to 50% (ie the first half of the relaxation phase) was recorded. No 
significant differences were observed across the genotype groups, although KO muscles did show a strong trend for 
slower relaxation compared to WT (WT mean: 16.2 ms, KO: 18.6 ms, p = 0.07). Mean ± SEM (WT & KO n = 10, HET n 
= 8). 
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3.3.2.3 Fatigue Recovery 
As described in Section 3.3.1 above, enhanced endurance capacity is a well-established consequence 
of α-actinin-3 deficiency. We aimed to supplement our forced treadmill running experiments by 
subjecting the isolated EDLs to a series of repeated tetanic contractions to fatigue the muscle, and then 
followed their recovery over a 10 min period. Figure 3.9 shows the results obtained from isolated EDLs. 
The descending part of the curve shows the decline in 100 Hz force with each successive tetanus during 
the 30 second (s) fatigue protocol. The ascending part of the curve shows the recovery from fatigue over 
a 10 minute period. 
KO muscles were significantly more resistant to fatigue during the 30s protocol (Fig. 3.10); WT 
muscles declined to 33% of their original 100 Hz force on average, whereas KO declined to 42% (p < 
0.05). This has not been observed in previous studies in the R129 strain, but is consistent with the 
results of the forced treadmill running experiments presented earlier in this chapter. KO muscles also 
showed a trend for greater recovery from fatigue as they produced 83% of their original 100 Hz force 
after resting for 10 min, compared to WT which recovered to 74% (p = 0.12). No significant differences 
were observed between WT and HET muscles in either the susceptibility to or recovery from fatigue. 
 The rate of recovery slows significantly between 5 and 10 min in Fig. 3.9 and the muscles never 
reach 100% recovery following the protocol. The ex vivo set-up relies on passive perfusion of oxygen 
from the bath to the muscle fibres. Although the EDL is a small muscle, it is possible that the fibres at its 
core gradually become anoxic and are unable to contract to produce force. However, when we dissected 
small bundles of fibres from the EDL to remove this diffusion issue, we still did not see them recover 
completely from the fatigue protocol. The repeated contractions during the fatigue protocol may 
damage the muscle and cause the loss of force, although this is unlikely as the muscles are remarkably 
resistant to contraction-induced damage at this age (Chan et al., 2008). It seems that the imperfect 
recovery is likely a product of the experimental set-up, as isolated muscles will show a gradual drop in 
force over time, even with intermittent stimulation (S. Head, personal communication). 
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Figure 3.9: Rate of muscle fatigue and recovery. Muscles were subjected to a fatigue protocol consisting of a 1-s, 100-Hz tetanus every 2 s for 30 s. The 
descending part of the curve shows the decline in 100-Hz force over the duration of the fatigue protocol. Muscles were then allowed to recover for a period of 
10 min. The ascending part of the curve shows the recovery in 100-Hz force during the recovery period. Mean ± SEM (WT & KO n = 10, HET n = 6).  
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Figure 3.10: Analysis of force recovery following fatigue. The relative 100 Hz force at 30s (Post Fatigue) and 
after the 10 min recover period were analysed from Fig 3.9. KO muscles retained a greater percentage of force 
following the fatigue protocol (42% of pre-fatigue force) compared to WT (33%, p < 0.05). No significant differences 
were observed after 10 min, but KO muscles did show a trend for increased recovery (83% of pre-fatigue force vs 
WT 73%, p = 0.12). Mean ± SEM (WT & KO n = 10, HET n = 6).  
3.3.3 Fibre Size and Type Analysis 
Given the incremental reduction in muscle mass associated with α-actinin-3 deficiency (Fig. 3.4), we 
further examined the muscle for changes in fibre size and type. The fast 2B fibres are smaller in KO 
muscle, which may account for the reduction in muscle mass (MacArthur et al., 2008a). Using antibodies 
against myosin heavy chains (MyHC) 2B, 2A, 2X and 1, we immunostained transverse sections of the 
quadriceps from WT, HET and KO mice and used MetaMorph software to analyse the average fibre size 
(Fig 3.11). We saw no shift in fibre type associated with Actn3 genotype, as WT, HET and KO muscles 
showed remarkably consistent fibre type proportions (Fig. 3.12). 
We did see a significant reduction in the average size of 2B fibres in KO muscle. No change was 
observed in the size of type 1, 2A or 2X fibres. In WT muscle, α-actinin-3 expression is restricted to 2B 
fibres (Mills et al., 2001), suggesting that the specific reduction of 2B fibres only is a direct consequence 
of α-actinin-3 deficiency. Interestingly, HET muscles showed an intermediate 2B fibre size, suggesting 
that α-actinin-3 may influence this phenotype in a dose-dependent fashion. 
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Figure 3.11: MyHC labeling to analyse fibre size and type proportion. Cross-section of a whole quadriceps 
from a KO mdx mouse, antibodies against the various MyHC isoforms were used to label Type 1 (green), 2A (blue), 
2X (unstained) and 2B (red). 
 
 
Figure 3.12: Quadriceps fibre type composition. All fibres (~5,000) in the mouse quadriceps were analysed 
from which the overall percentage of each fibre type was calculated. No shift in fibre type was observed to be 
associated with Actn3 genotype. Mean ± SEM (n = 6 for each genotype). 
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Figure 3.13: Mean fibre size. Using MetaMorph software, the area of each individual fibre was calculated 
(Garton et al., 2010). No difference was seen in the size of Type 1, 2A or 2X fibres, but KO mice showed a significant 
reduction in 2B fibre size (WT mean: 2132 µm
2
, KO: 1180 µm
2
 , p < 0.001). A trend was also observed for reduced 2B 
size in HET muscle compared to WT (HET mean 1729 µm
2
, p = 0.07). Mean ± SEM (n = 6 for each genotype). 
3.3.4 α-Actinin Expression Analysis   
Heterozygous mice show an intermediate phenotype in a number of the analyses presented in this 
chapter, suggesting that they may also display an intermediate level of α-actinin-3 compared to WT and 
KO. We analysed the mRNA and protein expression of both α-actinin-2 and -3 across each of the three 
genotypes to investigate the influence of Actn3 on sarcomeric composition. 
3.3.4.1 mRNA Analysis of the Sarcomeric α-Actinins 
  We extracted RNA from the quadriceps of WT, HET and KO mice, then synthesised cDNA to analyse 
the expression of Actn2 and Actn3 by qPCR using TaqMan probes (Life Technologies). We saw a 
significant increase in the level of Actn2 transcript in KO muscle (Fig 3.14), which we estimated to be a 
1.8 fold increase over WT levels after normalisation to Rer as a housekeeping gene (Fig. 3.15). Rer was 
chosen as a housekeeper as it showed stable expression between WT and KO at similar expression levels 
to Actn2 & 3 in WT by microarray and confirmed by qPCR. Previous microarray analysis in R129 mice 
showed a 1.24 fold up regulation of Actn2 in KO muscle (Seto et al., 2011). As expected, Actn3 mRNA 
was virtually undetectable in KO muscle. 
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We did not see a difference in the expression of Actn2 in WT and HET muscle, both in the raw copy 
number and after normalisation to Rer. However, HET muscle did show a significantly lower Actn3 
transcript level compared to WT, which we estimated to be a 50% reduction after normalisation to Rer. 
Hence, at least at the level of mRNA, HET muscle shows reduced α-actinin-3 expression which appears 
to correlate with the intermediate muscle phenotypes we have observed in these mice. 
 
Figure 3.14: mRNA expression level of Actn2 and Actn3. TaqMan probes were used to analyse the mRNA 
levels of Actn2 and Actn3 in mouse quadriceps. Total transcript copy number was estimated from 2 µg of total RNA. 
Mean ± SEM (WT & HET n = 4, KO n = 2). 
 
Figure 3.15: Relative expression of Actn2 and Actn3. Rer was used as a housekeepting gene to normalise the 
expression levels for analysis. KO muscles showed a 1.8 fold up regulation in Actn2 transcript (p = 0.07) compared 
to WT, while HET expression levels were unchanged. Actn3 expression was reduced in a dose-dependent fashion as 
HET muscles showed a 52% reduction (p < 0.05) compared to WT. Actn3 mRNA was not detected in KO muscle. 
Mean ± SEM (WT & HET n = 4, KO n = 2). 
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3.3.4.2 Sarcomeric α-Actinin Protein Quantification 
Naturally, we were interested in whether the transcriptional changes in Actn2 and Actn3 were 
reflected at the protein level. We used serial dilutions of purified, recombinant α-actinin-2 and -3 to 
determine the total sarcomeric α-actinin content of WT, HET and KO muscles. No α-actinin-3 expression 
was seen in KO muscle (Fig. 3.16), while α-actinin-2 was markedly upregulated (Fig. 3.17). In HET muscle, 
α-Actinin-3 was reduced by ~26% compare to WT 
In C57/Bl6  WT muscle, α-actinin-3 represented almost a 10x greater percentage of the total muscle 
protein than α-actinin-2. This is contrary to previous work in R129 mice which showed equal amounts of 
α-actinin-2 and -3 (Seto et al., 2011). However the predominance of α-actinin-3 protein does appear to 
reflect both our qPCR data which suggests a higher Actn3 copy number compared to Actn2, and the 
fibre type proportions of the mouse quadriceps as ~80% are (α-actinin-3 expressing) 2B (Fig. 3.11). 
Consistent with previous findings in R129 strains, we did not see significant differences in the total 
amount of sarcomeric α-actinin across the three genotypes, but simply alterations in the ratios of α-
actinin-2 and -3 (Fig. 3.18). 
 
Figure 3.16: Quantification of α-actinin-3 protein expression. Known concentrations of recombinant α-actinin-
3 protein was serially diluted and loaded on a 3–8% tris-acetate gel to generate a standard curve (R
2
=0.962). Total 
protein concentration of muscle lysates from WT, HET and KO quadriceps was determined the amount of α-actinin-
3 in each sample was calculated and expressed as a percentage of the total muscle protein. Mean ± SEM (n = 4 for 
each genotype). 
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Figure 3.17: Quantification of α-actinin-2 protein expression. Known concentrations of recombinant α-actinin-
2 protein was serially diluted and loaded on a 3–8% tris-acetate gel to generate a standard curve (R
2
=0.989). Total 
protein concentration of muscle lysates from WT, HET and KO quadriceps was determined the amount of α-actinin-
2 in each sample was calculated and expressed as a percentage of the total muscle protein. Mean ± SEM (n = 4 for 
each genotype). 
 
Figure 3.18: Total sarcomeric α-actinin expression. We saw no significant differences in the combined amount 
of α-actinin-2 and -3 expressed in WT, HET and KO muscle, although KO muscles did show a slight trend (p = 0.2) for 
increased α-actinin content. 
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3.3.5 Z-Line Protein Composition 
 α-Actinin-3 deficiency is known to influence the protein composition of the sarcomere (Seto et al., 
2011) and alter the metabolic profile of the muscle (MacArthur et al., 2007). In C57Bl/10 mice, we again 
saw a significant up regulation of α-actinin-2 in KO muscle (Fig. 3.19). This was accompanied by 
increased expression of desmin and myotilin, Z-line associated proteins that interact with α-actinin. We 
also saw a trend for increased cytochrome oxidase (COX IV) and significant up regulation of the 
mitochondrial membrane protein, porin in KO compared to WT, which reflects a shift in muscle fibre 
metabolism towards an slower oxidative phenotype associated with α-actinin-3 deficiency. 
We observed a significant reduction in α-actinin-3 expression in HET muscle compared to WT. α-
Actinin-2, myotilin and desmin were all upregulated in HET muscle by approximately half the magnitude 
seen in KO, suggesting a change in Z-line composition associated with a decrease in α-actinin-3. 
Similarly, both COX IV and porin were significantly upregulated in HET muscle when compared to WT, 
and again showed an intermediate level of expression. 
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Figure 3.19: Protein expression analysis in C57/Bl10 muscle. A) 2 µg of total muscle protein from the 
quadriceps of WT, HET and KO mice was loaded onto a 4-12% Bis-Tris precast mini gel (Life Technologies) and 
separated by SDS-PAGE. B) KO muscles showed significant up regulations of α-actinin-2 (2.3 fold), desmin (1.3), 
myotilin (1.9) and porin (1.36) and a trend for increased COX IV (1.87 fold, p = 0.11).  HET muscles showed a 15% 
reduction in α-actinin-3 and significant up regulation of α-actinin-2 (1.5 fold), myotilin (1.34), COX IV (1.44) and 
porin (1.2) when compared to WT. Mean ± SEM, * p < 0.05 (n = 3 for each genotype). 
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3.4 Discussion 
α-Actinin-3 deficiency occurs at high frequency in the general population (North et al., 1999), and 
studies in athletes and non-athletes have shown that α-actinin-3 deficiency is detrimental to human 
sprint and power performance (Eynon et al., 2013, Yang et al., 2003), and may enhance endurance 
performance  (Eynon et al., 2009, Yang et al., 2003). Interestingly, quantitative assessment of muscle 
function in the general population showed an intermediate phenotype in heterozygous individuals 
(Clarkson et al., 2005, Delmonico et al., 2007, Moran et al., 2006), suggesting a dose-dependent effect of 
α-actinin-3. This chapter attempted to define the heterozygous phenotype in a novel Actn3 KO mouse 
strain. 
3.4.1 The Actn3 KO Phenotype is maintained on different genetic backgrounds 
To date, published studies in the Actn3 KO mouse model have predominantly performed on the 
R129 genetic background. We aimed to test the reproducibility of these phenotypes in a second mouse 
strain (C57/Bl10) to strengthen our analysis of α-actinin-3 deficient muscle. The α-actinin-3 deficient 
phenotype was remarkably consistent between the two strains; C57/Bl10 KO mice showed increased 
endurance performance, decreased muscle strength, reduced fast fibre size, a compensatory up 
regulation of α-actinin-2, sarcomeric remodelling and a shift in metabolic profile – all key phenotypes 
which had previously been identified in the R129 genetic background. 
Differences in muscle performance were evident between strains; WT C57/Bl10 mice ran 729m until 
exhaustion, R129 WTs only 545m. This is a reflection of the genetic differences between the strains, 
which resembles variation in the human population to some degree (Wade et al., 2002). This suggests 
that Actn3 significantly influences muscle function in a monogenic fashion independent of normal 
genetic variation, which is reflected in the high reproducibility of ACTN3 association studies in 
populations across the world (Eynon et al., 2013). 
3.4.2 Heterozygous Mice Have an Intermediate Phenotype 
When compared to WT and KO, HET mice show an intermediate phenotype in endurance capacity, 
isolated muscle mass and 2B fibre size. This is consistent with quantitative muscle tests in humans, 
which have showed an intermediate heterozygous phenotype in adolescent 40m sprint time (Moran et 
al., 2006), and strength training in adult women (Clarkson et al., 2005). However, we did not see an 
intermediate phenotype across all assessments of muscle function; no difference was seen in muscle 
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strength between WT and HET, both by in vivo forelimb grip strength and ex vivo muscle force 
production, nor in the contractile kinetics of the isolated EDL. 
This phenomenon has also been observed in humans, as some studies have failed to show a dosage 
effect of α-actinin-3 on aspects of muscle function (Delmonico et al., 2008, Norman et al., 2009, Walsh 
et al., 2008). The effects of α-actinin-3 are a variation on normal muscle function and as a result it can 
often be a challenge to observe differences between RR and XX humans as they can be relatively subtle.  
Given that the potential differences between RR and RX are likely to be even smaller in magnitude, 
failure to detect a dosage effect in these studies may be explained by confounding factors such as age, 
sex and lifestyle. 
Studies in Actn3+/- mice remove these variables, and suggest that certain aspects of muscle function 
may be more responsive to the level of α-actinin-3 than others. In particular, HET mice showed an 
intermediate endurance capacity, but no difference in strength when compared to WT. This may suggest 
that the metabolic properties which underlie the endurance phenotype are more sensitive to the 
reduction in α-actinin-3, whereas the complete absence of α-actinin-3 is required before any difference 
in muscle force output is evident. 
3.4.3 Sarcomeric α-Actinins appear to be Post-Transcriptionally Regulated 
In HET muscle, we observed a 50% reduction in Actn3 mRNA, but no change in the level of Actn2 
mRNA expression when compared to WT. However, at the protein level, while we saw a significant 
reduction in α-actinin-3 in line with the reduced mRNA, we also saw up regulation of α-actinin-2 despite 
Actn2 expression being unchanged. This suggests that there is a mechanism in heterozygous muscle by 
which the muscle fibre is able to detect the shortage in α-actinin-3 and increase α-actinin-2 protein to 
compensate, which is independent of transcript levels. α-Actinin-2 is expressed during embryonic 
development, while α-actinin-3 expression is not evident in mouse skeletal muscle until 1-2 weeks of 
age (Quinlan et al., 2010). It is therefore possible that, in fast fibres, α-actinin-3 substitutes for α-actinin-
2 as Actn3 is ‘switched on’ during the process of post natal fibre type specification.  In HET muscle there 
would be a proportion of α-actinin-2 which persists as a result of the reduced α-actinin-3 protein 
expression, which may explain the apparent ‘up regulation’ of α-actinin-2 independent of Actn2 
expression level. 
Chapter 3: α-Actinin-3 Dosage 
73 
 
We did not observe any significant difference in the total level of sarcomeric α-actinin in skeletal 
muscle across each of the three Actn3 genotypes. Likewise there was no difference associated with 
Actn3 genotype in the total number of fibres in the mouse quadriceps. Together this would suggest that 
there is a fixed pool of sarcomeric α-actinin required for normal muscle function, and that Actn3 
genotype controls the ratio of α-actinin-2 to α-actinin-3, which in turn influences muscle function. 
However we did observe a trend for an incremental increase in total α-actinin with the absence of α-
actinin-3, suggesting that further studies are needed before we can draw this conclusion with any 
certainty. 
3.4.4 Z-Line Composition is Altered in a Dose-Dependent Fashion 
α-Actinin-3 deficiency results in an alteration of the protein complex at the Z-line. In particular, α-
actinin-2 is upregulated in KO muscle (MacArthur et al., 2007), along with the Z-line associated proteins 
myotilin and desmin (Seto et al., 2011). Heterozygous muscle shows an intermediate level of α-actinin-2, 
myotilin and desmin when compared to WT and KO, suggesting that sarcomeric remodelling occurs in a 
dose-dependent fashion according to the level of α-actinin-3 expression.  
We also observed a shift in the metabolic profile of HET muscle, as evidenced by significant up 
regulation of both COX IV and porin. Again, the expression levels of these proteins were altered in a 
pattern which suggests a dose-dependent effect of α-actinin-3 on muscle metabolism. Interestingly, the 
sarcomeric α-actinins do not interact directly with either of these mitochondrial proteins, so that there 
is likely to be a mechanism by which the mitochondria are sensitive to the alteration in Z-line 
composition. Glycogen phosphorylase (GPh), a key metabolic regulator, interacts directly with the α-
actinins and GPh activity is 50% lower in KO muscle (Quinlan et al., 2010). It is likely that the dose-
dependent remodelling of the Z-line in HET muscle extends to GPh which may underlie the metabolic 
phenotype in HET muscle. 
Differences in functional protein interactions between α-actinin-2 and -3 are thought to underlie the 
phenotype associated with α-actinin-3 defciency (Seto et al., 2011). In this study we show that the 
reduction in α-actinin-3 levels in HET muscle translate to a dose-dependent alteration of fast fibre Z-line 
protein composition which is consistent with this hypothesis.  This alteration in Z-line structure is 
reflected in muscle function as heterozygous mice and humans both show intermediate phenotypes 
which are consistent with a dose-dependent effect of α-actinin-3. 
 Chapter 4: ACTN3 Genotype Modifies DMD 
4.1 Introduction 
Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder with a frequency of 1 in 3500 
male births (Emery, 1991). DMD is due to mutations in the dystrophin gene, resulting in loss of 
dystrophin protein at the muscle membrane (Hoffman et al., 1987). Identification of the molecular basis 
of DMD has provided a focus for the development of therapeutic options, which aim to restore 
functional dystrophin; unfortunately these are not yet routinely available in clinical practice. To date the 
only proven palliative therapy for DMD is chronic corticosteroid (i.e. prednisone) treatment, (Bushby et 
al., 2004, Moxley et al., 2005, Desguerre et al., 2009) the effects of which can be highly variable between 
patients. There is also considerable inter-patient variability in disease onset and progression (Desguerre 
et al., 2009). This presents a significant challenge to clinicians in counseling patients and threatens to 
mask the benefits of novel treatments and confound the results of clinical trials. 
It has long been hypothesised that genetic variation at loci independent from dystrophin (i.e. disease 
modifiers), are responsible for unexplained variability in the progression of muscle weakness and 
response to therapies in patients with DMD. In theory, the discovery of these genetic modifiers is of 
immediate importance in the stratification of clinical trials to increase statistical power, but moving 
forward, these genes also have the potential to shed light on the pathological mechanisms which 
underpin muscle degeneration in DMD. 
 The concept of genetic modifiers is not without experimental precedent – studies using the mdx 
mouse model of DMD demonstrate that altered expression of a number of muscle genes is capable of 
significantly influencing the pathology. Co-deletion of utrophin exacerbates muscle breakdown 
(Deconinck et al., 1997a), whilst over-expression ameliorates the dystrophic phenotype (Tinsley et al., 
1998). Altered expression of the α7 integrin subunit (Burkin et al., 2001b, Rooney et al., 2006) and 
myostatin (Wagner et al., 2002) similarly affect disease progression in the mdx mouse. 
 However, the influence of these particular genes on disease severity in DMD patients remains 
unclear. Studies have shown increased utrophin protein expression is associated with milder disease 
progression, but this is thought to occur via alterations in translation rather than an effect on 
transcription (Moghadaszadeh et al., 2003).In fact, utrophin mRNA expression may actually be reduced 
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in ‘mild’ DMD patients (Pegoraro et al., 2011). In addition, single nucleotide polymorphisms (SNPs) that 
significantly alter the expression or activity of potential modifying genes (such as utrophin, myostatin 
and α7 integrin), have yet to be identified in DMD patients. 
The first disease modifying gene to be identified in humans with DMD, osteopontin (SPP1), was 
reported in early 2011. A SNP in SPP1, resulting in reduced gene expression, was associated with greater 
muscle weakness and earlier loss of ambulation (Pegoraro et al., 2011). The mechanism for this 
association has not been explored, but SPP1 mRNA expression is known to affect muscle regeneration 
(Uaesoontrachoon et al., 2008) and is upregulated in DMD patients (Chen et al., 2000). Importantly, 
when segregating cohorts based on SPP1 genotype the number of patients required to detect a 
significant difference in a clinical trial setting is reduced by 75%(Pegoraro et al., 2011). More recently, 
LTBP4 was also found to influence the age at which patients became non-ambulant via modulation of 
the TGFβ signalling pathway.(Flanigan et al., 2013) The continued identification of these modifier genes 
is vital in understanding the pathological mechanisms which underpin DMD. 
In skeletal muscle, the sarcomeric α-actinins are the major components of the z-line where they bind 
and crosslink the actin thin filaments. α-Actinin-2 is expressed in all muscle fibres, but the highly 
homologous α-actinin-3 isoform is restricted to fast, glycolytic fibre types. Importantly, a common null 
polymorphism (R577X) exists in the gene coding for α-actinin-3 (ACTN3) resulting in its complete 
absence in homozygous (XX) individuals (North et al., 1999). α-Actinin-3 deficiency is detrimental to 
sprint and power performance in both elite athletes(Eynon et al., 2013, Yang et al., 2003) and the 
general population(Clarkson et al., 2005, Moran et al., 2006, Walsh et al., 2008). Conversely, α-actinin-3 
deficiency appears to be associated with increased endurance performance (Eynon et al., 2009, Yang et 
al., 2003) and improved response to resistance training (Clarkson et al., 2005).  Actn3 KO mice appear to 
model the phenotype seen in α-actinin-3 deficient humans, as KO mice display reduced muscle mass and 
strength (MacArthur et al., 2008a), but display increased endurance capacity (MacArthur et al., 2007) 
and response to training (Seto et al., 2013).  
It is clear that ACTN3 genotype significantly influences muscle function in both elite athletes and 
healthy individuals. As a result, we hypothesise that ACTN3 genotype also modifies muscle strength and 
performance in DMD. This chapter outlines the influence that α-actinin-3 deficiency has on the primary 
pathology in dystrophic muscle at baseline. 
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4.2 Methods 
4.2.1 Downhill Run 
In order to induce eccentric contractions in vivo we modified a protocol published previously 
(Rooney et al., 2009) where mice were forced to run downhill in the presence of Evans blue dye (EBD). 
Mice were injected with EBD 30 min prior to the downhill run protocol. Following this they were placed 
on an Accupacer treadmill set on a 15° decline and run for 10 min at a speed of 15 m/min. Mice were 
culled 24 h after the downhill run, and all hindlimb muscles and the diaphragm were harvested and snap 
frozen. To visualize muscle damage, 8 µm sections were cut from the midpoint of the gastrocnemius 
muscle. These were fixed with 4% paraformaldehyde at 27° for 10 min and then incubated with 
Alexa488-conjugated wheat germ agglutinin (Life Technologies) for 1 h to mark the boundaries between 
fibres. EBD inclusion was imaged using fluorescent microscopy, using a 620 nm excitation laser and 
collecting emission at 680 nm. Fibres were delineated using the Alexa488 wheat germ agglutinin to 
determine the number and size of fibers which were positive for dye inclusion. 
4.3 Results 
All of the experiments presented in this chapter are performed on 8 to 10 week old mice from the 
Actn3 x mdx colony. At this age, the mdx phenotype is minimal (Chan and Head, 2011), but α-actinin-3 
has a significant effect on muscle function (Chapter 3). Hence, this age provides a baseline measurement 
against which we can assess the influence of α-actinin-3 as the disease progresses. 
For simplicity’s sake, genotypes are annotated in the text as follows; Actn3+/+ (WT), Actn3-/- (KO), 
Actn3+/+ mdx (mdx) and Actn3-/- mdx (KO mdx). WT and KO mice are included in each experiment as 
controls, but because both the mdx and Actn3 KO phenotypes relative to WT have been published 
extensively prior to this work, the comparisons presented in this study are between mdx and KO mdx; 
WT and KO data is included as a reference point for the effect of α-actinin-3 deficiency in healthy 
muscle. 
4.2.1 CINRG Natural History Cohort Analysis 
To assess muscle function in DMD, we analysed the Cooperative Neuromuscular Research Group 
(CINRG) natural history cohort, in collaboration with Prof. Eric Hoffman at the Children’s National 
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Medical Centre, Washington DC, USA (Table 4.1). We stratified this cohort to include steroid treated, 
ambulant, (young) 6-10 year olds (n = 61) and analysed quantitative muscle testing (QMT) and timed 
functional testing (10 m walk velocity); this is considered to provide the most sensitive and reliable 
phenotype to assess genetic modifiers (Mayhew et al., 2007).  
At baseline, ACTN3 genotype had a significant effect on both isolated muscle strength (grip, knee 
and elbow extensor QMTs) and overall muscle function (10m walk test). In all cases, the ACTN3 X allele 
was associated with poorer muscle performance; ACTN3 577RX patients display significantly less 
strength across the QMTs and completed the 10m walk test significantly slower than patients with 
ACTN3 577RR genotype. Similarly, patients with the ACTN3 577XX genotype show a trend for reduced 
muscle power output across all outcome measures in the cohort. 
Table 4.1: Analysis of the CINRG Natural History Cohort at baseline. Muscle strength and overall function was 
analysed by ACTN3 genotype in ambulant, steroid-treated, 6-10 year old patients (n = 62). A one-way ANOVA was 
performed to test for an ACTN3 genotype effect, where significant genotype effects were observed post-hoc tests 
were run to compare individual genotypes; these are presented in the final column.  
Phenotype 
Genotype 
effect p-value 
N: mean ± SD 
p-value for 
significantly different 
means 
10 m Walk Velocity 
(ms-1) 
0.0366 
RR (N=16; 2.22 ± 0.77)* 
RX(N=29; 1.69 ± 0.65)* 
XX (N=16; 1.79 ± 0.54) 
*p=0.034 
Grip QMT 0.0228 
RR (N=16; 4.02 ± 0.66)* 
RX(N=29; 3.43 ± 0.60)* 
XX (N=16; 3.67 ± 0.79) 
*p=0.019 
Elbow extensor QMT 0.0381 
RR(N=16; 2.84 ± 0.63)* 
RX (N=27; 2.36 ± 0.55)* 
XX (N=16; 2.54 ± 0.57) 
*p=0.032 
Elbow flexor QMT 0.06 
RR (N=16; 3.10 ± 0.56) 
RX(N=27; 2.68 ± 0.60) 
XX (N=16; 2.77 ± 0.52) 
NONE 
Knee extensor QMT 0.0222 
RR (N=16; 4.09 ± 1.15)* 
RX(N=27; 3.26 ± 0.95)* 
XX (N=16; 3.24 ± 0.93) 
*p=0.033 
Knee flexor QMT 0.0384 
RR (N=16; 3.72 ± 0.43)* 
RX (N=27; 3.32 ± 0.51)* 
XX (N=16; 3.54 ± 0.54) 
*p=0.0384 
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4.2.2 Gross Mouse Phenotyping 
To explore the ACTN3 genotype effect observed in DMD patients, we crossed Actn3 KO mouse with 
the mdx model of DMD as outlined in Chapter 2.3. This section details the initial phenotypic assessment 
of this novel mouse model. 
4.2.2.1 α-Actinin-3 & Dystrophin Expression 
We first confirmed the accuracy of our model by ensuring that both α-actinin-3 and dystrophin 
protein expression was completely absent in the muscle of KO mdx mice. Using sarcomeric actin as a 
loading control, we confirmed the absence of dystrophin in the mdx mouse line and demonstrated the 
successful deletion of α-actinin-3 expression in KO mdx mice (Fig. 4.1). 
4.2.2.2 Body weight 
To analyse the phenotype of our mouse model, we looked at the gross morphology of the mice. KO 
mice showed reduced body weight compared to WT controls; WT 32.7 ± 2.4 g, KO 27.2 ± 2.0  g; p > 0.05 
(Fig. 4.2), which is agreement with what has been previously published on the KO mouse model 
(MacArthur et al., 2008a). No difference was observed in the body weight of mdx and KO mdx; mdx 29.4 
± 1.1 g, KO mdx 29.0 ± 0.3 g. Body weight measurements in dystrophin-deficient mice were similar to 
controls at this age. 
4.2.2.3 Grip Strength 
α-Actinin-3 deficiency has previously been associated with reduced strength in both humans 
(Vincent et al., 2007) and mice (MacArthur et al., 2008a). Importantly, in a cohort of DMD patients, we 
observed a trend for reduced strength in XX (α-actinin-3 deficient) patients when compared to RRs. As a 
result we examined the grip strength in our KO mdx model and saw it was no different to mdx mice; mdx 
0.49 ± 0.15 N, KO mdx 0.48 ± 0.10 N (Fig. 4.3). However, we did observe a significant reduction in KO 
controls compared to WT; WT 1.27 ± 0.16 N, KO 0.80 ± 0.18 N, p > 0.001. Grip strength is reduced 
markedly in the mdx model and the readings recorded are approaching the minimum detection possible 
using this method, hence these results may not accurately reflect muscle strength in the mice tested. 
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Figure 4.1: Confirming the KO mdx mouse model. Protein samples from the quadriceps of two WT, KO, mdx and 
KO mdx mice were analysed by western blot for the expression of both dystrophin and α-actinin-3. KO mdx samples 
were negative for both proteins as expected. Sarcomeric actin was used as a loading control. 
 
 
Figure 4.2: Body weight in the KO mdx model. KO mice show significantly reduced body weight compared to WT 
controls (p > 0.05).No difference was observed between mdx and KO mdx. Mean ± SEM (n = 6 for each genotype). 
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4.2.2.4 Endurance Capacity 
In both humans (Eynon et al., 2009, Yang et al., 2003) and mice (MacArthur et al., 2007), α-actinin-3 
deficiency has been associated with increased endurance performance. We aimed to test this 
phenotype in our KO mdx model by running the mice on a mechanised treadmill until they reached 
exhaustion. We saw that KO mice ran significantly further than their WT counterparts (Fig. 4.4), 
replicating the phenotype which has previously been published. Interestingly, KO mdx mice also showed 
a trend for increased endurance capacity when compared to mdx (mdx 269m, KO mdx 377 m, p = 0.1). 
However, it is clear that dystrophin deficiency significantly reduces endurance capacity in general, 
making differences between mdx and KO mdx more difficult to detect than in healthy mice. 
4.2.2.5 Isolated Muscle Mass 
Previous studies have observed α-actinin-3 deficiency to be associated with reduced muscle mass in 
both humans (Zempo et al., 2010) and mice (MacArthur et al., 2008a). Because muscle mass is known to 
influence muscle strength, we analysed the mass of isolated hindlimb muscles as this could underlie any 
the influence α-actinin-3 deficiency has on muscle strength. Significant hypertrophy was evident in all 
muscles from the hindlimb of mdx mice (Fig. 4.5), which is consistent with previous observations in the 
model (Pastoret and Sebille, 1995) and the clinical features of DMD patients. Interestingly, we saw a 
trend for reduced muscle mass in the muscles of KO mdx mice, which was significant in both the 
gastrocnemius and quadriceps. This is in line with what is observed in healthy muscle, and may suggest a 
reduction of the hypertrophy associated with the dystrophic process in mdx muscle. 
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Figure 4.3: Grip strength. Mice were allowed to hang onto a horizontal bar with their forelimbs and pulled gently 
backwards by the base of their tail, the maximum grip force before they released the bar was recorded by a force 
transducer.  Dystrophin deficient mice showed vastly reduced grip strength compared to controls, but no difference 
was observed between mdx and KO mdx mice. Mean ± SEM (n = 6 for each genotype). 
 
Figure 4.4: Intrinsic exercise capacity. Endurance capacity of 8 week old mdx mice was tested on a treadmill at a 
constant grade of 15° and increasing speed of 1m/min every 2 min. KO mdx showed a trend for increased distance 
to exhaustion (KO mdx 378m, mdx 269m p = 0.09). Mean ± SEM (n = 6 for each genotype). 
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Figure 4.5: Isolated hindlimb muscle mass. Individual muscles were dissected from the hindlimb and immediately 
weighed. A: Mass of the extensor digitorum longus (EDL) and soleus (SOL). B: Mass of the tibialis anterior (TA), 
gastrocnemius (GST) and quadriceps (QUAD). Dystrophin deficiency causes considerable hypertrophy, KO mdx show 
a trend for reduced muscle mass compared to mdx which is statistically significant in both the GST (mdx 183.1 mg, 
KO mdx 159.2, p <0.05) and QUAD (mdx 296.5 mg, KO mdx 264.1 mg, p < 0.05). Mean ± SEM (n = 6 for each 
genotype). 
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4.2.3 Ex Vivo Muscle Physiology 
Because dystrophin deficiency reduces muscle function to such a large degree in the mdx model, it 
was difficult to accurately determine the influence of Actn3 genotype using the in vivo phenotyping 
studies described above. To more accurately dissect the effect of α-actinin-3 deficiency we employed an 
ex vivo technique to assess the contractile properties of isolated EDL muscles. The EDL is composed of 
mostly fast muscle fibres, and α-actinin-3 deficiency has a significant influence on muscle function in this 
model (Chan et al., 2011). This work was performed in collaboration with Dr. Stewart Head at the 
University of New South Wales. 
4.2.3.1 Maximum Force 
We tested the maximum force by stimulating the isolated EDLs with platinum electrodes at 
increasing frequencies to determine the maximum force producing capacity of the muscle. We observed 
a significant (~30%) reduction in the maximum force produced by KO mdx muscles compared to mdx 
(Fig. 4.6). However, KO mdx muscles were smaller than their mdx counterparts, which may explain the 
difference in force. When we corrected for cross-sectional area, KO mdx muscles still produced less 
maximum specific force than mdx (Fig 4.7), although the magnitude of this difference was reduced (mdx 
227 mN/mm2, KO  mdx 201 mN/mm2, p = 0.11). These results are in direct agreement with what we 
observed in DMD patients at baseline and suggest that α-actinin-3 deficiency reduces strength in 
dystrophic muscle. 
4.2.3.2 Twitch Kinetics 
In addition to the maximum force measurements, we also analysed the kinetics of a single twitch to 
further dissect the contractile properties of KO mdx muscle. The isolated EDLs were subjected to a single 
250ms pulse, simulating a single action potential activating each fibre, and we measured the time taken 
to reach peak force, and the first half of the relaxation phase. We saw no differences in the time to peak 
across the genotypes (Fig. 4.8), but did observe significantly longer half-twitch relaxation times in KO 
mdx muscles when compared to mdx (Fig. 4.9). 
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Figure 4.6: Maximum force producing capacity. The force generated by the isolated EDL muscles at maximal 
stimulation was significantly lower in KO mdx compared to mdx (mdx 204.8 mN, KO mdx 138.3 mN, p > 0.001). 
Mean ± SEM (n = 10 for each genotype). 
 
Figure 4.7: Maximum specific force from isolated EDLs. To mitigate the effects of muscle size, the maximum force 
data from Fig. 4.6 was normalised by the cross-sectional area of each muscle to give the specific force. KO mdx 
showed a trend for reduced maximum specific force compared to mdx (mdx 227 mN/mm2, KO  mdx 201 mN/mm2, 
p = 0.11). Mean ± SEM (n = 10 for each genotype). 
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Figure 4.8: Twitch time to peak. The time to reach maximum force following a single 250 ms stimulus was no 
different across all genotypes. Mean ± SEM (n = 10 for each genotype). 
 
Figure 4.9: Half-twitch relaxation time. Following excitation by a single 250 ms stimulus, the time taken for the 
muscle to relax from maximal activation to 50% (ie the first half of the relaxation phase) was recorded. KO mdx 
showed significantly longer half relaxation times than mdx muscles (mdx 13.8 ms, KO mdx 17.5 ms, p > 0.001). 
Mean ± SEM (n = 10 for each genotype). 
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4.2.3.3 Fatigue Recovery 
Our forced treadmill run protocol suggested that KO mdx mice showed increased endurance 
capacity when compared to mdx. We aimed to more closely analyse this potential phenotype by 
subjecting the isolated EDLs to a series of repeated tetanic contractions to fatigue the muscle, and then 
followed their recovery over a 10 min period. Figure 4.10 shows the results obtained from six muscles of 
each genotype. The descending part of the curve shows the decline in 100 Hz force with each successive 
tetanus during the 30s fatigue protocol. By the end of the protocol, 100 Hz force had declined to 39.9% 
of original in mdx and to 36.9% of original in KO mdx. No difference was observed in the rate of fatigue 
across the respective genotypes.  
The ascending part of the curve shows the recovery in 100 Hz force over the 10 min following the 
fatigue protocol. By the end of this period, KO mdx had recovered to 92.3% of their original force, but 
mdx recovered to only 85.9% of original (Fig. 4.11). Interestingly, dystropin deficient muscles showed 
increased (% maximum) recovery compared to healthy controls in this model, but this may be a product 
of their reduction in force generation (Fig. 4.6), as it is well known that the greater force exerted by a 
muscle, the more it will fatigue(Enoka and Stuart, 1992). Increased fatigue recovery has been observed 
in DMD patients (Scott et al., 1990, Sharma et al., 1995), but others have reported no difference, making 
the issue contentious (Ratel et al., 2006, Scott et al., 1986, Zupan, 1992). 
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Figure 4.10: Rate of muscle fatigue and recovery. Muscles were subjected to a fatigue protocol consisting of a 1-s, 100-Hz tetanus every 2 s for 30 s. The 
descending part of the curve shows the decline in 100 Hz force over the duration of the fatigue protocol. Muscles were then allowed to recover for a period 
of 10 min. The ascending part of the curve shows the recovery in 100 Hz force during the recovery period. Mean ± SEM (n = 10 for each genotype).  
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Figure 4.11: Analysis of force recovery following fatigue. No difference was observed in relative force immediately 
following the fatigue protocol illustrated in Figure 4.10. However KO mdx showed a significantly increased force 
production after being allowed to recover for 10 min following the fatigue protocol (KO mdx 92.3% recovery, mdx 
85.9%, p < 0.05). Mean ± SEM (n = 10 for each genotype).  
4.2.3.4 Eccentric Contraction 
Dystrophic muscle is known to be susceptible to stretch-induced damage (Head et al., 1992), hence 
the muscles were subjected to eccentric contractions of 20% strain to determine any differences in their 
propensity for eccentric damage. A series of 6 eccentric contractions was performed on each muscle 
(Fig. 4.12), causing significant injury in the dystrophin deficient muscle. 
Following the eccentric protocol, muscles were allowed to recover for 15 min, before their 
maximum force generation was tested. This value was compared to their pre-test maximum force and 
the percentage of force lost (force deficit) was calculated as a measure of damage incurred during the 
eccentric contractions. We observed significant force deficits in the muscles from both KO mdx and mdx 
mice indicating considerable damage, but saw no statistical difference between the two groups (Fig. 
4.13). 
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Figure 4.12: 20% Eccentric contraction profile. A) The diagrams show recordings of force (top) and muscle length 
(bottom), obtained during one lengthening contraction in a muscle from an 8-wk-old mdx mouse. Electrical 
stimulation starts at time = 0 ms. At time = 750 ms, the muscle is stretched at 2 mm/s until it is 20% longer than its 
optimum length (Lo), held at this length for 2 s, then returned at the same rate to its original length. Stimulation is 
stopped at time = 4,000 ms. Six such contractions were performed, at intervals of 3 min. B) Force traces showing 
the first, third and sixth eccentric contractions. There is an appreciable drop in force as the number of contractions 
increases 
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Figure 4.13: Force deficit following eccentric contraction. EDLs were subjected to a series of 6 lengthening 
contractions, where they were stretched by 20% of their resting length while contracted at 100 Hz. Both mdx and 
KO mdx showed substantial loss of force (mdx 44.6%, KO mdx 37.6%), but no statistical significance was observed 
between the groups (p = 0.09). Mean ± SEM (WT & KO n = 6, mdx & KO mdx n = 10). 
 
4.2.4 Downhill Run 
The susceptibility to stretch-induced damage is a highly significant phenotype associated with 
dystrophic muscle and hence, is of great interest in this project. The ex vivo eccentric contractions 
presented above, despite producing robust data, do not completely mimic natural physiological 
conditions. In order to extend our analysis of this phenotype, we used an in vivo model of stretch-
induced damage by forcing the mice to run downhill. 
Mice were run on a treadmill set on a 15° decline at a constant speed (15 m/min) for 10 min. Prior to 
the running exercise, mice were injected with Evans blue dye (EBD) as a marker of membrane injury. The 
gastrocnemius muscle was isolated 24 hours after the downhill run and the percentage of fibres 
including the dye were calculated as a marker of eccentric damage (Fig 4.14). While we saw no 
difference in force deficit using our ex vivo muscle setup, KO mdx mice showed a significant increase in 
the percentage of fibres including EBD, suggesting that they suffer greater damage in this paradigm (Fig. 
4.15). 
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Figure 4.14: Evans blue dye uptake following downhill running exercise. A) 8 µm section from the midbelly of the 
gastrocnemius. Membranes are marked with Alexa-488 conjugated to wheat germ agglutinin, EBD visualised via 
auto fluorescence at 680 nm. B) Higher magnification image of the marked area, displaying fibres which include 
EBD and those which do not. 
 
 
Figure 4.15: Percentage of GST fibers including EBD following a forced downhill run. After running downhill at 15° 
for 10 min at 15 m/min, isolated GST muscles from KO mdx show a higher proportion of fibres which include EBD 
compared to mdx (mdx 14.7%, KO mdx 25.8, p > 0.05). No dye was observed in dystrophin positive controls, so 
these have been omitted from results. Mean ± SEM (n = 5 for each genotype). 
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4.2.4 Histological Analysis 
 Dystrophic muscle is characterised by a number of histological changes, including fibre size 
disproportion, centralised nuclei, and the gradual infiltration of fibrotic and adipose tissue. Although 
young mdx mice do not show many of these features due to their mild pathology, they do show 
widespread internalisation of nuclei, which is thought to be a result of the gross muscle fibre destruction 
and regeneration which occurs between 3 and 8 weeks of age (Tanabe et al., 1986). Given that we 
observed differences in the functional properties of KO mdx muscle, we examined their histology to 
search for clues as to the mechanisms which may underlie these phenotypes. 
4.2.4.1 H&E Staining 
In order to examine the gross histological profile, we stained cross sections from the mid-belly of the 
quadriceps with hematoxylin and eosin. Consistent with the mild muscle phenotype, we observed very 
little evidence of fibrotic tissue or inflammation in both mdx and KO mdx muscle (Fig. 4.16). However, 
there was extensive internalisation of nuclei in dystrophin-deficient tissue, although Actn3 genotype had 
no influence on this phenotype (Fig. 4.17).  
4.2.4.2 Fibre Size and Type Proportion 
α-Actinin-3 deficiency is known to reduce the size of 2B fibres (MacArthur et al., 2008a) and small 
calibre fibres appear to be spared from the pathogenesis of DMD (Karpati et al., 1988). Because this 
could be a possible mechanism by which ACTN3 could influence the dystrophic pathology, we analysed 
the average fibre size in our KO mdx model using IHC against the different MyHC isoforms (Fig. 4.18).  
Overall, we did not see a difference in the fibre size distribution or mean diameter (Fig. 4.19) 
between mdx and KO mdx. We also observed no difference in the proportion of each of the respective 
fibre types, indicating the absence of any shift in MyHC isoform expression associated with the absence 
of α-actinin-3. 
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Figure 4.16: H&E staining of 8 week tibialis anterior. Dystrophic features including inflammation, fibrosis and 
adipose tissue infiltration were not evident in either mdx or KO mdx muscles when compared to WT. However, 
extensive internalisation of nuclei was observed in both mdx and KO mdx muscle, compared to WT where nuclei are 
peripherally located. 
 
Figure 4.17: Percentage of fibres which show centralised nuclei at 8 weeks of age. The position of nuclei was 
analysed in all fibres of the H&E stained TA muscles. Dystrophin deficient muscle showed widespread 
internalisation of nuclei, but no difference was observed in the percentage of fibres with centralised nuclei in mdx 
(82%) or KO mdx (83%). Mean ± SEM (n = 4 for each genotype)  
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Figure 4.18: MyHC labeling to analyse fibre size and type proportion. A) Cross-section of a whole quadriceps from 
a KO mdx mouse, antibodies against the various MyHC isoforms were used to label Type 1 (green), 2A (blue), 2X 
(unstained) and 2B (red). Membranes were labelled with Alexa-488 conjugated wheat germ agglutinin to delineate 
individual fibres. B) Higher magnification image of the indicated area. The area of each individual fibre was 
analysed using MetaMorph software (Garton et al., 2010).  
A 
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Figure 4.19: Analysis of fibre size and type proportion in 8 week mice. A) Frequency distribution of all quadriceps muscle fibres fibres by area. No significant 
difference is observed in fibre size between mdx and KO mdx. B) Frequency distribution of Type 2B fibres by area. No difference is observed in 2B fibre size 
between mdx and KO mdx. C) Mean fibre diameter across each individual fibre type. No significant difference in mean fibre size is observed between mdx and 
KO mdx for any of the individual fibre types. D) Proportion of each fibre type in the mouse quadriceps. No significant shift in fibre type is observed between mdx 
and KO mdx. 
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4.2.5 Protein Expression Analysis 
α-Actinin-3 deficiency has been shown to alter the expression of numerous muscle proteins (Seto et 
al., 2011); both structural (α-actinin-2, desmin, myotilin) and metabolic (COX IV, porin). Perhaps most 
significant is the observed increase in calcineurin signalling, which drives the shift towards ‘slow’ muscle 
properties associated with α-actinin-3 deficiency (Seto et al., 2013). In dystrophic muscle, the expression 
of utrophin is known to directly influence disease phenotype in both mice (Tinsley et al., 1998) and DMD 
patients (Kleopa et al., 2006). 
We analysed the expression of these proteins in KO mdx muscle to uncover the molecular 
consequences of α-actinin-3 deficiency in the context of DMD (Fig. 4.20). As previously observed in 
healthy muscle, we observed a significant increase in the expression of α-actinin-2, which we believe to 
be a compensatory mechanism for the loss of α-actinin-3 (Seto et al., 2011). No change was seen in the 
levels of utrophin in KO mdx muscle, however we did observe a significant increase in the expression of 
myotilin and a trend for desmin up regulation. Finally, we saw significant increases in both RCAN 1.4 (an 
indicator of calcineurin activity) and AMPK, signalling factors which promote fast to slow fibre type 
conversion.  
Given the significant increase in two of the key regulators of oxidative metabolism (calcineurin and 
AMPK) we assessed the Actn3 KO mdx mouse at baseline for changes in oxidative phosphorylation. We 
observed a significant upregulation in the expression of both cytochrome c oxidase (44%, COX IV), and 
succinate-Q oxidoreductase (~30%, COX II) expression (Fig. 4.21) in the Actn3 KO mdx muscle compared 
to mdx controls, indicating an increase in oxidative metabolism in KO mdx muscle. 
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Figure 4.20: Protein expression analysis in 8 week mouse muscle. A) Quadriceps protein samples were separated 
by SDS-PAGE. Using sarcomeric actin as a loading control the expression of α-actinin-2, utrophin, RCAN 1.4, AMPK, 
desmin and myotilin were analysed. B) Relative protein expression between mdx and KO mdx. KO mdx show 
significant increases in the expression of α-actinin-2 (1.6 fold), RCAN 1.4 (2.5 fold), AMPK (1.4 fold) and myotilin 
(1.3 fold). Mean ± SEM (n = 4 for each genotype) 
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Figure 4.21: Oxidative metabolism is increased in KO mdx muscle. A) Quadriceps protein samples were separated 
by SDS-PAGE. Using sarcomeric actin as a loading control the expression of ATPase, COX I, COX II, COX III and COX 
IV was analysed. B) Relative protein expression between mdx and KO mdx. KO mdx show significant increases in the 
expression of both COX II (1.29 fold, p < 0.05) and COX IV (1.44 fold, p < 0.001). Mean ± SEM (n = 4 for each 
genotype) 
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4.3 Discussion 
Recent advances in muscular dystrophy research have resulted in an increased number of clinical 
trials of potential therapies to ameliorate the DMD phenotype and slow disease progression. As such, it 
is increasingly recognised that the identification of genetic modifiers is vital to minimise the confounding 
effects of inter-patient variability in the analysis of these trials. Here we present evidence that a 
common null polymorphism in the ACTN3 gene has a significant influence on muscle function in DMD. 
4.3.1 ACTN3 Genotype Influences Muscle Strength in DMD 
In ambulant, 6 – 10 year old DMD patients treated with corticosteroids, we observed a significant 
effect of ACTN3 genotype on muscle function as the X allele was associated with reduced muscle 
strength and poorer performance in the 10m walk test. Interestingly, the XX genotype is also associated 
with both reduced muscle strength (Clarkson et al., 2005) and reduced  40m sprint times (Moran et al., 
2006) in healthy individuals, which mirrors our findings in DMD patients. Hence, it appears that ACTN3 
exerts a similar influence on DMD muscle at baseline as has previously been described in both elite 
athletes and the general population. 
We do recognise that the human cohort analysis is confounded to some degree by the low number 
of patients included. However, given that DMD is a rare disorder, it is difficult to assemble large cohorts 
in order to examine the effect of ACTN3 in greater depth. We did attempt to replicate our findings in 
two alternative patient cohorts, however only qualitative data was available on muscle function in these 
groups, which we considered too imprecise to determine the effect of α-actinin-3 deficiency in 
dystrophic muscle. 
We developed our Actn3 KO mdx model to more carefully dissect the phenotypes we observed in 
our human cohort analyses. Interestingly, muscles from KO mdx mice also produce significantly less 
force than their mdx counterparts. Taken together with our human cohort analyses, these data strongly 
suggest that α-actinin-3 deficiency results in reduced power output in dystrophic muscle. Given that 
muscle strength is widely used, both clinically as an indication of DMD severity and in the assessment of 
putative therapies, consideration of ACTN3 genotype may result in more accurate predictions of disease 
course and the efficacy of novel treatments. 
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4.3.2 KO mdx Show a Shift Towards Slow Muscle Contractile Properties 
KO mdx mice show reduced grip strength and increased endurance capacity at 8 weeks of age. This 
is in direct agreement with what has previously been observed in healthy Actn3 KO mice (MacArthur et 
al., 2007) and consistent with findings in elite athletes where α-actinin-3 deficiency is detrimental to 
sprint and power performance, but beneficial to endurance athletes (Yang et al., 2003). In addition to 
producing less force, KO mdx muscles also show increased recovery from fatigue and slowed relaxation 
following contraction. Together, these are phenotypes traditionally associated with ‘slower’ muscle fibre 
types (Spangenburg and Booth, 2003) and suggest a shift in the functional properties of KO mdx muscle. 
Identical shifts have previously been reported in the contractile properties of Actn3 KO muscles (Chan et 
al., 2011). 
The induction of a slow muscle phenotype in KO mdx is significant, as slow muscle fibres are 
relatively spared from degeneration in DMD patients (Webster et al., 1988). As such, a shift towards 
slow muscle properties as a result of α-actinin-3 deficiency could potentially have a protective effect 
against muscle fibre necrosis in DMD. 
4.3.3 α-Actinin-3 Deficiency does not Effect Susceptibility to Damage at Baseline 
Susceptibility to stretch-induced damage is a well-established phenotype associated with dystrophic 
muscle (Head et al., 1992). Although the exact mechanism behind this is unclear, it is thought that the 
absence of dystrophin results in increased membrane fragility, which is particularly evident when 
stretched (Allen et al., 2005). 
When we subjected isolated EDLs to a series of 20% eccentric contractions, we saw a slight, but 
statistically insignificant, reduction in the damage occurred by KO mdx. However, when we forced the 
mice to run downhill KO mdx muscles had a significantly higher percentage of muscle fibres which 
labeled positive for EBD. This suggests that KO mdx mice suffered greater damage, as the EBD is 
excluded by fibres with intact membranes. 
 In this experimental paradigm it is important that mice run a fixed distance, to ensure that the 
number of eccentric contractions suffered by each mouse is consistent. Because KO mdx mice show 
increased endurance capacity, they tended to complete the exercise more easily than mdx controls, 
which may explain the increase in dye inclusion. It should also be noted that even in KO mdx muscles, 
the vast majority of fibres were undamaged as only 25.8% of fibres were positive for EBD. Hence, while 
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statistically significant, one might argue that the difference in dye inclusion between mdx and KO mdx 
bears little biological relevance in the context of DMD. 
The presence of centralised nuclei is a marker of damaged muscle fibres subsequently undergoing 
regeneration. Both mdx and KO mdx muscles showed extensive centralisation of nuclei as α-actinin-3 
deficiency had no influence on this phenotype. Overall, our data suggests that there is little difference in 
the susceptibility to damage between mdx and KO mdx at 8 weeks of age. This is largely unsurprising as, 
at this age, we are examining the primary disease pathology; the absence of dystrophin. Because α-
actinin-3 is a sarcomeric protein with no direct link to the DAPC, it is unlikely to be involved in any 
compensatory mechanism for the loss of dystrophin from the sarcolemma. 
4.3.4 α-Actinin-3 Deficiency Results in a Shift towards Oxidative Metabolism 
Which May Ameliorate Disease Progression 
The expression of α-actinin-2 and α-actinin-3 appear tightly linked; α-actinin-2 is upregulated in fast 
fibres to compensate for the lack of α-actinin-3 in both KO mice and XX humans (Seto et al., 2011). 
Unsurprisingly, we also see a significant increase in the expression of α-actinin-2 in KO mdx muscle. 
Similarly, the expression of both myotilin and desmin is increased in KO mice (Seto et al., 2011), and we 
see a similar phenotype in KO mdx. It is difficult to interpret the significance of their up regulation in this 
model, but both are myofibrillar proteins associated with the sarcomere, which do not interact with the 
DAPC and hence their expression is not likely to directly influence the dystrophic phenotype.  
We have previously shown that an increase in calcineurin activity causes a ‘slowing’ of α-actinin-3 
deficient muscle, resulting functionally in reduced force generation and increased recovery from fatigue, 
but no shift in fibre type (Seto et al., 2013). Interestingly, we see a considerable increase in the 
expression of RCAN 1.4 in KO mdx muscle, suggesting increased calcineurin activity (Yang et al., 2000). 
This up regulation likely underlies the shift towards slower muscle properties in KO mdx muscle. We also 
observed an increase in the expression of AMPK in KO mdx. AMPK is a key regulator of muscle 
metabolism and also plays a role in slow fibre type conversion (Winder et al., 2000). AMPK activity is 
increased in Actn3 KO mice (P. Houweling, unpublished data), and together with calcineurin, likely drives 
the increase in oxidative metabolism seen in α-actinin-3 deficient muscle. Like Actn3 KO mice 
(MacArthur et al., 2007), we see a significant increase in COX IV and COX II in KO mdx muscle, which 
suggests an increase in aerobic metabolism associated with the increases in calcineurin and AMPK 
activity. 
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Slow fibres are relatively spared from degeneration in both DMD biopsies (Webster et al., 1988) and 
mdx mice (Head et al., 1992). Promoting fast-to-slow fibre type conversion either by calcineurin 
overexpression (Chakkalakal et al., 2004, Stupka et al., 2006) or chronic pharmacological activation of 
AMPK (Jahnke et al., 2012, Ljubicic et al., 2011) in mdx mice ameliorates the progression of the 
dystrophic pathology in mdx mice. Importantly, we see increased expression of both calcineurin and 
AMPK in KO mdx mice accompanied by a shift towards slow muscle properties. Although α-actinin-3 
deficiency does not appear to influence the primary pathology in DMD, these data suggest that it may 
act to slow the progression of disease features over time.
 Chapter 5: ACTN3 Modifies Disease 
Progression in DMD 
5.1 Introduction 
DMD is characterised by progressive muscle weakness; initial symptoms become evident around two 
years of age, patients are typically wheelchair-bound by 12 years and have a life expectancy in their 
early 20’s (Emery, 1993). Slowing the rate of disease progression is the major focus of therapeutic 
development in DMD (Fairclough et al., 2013, Fairclough et al., 2012). Although they do not exactly 
mirror the time course seen in patients, mdx mice also show a progressive muscle weakness; muscle 
fibre necrosis is evident at 3-4 weeks of age (Tanabe et al., 1986) and a rapid decline is seen in muscle 
mass and strength with age (Pastoret and Sebille, 1995). 
The pathological mechanisms which underlie the progression of DMD are still relatively unclear. The 
absence of dystrophin significantly increases the susceptibility of a muscle fibre to damage (Head et al., 
1992), but this is perpetuated over time as muscles from aged mdx show far greater susceptibility to 
damage than those from young mdx (Chan et al., 2011). These observations have led us to believe that 
the progression of DMD is driven by secondary processes which arise as a consequence of the absence 
of dystrophin. Indeed, dystrophic muscle features a chronic inflammatory response (Porter et al., 2002), 
gradual depletion of the regenerative capacity of satellite cells (Mouly et al., 2005) and the accumulation 
of branched fibres (Chan et al., 2007), all of which correlate with the progression of muscle weakness as 
the disease advances. 
Interestingly, slow muscle fibre types are largely spared from degeneration in the pathogenesis of 
DMD (Webster et al., 1988). Promotion of a fast-to-slow fibre type conversion, either by calcineurin 
overexpression (Stupka et al., 2008) or chronic AMPK activation (Ljubicic et al., 2011) ameliorates the 
progression of the dystrophic pathology in mdx mice. We have previously shown that both calcineurin 
(Seto et al., 2013) and AMPK (Peter Houweling, unpublished data) are upregulated in α-actinin-3 
deficient muscle and cause a shift towards a slower muscle phenotype. On this basis we hypothesise 
that, in addition to influencing muscle strength at baseline, ACTN3 genotype may also modify the 
progression of DMD. 
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5.2 Results 
All of the experiments presented in this chapter are performed on 11 ± 1 month old mice from the 
Actn3 x mdx colony. At 11 months old associate supervisor Dr Head’s research has previously shown a 
significant mdx phenotype, both in their susceptibility to stretch-induced damage (Head, 1993) and the 
development of branched fibres (Chan et al., 2007). The focus of these studies was to assess the 
influence of α-actinin-3 on the development of these phenotypes in comparison with the baseline 
measurements presented in the previous chapter.  
For simplicity’s sake, genotypes are annotated in the text as follows; Actn3+/+ (WT), Actn3-/- (KO), 
Actn3+/+ mdx (mdx) and Actn3-/- mdx (KO mdx). As in Chapter 4, groups of WT and KO mice are included 
in each experiment as controls and included as a reference point for the effect of α-actinin-3 deficiency 
in healthy muscle. 
5.2.1 Gross Mouse Phenotyping 
In our studies at baseline, we analysed muscle function in vivo by testing both grip strength (Fig. 4.3) 
and endurance capacity (Fig. 4.4). In these studies we observed a trend for increased endurance 
capacity in KO mdx when compared to mdx. Naturally, we attempted to investigate these phenotypes in 
the 11 month old mice used for the studies presented in this chapter. However, we found that the 
dystrophic phenotype (which is more evident in aged mdx mice) made both experiments impossible to 
complete as the performance of the mice was too poor to accurately record. As such, we used the ex 
vivo physiology studies to assess muscle function in these aged mice. 
5.2.1.1 Isolated Muscle Mass 
At baseline we observed a reduction in muscle mass in the larger hindlimb muscles from KO mdx 
mice when compared to mdx (Fig. 4.5), suggesting a reduction in hypertrophy. In aged mice we saw a 
greater degree of muscle hypertrophy in dystrophin deficient muscle than at baseline, but saw no effect 
of α-actinin-3 deficiency on this phenotype (Fig 5.1). Across each of the hindlimb muscles we isolated, 
there was no difference in the wet weight of mdx muscles when compared to their KO mdx 
counterparts. 
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Figure 5.1: Mass comparison of muscles isolated from the hindlimb of 11 month old mice. A) Whilst both the 
extensor digitorum longus (EDL) and soleus (SOL) show considerable hypertrophy, no difference in mass was 
observed between mdx and KO mdx. B) In the larger hindlimb muscles, both mdx and KO mdx showed considerable 
hypertrophy, but no difference was observed between either genotype. Mean ± SEM. 
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5.2.2 Ex Vivo Muscle Physiology 
Because aged mdx mice show an advanced dystrophic pathology, it was impossible to determine the 
influence of Actn3 genotype using the in vivo phenotyping studies described above. As a result we again 
employed an ex vivo technique to assess the contractile properties of isolated EDL muscles. The EDL is 
composed of mostly fast muscle fibres, and α-actinin-3 deficiency has a significant influence on muscle 
function in this model (Chan et al., 2011). This work was performed in collaboration with Dr. Stewart 
Head at the University of New South Wales. 
5.2.2.1 Maximum Force Generation 
We tested the maximum force by stimulating the isolated EDLs with platinum electrodes at 
increasing frequencies to determine the maximum force producing capacity of the muscle. We observed 
a significant (~25%) reduction in the maximum force produced by KO mdx muscles compared to mdx 
(Fig. 5.2). The maximum force produced by these aged muscles was lower than what was observed at 
baseline (8 weeks) for both of these genotypes, but not statistically significant. 
Unlike our baseline experiments in 8 week old mice, no significant difference between the size of 
muscles from mdx and KO mdx was observed. Hence, when we corrected for cross sectional area, KO 
mdx muscle still showed a 28% percent reduction in maximum specific force (Fig 5.3). The muscles from 
aged mice were much larger than in the young mice tested at baseline, and the calculation of specific 
forces allows comparison between the two ages. Unsurprisingly, both genotypes showed a significant 
reduction in maximum specific force between 8 weeks and 11 months of age (mdx 33% reduction, p < 
0.001, KO mdx 48%, p < 0.001). Unfortunately, because the procedure is terminal, we are unable to 
track the force production from each mouse over time, which would allow us to assess the progression 
of muscle weakness. 
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Figure 5.2: Maximum force produced by isolated EDLs from 11 month old mice. Muscles from KO mdx mice 
generate significantly less force than mdx (mdx 197.5 mN, KO mdx 154.3 mN, *p < 0.05). Mean ± SEM (n = 6 for 
each genotype). 
 
 
Figure 5.3: Maximum specific force produced by EDLs isolated from 11 month old mice. When the maximum 
force in Fig 5.2 is corrected for cross sectional area, KO mdx still show a decrease in maximum specific force when 
compared to mdx (mdx 152.8 mN/mm2, KO mdx 103.8 mN/mm2, *p < 0.05). Mean ± SEM (n = 6 for each 
genotype). 
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5.2.2.2 Twitch Kinetics 
In addition to the maximum force measurements, we also analysed the kinetics of a single twitch to 
further dissect the contractile properties of KO mdx muscle. The isolated EDLs were subjected to a single 
250ms pulse, simulating a single action potential activating each fibre. We then measured the time 
taken to reach peak force, and the first half of the relaxation phase. Dystrophin deficient muscles 
showed shorter times to reach peak, but this is likely a result of the smaller amplitude of the force 
output (Fig. 5.4). No difference was observed in the time to peak between mdx and KO mdx, but we did 
observe significantly longer half-twitch relaxation times in KO mdx muscles when compared to mdx (Fig. 
5.5). 
5.2.2.3 Fatigue Recovery 
We previously observed an increased endurance capacity and increased recovery from fatigue in KO 
mdx mice at 8 weeks (Fig 4.11). We aimed to analyse this phenotype in aged KO mdx muscle by again 
subjecting the isolated EDLs to a series of repeated tetanic contractions to fatigue the muscle, and 
following their recovery over a 10 min period. Figure 5.6 shows the results obtained from six muscles of 
each genotype. The descending part of the curve shows the decline in 100 Hz force with each successive 
tetanus during the 30s fatigue protocol. By the end of the protocol, 100 Hz force had declined to 34.2% 
of original in mdx and to 32.6% of original in KO mdx. No difference was observed in the rate of fatigue 
across the respective genotypes (Fig. 5.7).  
The ascending part of the curve shows the recovery in 100 Hz force over the 10 min following the 
fatigue protocol. By the end of this period, KO mdx had recovered to 79.2% of their original force, but 
mdx recovered to only 60.0% of original (Fig. 5.7). In general, recovery from fatigue was poorer in the 
aged muscle when compared to the results obtained at 8 weeks. Interestingly, the difference in fatigue 
recovery between mdx and KO mdx was more obvious in aged mice than had been observed previously 
at baseline, which may suggest an altered progression in disease phenotype. 
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Figure 5.4: Twitch time to peak. The time to reach maximum force following a single 250 ms stimulus was 
recorded in isolated EDLs. No difference was observed in the time to reach peak force between mdx and KO mdx. 
Mean ± SEM (n = 6 for each genotype). 
 
 
Figure 5.5: Half-twitch relaxation time. Following excitation by a single 250 ms stimulus, the time taken for the 
muscle to relax from maximal activation to 50% (i.e. the first half of the relaxation phase) was recorded. KO mdx 
showed significantly longer half relaxation times than mdx muscles (mdx 10.2 ms, KO mdx 18.3 ms, *p < 0.05). 
Mean ± SEM (n = 10 for each genotype). 
 
  Chapter 5: ACTN3 Modifies Disease Progression 
110 
 
 
Figure 5.6: Rate of muscle fatigue and recovery. Muscles were subjected to a fatigue protocol consisting of a 1-s, 100-Hz tetanus every 2 s for 30 s. The 
descending part of the curve shows the decline in 100-Hz force over the duration of the fatigue protocol. Muscles were then allowed to recover for a period of 
10 min. The ascending part of the curve shows the 100-Hz force during the recovery period. Mean ± SEM (n = 6 for each genotype).  
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Figure 5.7: Analysis of force recovery following fatigue. No difference was observed in relative force 
immediately following the fatigue protocol illustrated in Figure 5.6. However KO mdx showed a significantly 
increased force production after being allowed to recover for 10 min following the fatigue protocol (KO mdx 79.2% 
recovery, mdx 60.0%, p < 0.001). Mean ± SEM (n = 6 for each genotype).  
5.2.2.4 Stretch-Induced Damage 
The susceptibility to stretch-induced damage in dystrophic muscle increases as the pathology 
progresses (Chan and Head, 2011). As a result, we had to adjust the eccentric contraction protocol we 
employed in Chapter 4. The 20% stretch protocol used in 8 week old muscles caused extreme damage in 
aged mdx muscles, such that some muscles lost all contractile function. Hence, we subjected aged 
muscles to a milder 15% stretch at a reduced speed (Fig. 5.8), which is in line with protocols which had 
been used previously (Head et al., 1992). 
Following a series of 3 eccentric contractions, the aged muscles were allowed to rest for 10 minutes 
to remove any effects of fatigue, before the force deficit was calculated in the same manner as 
described in Chapter 4. We observed a significant reduction in the force deficit incurred by KO mdx 
muscles compared to mdx (Fig. 5.9), indicating a protective effect of α-actinin-3 deficiency against 
stretch-induced damage in dystrophic muscle. 
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Figure 5.8: 15% Eccentric contraction profile. A) The diagrams show recordings of force (top) and muscle 
length (bottom), obtained during one lengthening contraction in a muscle from an 11 month old mdx mouse. 
Electrical stimulation starts at time = 0 ms. At time = 750 ms, the muscle is stretched at 1 mm/s until it is 15% 
longer than its optimum length (Lo), held at this length for 2 s, then returned at the same rate to its original length. 
Stimulation is stopped at time = 5,000 ms. Three such contractions were performed, at intervals of 5 min. B) Force 
traces showing the three consecutive eccentric contractions. There is an appreciable drop in force as the number of 
contractions increases. 
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Figure 5.9: Force deficit following eccentric contraction. Aged EDLs were subjected to a series of 3 lengthening 
contractions, where they were stretched by 15% of their resting length while contracted at 100 Hz. Substantial loss 
of force was seen in dystrophin deficient muscle, but a significant reduction in force deficit was observed in aged KO 
mdx muscles (mdx 79.6% loss of force, KO mdx 46.7%, *p < 0.05). Mean ± SEM (n = 6 for each genotype). 
5.2.3 Individual Fibre Morphology 
The protective effect of α-actinin-3 deficiency against stretch induced damage in aged KO mdx 
muscle is an important phenotype in understanding the effect of ACTN3 genotype on the progression of 
DMD. To explore this phenotype further, we studied the morphometry of individual muscle fibres 
isolated from the EDLs of mdx and KO mdx mice. We observed a marked reduction in the proportion of 
fibre branching in muscles from KO mdx mice (Fig.5.10). Of the fibres which were branched, KO mdx 
muscles also showed a trend for reduced number of branches per fibre when compared to mdx (Fig 
5.11).  
Interestingly, the percentage of branched fibres appears to correlate directly with the force deficit 
following eccentric contraction (Fig. 5.9). Fibre branches are known to accumulate over time as a marker 
of muscle damage (Chan et al., 2007), hence the reduction of branching in aged KO mdx muscle is 
consistent with an amelioration of disease progression over time. 
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Figure 5.10: Actinin-3 deficiency reduces the extent of fibre branching in dystrophic muscle. A) Example of 
fibre branching, with small processes which arise from the main body of the fibre clearly distinguishable (Chan and 
Head, 2011). B) α-Actinin-3 deficiency results in a 42% reduction in the number of fibres which are branched in aged 
EDLs (mdx 89% of fibres branched, KO mdx 52%). Counts were pooled, approximately 300 fibres counted per 
genotype. 
 
 
Figure 5.11: α-Actinin-3 deficiency reduces the complexity of branching. For all fibres which displayed a 
branch, the total number of branches was counted. Muscles from mdx mice showed an increased frequency of 
fibres with 3, 4 or more branches, whereas KO mdx fibres tended to only have 1 or 2 branches per fibre. Counts 
were pooled, approximately 300 fibres counted per genotype. 
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5.2.4 Longitudinal Analysis of CINRG Cohort 
Given that α-actinin-3 deficiency appears to ameliorate the dystrophic phenotype progression in KO 
mdx mice, we proceeded to analyse the muscle strength of DMD patients in the CINRG natural history 
cohort over time. When we examined grip strength over time in 6 to 10 year olds, α-actinin-3 deficient 
(XX) patients showed increasing force over time (as would be expected with age) whereas RR individuals 
tended to plateau (Fig.5.12). This suggests that the progression of muscle weakness is slowed in XX 
patients; however there is currently insufficient data to support such a conclusion. Data is being 
collected prospectively, and we plan on revisiting these analyses in the future to get an accurate idea of 
the influence of ACTN3 genotype has on the progression of DMD.  
 
Figure 5.12: Longitudinal analysis of grip QMT over time. Grip QMT recordings were recorded over a 4 year 
period in ambulant, 6 – 10 year old patients in the CINRG natural history cohort. XX patients show a trend for a 
reduction in the progression of muscle weakness, but there is insufficient data collected at this point to accurately 
test the phenotype. Analysis performed in collaboration with Heather Gordish-Dressman, Eric Hoffman and CINRG 
Investigators.  
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5.2.5 Fibre Size and Type Analysis 
Small caliber fibres are known to be protected from degeneration in dystrophic muscle (Karpati et 
al., 1988). This is likely a mechanical phenomenon, as the smaller diameter means less strain on the 
membrane when the fiber is stretched. We investigated the fibre size profile of KO mdx muscles (Fig. 
5.13), to test whether the observed protective effect against stretch induced damage was a product of a 
reduction in fibre size. 
Similar to our observations at 8 weeks of age (Fig. 4.18), we did not see a difference in the fibre size 
distribution or mean diameter in the quadriceps of 11 month old mdx and KO mdx (Fig. 5.14). We also 
observed no difference in the proportion of each of the respective fibre types, indicating the absence of 
any shift in MyHC isoform expression associated with the absence of α-actinin-3. 
 
 
Figure 5.13: MyHC labeling to analyse fibre size and type proportion. Cross-section of a whole quadriceps 
from a KO mdx mouse, antibodies against the various MyHC isoforms were used to label Type 1 (blue), 2A (green), 
2X (unstained) and 2B (red). 
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Figure 5.14: Fibre size and type analysis in 11 month old mice. A) Frequency distribution of all quadriceps muscle fibres by area. No significant difference is 
observed in fibre size between mdx and KO mdx. B) Frequency distribution of type 2B fibres by area. No difference is observed in 2B fibre size between mdx and 
KO mdx. C) Mean fibre diameter across each individual fibre type. No significant difference in mean fibre size is observed between mdx and KO mdx for any of 
the individual fibre types. D) Proportion of each fibre type in the mouse quadriceps. No significant shift in fibre type is observed between mdx and KO mdx.
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5.2.5 Protein Expression Analysis 
In order to further investigate the effect of α-actinin-3 deficiency on disease progression, we 
analysed the expression of numerous proteins that were altered in KO mdx muscle at baseline (Fig. 
4.20). In 11 month old muscle, we again observed a significant up regulation of α-actinin-2 in KO mdx 
(Fig. 5.15). Again we saw a significant increase in the expression of AMPK and a trend for increased 
RCAN 1.4, indicating that both the AMPK and calcineurin signalling pathways are still elevated at 11 
months of age in KO mdx muscle. We did however see a trend for increased utrophin expression in aged 
KO mdx, which contrasts with our results at 8 weeks where it was unchanged. Finally, we observed a 
trend for increased COX IV expression in KO mdx, suggesting that the shift towards oxidative metabolism 
seen at 8 weeks is maintained at 11 months of age. 
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Figure 5.15: Protein expression analysis in 11 month mouse muscle. A) Quadriceps protein samples were 
separated by SDS-PAGE. Using sarcomeric actin as a loading control the expression of α-actinin-2, utrophin, RCAN 
1.4, AMPK and COX IV were analysed. B) Relative protein expression between mdx and KO mdx. KO mdx show 
significant increases in the expression of α-actinin-2 (2.8 fold, p < 0.05) and AMPK (1.9 fold, p < 0.05). Trends were 
observed for an increase in utrophin (1.8 fold), RCAN 1.4 (1.2 fold) and COX IV (1.2 fold) in KO mdx. Mean ± SEM (n 
= 4 for each genotype) 
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5.3 Discussion 
Slowing the progression of muscle weakness is the main aim of therapeutic development in DMD. 
Historically it has been observed that fast fibres are preferentially lost in the pathogenesis of DMD 
(Webster et al., 1988), suggesting that slow fibres are somehow protected against the dystrophic 
pathology. At baseline, we saw that ACTN3 genotype influences muscle strength in DMD, but also that 
α-actinin-3 deficiency causes a shift towards a slow fibre phenotype in dystrophic muscle. Hence, it is 
reasonable to presume that this shift in muscle properties may confer a protective effect against the 
progression of myofibre degeneration associated with DMD. 
5.3.1 α-Actinin-3 Deficiency Reduces Strength in Aged mdx Muscle 
As in 8 week old mice, we observed a significant reduction in the maximum force generated by aged 
KO mdx muscles. This result again highlights the association between α-actinin-3 deficiency and reduced 
strength in dystrophic muscle and suggests that our observations at baseline in DMD patients are likely 
to be maintained across the disease course. We also saw a significantly reduced maximum specific force 
(corrected for cross-sectional area) in KO mdx at 11 months of age. 
 Comparing the specific forces between our analyses at 8 weeks and 11 months could theoretically 
be used as a measure of disease progression. When calculated, KO mdx (43%) showed a greater 
reduction in maximum specific force than mdx (33%), suggesting a more severe disease progression if 
strength is used as the sole indicator of severity. However this result is largely produced by a change in 
the muscle size, rather than their contractile properties; KO mdx muscles are smaller than mdx at 8 
weeks, but no different at 11 months. However, when the correction for cross sectional area is 
removed, there is no difference in the absolute force generated between the tests at 8 weeks and 11 
months for either mdx or KO mdx, because the natural increase in muscle size between 8 weeks and 11 
months counters the weakness associated with the dystrophic pathology.  Because the experimental 
procedure is terminal, we can’t follow the force production of a single mouse over time, which would 
give a more accurate picture of the progression of muscle weakness in each animal. Overall, it’s clear 
that very little information can be garnered about disease progression by comparing the force 
production between 2 time points. 
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5.3.2 KO mdx Show a Shift Towards Slow Muscle Contractile Properties 
In addition to a reduction in maximum force generation, the aged KO mdx muscles also show slower 
half-twitch relaxation times and an increased recovery from fatigue. Both of these phenotypes are 
consistent with our observations in KO mdx at 8 weeks of age (Fig. 4.9), and again suggest a shift in the 
contractile properties towards those of slow fibres. Interestingly, the magnitude of the difference 
between mdx and KO mdx was larger for both of these phenotypes at 11 months than we had observed 
at 8 weeks, suggesting that the shift in contractile properties may be more significant in aged muscles 
than at baseline.  
5.3.3 α-Actinin-3 Deficiency Protects Against Stretch-Induced Damage 
The susceptibility to stretch-induced damage is a well-established phenotype associated with 
dystrophic muscle (Head et al., 1992), which increases as the pathology progresses (Chan et al., 2007). In 
young mice, α-actinin-3 deficiency had no effect on the susceptibility of mdx muscle to stretch induced 
damage. In contrast, we saw a significant reduction in the force deficit incurred by aged KO mdx muscles 
following eccentric contraction, demonstrating a protective effect of α-actinin-3 deficiency. This data 
suggests that α-actinin-3 deficiency ameliorates disease progression, as the rate of increase in 
susceptibility to stretch-induced damage is slowed in KO mdx muscle. 
Malformed or ‘branched’ fibres are a feature of regenerating muscle following injury (Sadeh et al., 
1985). Importantly, these fibre branches are found both in muscle biopsies from DMD patients (Bell and 
Conen, 1968, Schmalbruch, 1984) and in the muscles of mdx mice (Head et al., 1992) where they 
accumulate with disease progression (Chan et al., 2007). In dystrophic muscle, these branches are 
thought to accumulate over time as a result of the repeated cycles of damage and regeneration (Chan 
and Head, 2011). We saw a vast reduction in fibre branching in the muscles of KO mdx, which is 
consistent with an amelioration of disease progression in these mice. 
There seems to be a mechanical weakness associated with fibre branches; isolated fibres will break 
at the branch point when submaximally activated and when re-tied the remaining part of the fibre 
appears inherently healthy (Head, 2010). The accumulation of branched fibres with age also correlates 
directly with the increase in susceptibility to stretch-induced damage; aged mdx muscles (containing 
~90% branched fibres) are considerably more susceptible than their adolescent counterparts (less than 
20%) (Chan and Head, 2011). Hence the reduced fibre branching in aged KO mdx muscle may underpin 
the protective effect of α-actinin-3 deficiency against stretch-induced damage in these mice. 
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5.3.4 Slow Fibre Metabolism Protects Against the Disease Progression 
There was no difference in susceptibility to eccentric contraction damage in Actn3 KO mdx muscle 
compared to mdx at baseline, however we did observe a significant decrease in muscle damage in aged 
Actn3 KO mdx mouse muscle. Fibre branching was also significantly reduced in KO mdx muscle. In 
combination, these data suggest suggesting that disease progression in dystrophic muscle is slowed by 
α-actinin-3 deficiency. Consistent with this, preliminary analysis of the CINRG natural history cohort 
showed the progression of muscle weakness to be slowed in XX patients. Although insufficient data has 
been collected to date to draw any definitive conclusion, it does suggest that our observations in mice 
are likely to be relevant to DMD patients. 
Slow fibres are relatively spared from degeneration in both DMD biopsies (Webster et al., 1988) and 
mdx mice (Head et al., 1992); understanding the basis of this protective effect of slow fibres  could 
provide important insights into potential  therapies for DMD. Inducing fast-to-slow fibre type conversion 
by the transgenic overexpression of calcineurin (CnA*) ameliorates the dystrophic pathology in mdx 
mice (Chakkalakal et al., 2004). Isolated muscles from these CnA* mdx mice show reduced force 
production and an increased recovery from fatigue, which are characteristic properties of slow fibres 
and reflect a significant shift towards type 1 and type 2a fibres (Stupka et al., 2006). Induction of a fast-
to-slow fibre type conversion has also been achieved in mdx via chronic pharmacological activation of 
AMPK by the drug AICAR (Ljubicic et al., 2011). Like the CnA* model, chronic AICAR administration 
causes a shift towards slow twitch contractile properties and ameliorates the dystrophic pathology in 
mdx mice (Jahnke et al., 2012).   
Interestingly, we see an increase in both calcineurin and AMPK in KO mdx muscle, which is 
maintained between our initial analysis at 8 weeks and the investigation of aged mice at 11 months. Like 
the CnA* and AICAR models, KO mdx show a shift towards slow twitch contractile properties and 
protection against stretch-induced damage. Hence, it is likely that the mechanisms by which calcineurin 
and AMPK signalling benefit mdx mice are responsible for the protective effect of α-actinin-3 deficiency 
in dystrophic muscle, without a shift in MyHC isoform. 
Both CnA* overexpression and AMPK activation result in a decrease in fibre size, increased utrophin 
expression and a shift towards oxidative metabolism; each of these characteristic properties of slow 
fibres may modify the dystrophic phenotype. KO mdx mice do not display a change in fibre size or a shift 
in fibre type at either 8 weeks or 11 months, suggesting that neither contributes to the amelioration of 
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dystrophic progression. The influence of utrophin is less clear; protein levels are unchanged at 8 weeks, 
but we observed a trend for increased expression in KO mdx at 11 months. When normalised to 
sarcomeric actin expression, aged mdx muscles showed lower levels of utrophin than at baseline, 
suggesting that utrophin expression is down regulated with disease progression. Hence, the increased 
levels in aged KO mdx appear to be a result of an amelioration of disease progression relative to mdx. 
We do however observe consistent up regulation of COX IV in both baseline and aged KO mdx, 
indicating a shift towards oxidative metabolism. A feature of slow fibres, mitochondrial oxidation is 
impaired in dystrophic muscle (Even et al., 1994, Kuznetsov et al., 1998) and results in ATP deficits. 
Mitochondria are also key regulators of intracellular Ca2+ and hence the defective mitochondria seen in 
mdx muscle may contribute to the rise in [Ca2+] which is thought to be a primary driver of disease 
pathology (Percival et al., 2013). We have previously demonstrated that α-actinin-3 deficiency results in 
an increase in anaerobic metabolism (MacArthur et al., 2007, MacArthur et al., 2008b), and we see a 
similar phenotype in KO mdx.  On this basis, we believe that the metabolic shift associated with α-
actinin-3 deficiency confers a protective effect against the progression of DMD. Because such metabolic 
dysfunction is a feature of many muscular dystrophies (Chen et al., 2000, Turk et al., 2006), we suggest 
that genetic modification by ACTN3 genotype is not restricted to DMD, but likely to be more broadly 
applicable to muscle disease in general. 
 Chapter 6: Final Discussion 
6.1 Thesis Summary 
α-Actinin-3 deficiency occurs at high frequency in the general population, and studies in athletes and 
non-athletes have shown that α-actinin-3 deficiency is detrimental to human sprint and power 
performance, and may enhance endurance performance. The overarching aims of my PhD research have 
been to further study the molecular mechanisms which underpin the α-actinin-3 deficient phenotype 
and to examine the consequences of α-actinin-3 deficiency in the context of muscle disease, an area 
which had not previously been explored. 
6.1.1 α-Actinin-3 Dosage 
Through the phenotypic assessment of Actn3+/- mice, we have demonstrated a dose-dependent 
effect of α-actinin-3 on muscle function. Heterozygous mice showed an intermediate phenotype in our 
analysis of endurance capacity, isolated muscle mass and fast fibre size. This is in agreement with 
quantitative assessments of muscle function in human populations, which show a dosage-effect pattern 
in which the RX genotype lies between the XX and RR genotypes (Delmonico et al., 2008, Norman et al., 
2009, Walsh et al., 2008). The reduced α-actinin-3 expression in HET muscle results in an up regulation 
of α-actinin-2 at the protein level, which causes a dose-dependent alteration in the protein complex at 
the muscle fibre Z-line. The intermediate expression level of myofibrillar and metabolic proteins in HET 
muscle when compared to WT and KO appears to correlates directly with the intermediate muscle 
phenotype displayed by both HET mice and RX humans. 
6.1.2 α-Actinin-3 and DMD 
Given that α-actinin-3 deficiency has reliably been shown to reduce sprint and power performance in 
both elite athletes and the general population, we were interested in the effect it may have on clinical 
severity in muscle disease. We chose to study Duchenne muscular dystrophy since it is the most 
common inherited myopathy.   Analysis of a cohort of patients with DMD that have been characterised 
as part of the CINRG natural history study revealed that ACTN3 genotype has a significant influence on 
muscle strength in DMD patients, as ACTN3 577XX patients showed reduced force and longer 10m walk 
times than RR. α-Actinin-3 deficiency also significantly reduced force production in the muscles of mdx 
mice, providing strong evidence that ACTN3 acts as a modifier of muscle strength in DMD. 
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While we observed no difference in susceptibility to damage at baseline, KO mdx mice were 
protected against stretch-induced damage at 11 month of age, suggesting an amelioration of disease 
progression associated with α-actinin-3 deficiency. We also saw reduced accumulation of branched 
fibres in KO mdx muscles at 11 months, which is further evidence of slowed disease progression. 
Because both fibre size and utrophin expression were unchanged, it appears that the shift towards 
oxidative metabolism is responsible for the amelioration of dystrophic pathology in KO mdx muscle. 
6.2 Significance of the ACTN3 heterozygous (577RX) Genotype 
6.2.1 Muscle Function 
ACTN3 genotype has been reliably shown to influence athletic performance, where the ACTN3 
577XX genotype is detrimental to sprint performance but advantageous to endurance athletes (Eynon et 
al., 2013, Yang et al., 2003). Given that heterozygous individuals show an intermediate muscle 
phenotype, it is difficult to predict a scenario where the RX genotype would be specifically advantageous 
to athletic performance. It is possible that the intermediate phenotype is beneficial in ‘mixed’ athletic 
pursuits which require a balance of power and endurance, but this is almost impossible to investigate as 
such sports pursuits almost always require particular skills which are independent of raw athletic ability, 
hence elite performance is not necessarily just a reflection of skeletal muscle properties. 
Certain studies have shown associations between the RX genotype and athletic performance in 
professional soccer players (Santiago et al., 2008) and elite swimmers (Chiu et al., 2011). However, these 
studies appear to be the exception to the rule, as analyses in elite athlete cohorts around the world 
have shown no difference in RX frequency between cases and controls (Eynon et al., 2013). What our 
investigation of the heterozygous genotype does show is that the recessive model used by some 
association studies, grouping RR and RX genotypes for comparison to XX (Gomez-Gallego et al., 2009), is 
not suitable for all analyses as RR and RX do not share an identical phenotype. 
6.2.2 Haploinsufficiency 
Altered protein levels are the basis of various diseases (Conrad and Antonarakis, 2007), highlighting 
the biological importance of the expression level of a gene product rather than simply its presence or 
absence. From our mouse studies it is clear that a single functional Actn3 allele is not sufficient to drive 
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wild-type levels of α-actinin-3 expression in skeletal muscle. Although organisms heterozygous for a loss-
of-function allele typically show no discernable phenotype due to the redundancy of cellular physiology 
(Kacser and Burns, 1981), haploinsufficiency is observed in genes which are required at high levels and 
are therefore more sensitive to a reduction in dose (Deutschbauer et al., 2005). 
Haploinsufficiency is often associated with genetic disease (Conrad and Antonarakis, 2007), although 
in this case α-actinin-2 is upregulated to compensate for the shortfall of α-actinin-3 to preserve the 
integrity of the Z-line. This raises the possibility of co-regulation between the sarcomeric α-actinin 
isoforms, as fast muscle fibres appear to increase the level of α-actinin-2 protein expression to maintain 
the total sarcomeric α-actinin pool in response to diminished α-actinin-3 levels. We performed in silico 
analysis of the promoter sequences for α-actinin-2 and -3 but saw no evidence of co-regulation (M. Lek, 
unpublished data). This is consistent with our qPCR analysis of HET muscle, as we saw no change in 
Actn2 expression despite a 50% reduction in Actn3 transcript. 
6.2.3 α-Actinin-3 Overexpression 
The natural extension of our work on the dosage effect of α-actinin-3 is to examine the effect of 
overexpression on muscle function. Structural proteins often display a linear relationship between gene 
dose and phenotype (Kondrashov and Koonin, 2004), suggesting that α-actinin-3 over expression may 
make muscles ‘faster’. We have developed an AAV vector to overexpress α-actinin-3 in skeletal muscle 
in collaboration with Dr Paul Gregorevic (Baker-IDI Heart and Diabetes Institute). Preliminary studies 
using this technique have shown that overexpression of α-actinin-3 in wild-type muscle causes 
downregulation of α-actinin-2, further highlighting the reciprocal relationship between the two isoforms 
(F. Garton, unpublished data). Increased α-actinin-3 expression also appears to alter the protein 
composition of the Z-line, but as yet it is unknown whether this results in a shift in muscle properties 
which correlate with the α-actinin-3 dose. 
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6.3 ACTN3: A Novel Genetic Modifier of DMD 
6.3.1 α-Actinin-3 Deficiency Reduces Strength in Dystrophic Muscle 
Overall, we show strong evidence that ACTN3 genotype is significantly associated with muscle 
strength in DMD patients. At baseline, ACTN3 genotype had a significant effect on both isolated muscle 
strength (grip QMT, knee and elbow extensor QMTs) and overall muscle function (10m walk test). In all 
cases, the ACTN3 X allele was associated with poorer muscle performance; ACTN3 577RX patients 
display significantly less strength across the QMTs and completed the 10m walk test significantly slower 
than patients with ACTN3 577RR genotype. Similarly, patients with the ACTN3 577XX genotype showed 
a trend for reduced muscle power output across all outcome measures in the cohort.  
While we recognise that this data is somewhat confounded by the small number of patients 
available for analysis, it should be noted that the CINRG natural history cohort represents the currently  
best available set of quantitative data on DMD patients and hence the most suitable for the 
investigation of genetic modifiers (Mayhew et al., 2007). We developed the double knockout (Actn3 KO 
mdx) mouse model to further investigate the genetic modification of DMD by ACTN3. Importantly, 
isolated muscles from KO mdx mice also displayed significantly reduced strength compared to mdx 
controls, allowing us to confidently conclude that α-actinin-3 deficiency reduces strength in DMD. 
6.3.2 Genetic Modifiers in DMD 
The extensive inter-patient variation that exists in DMD presents a significant challenge to clinicians 
in predicting disease outcomes for patients and in the evaluation of novel therapies (Desguerre et al., 
2009). While environmental factors undoubtedly contribute, genetic polymorphisms appear to underpin 
this variance in DMD phenotype. It is important to consider the influence of ACTN3 in the context of the 
previously discovered genetic modifiers, SPP1 and LTBP4. 
6.3.2.1 SPP1 
A SNP in the promoter region of SPP1 was associated with reduced muscle strength and earlier loss 
of ambulation in two separate DMD cohorts (Pegoraro et al., 2011). In cell culture experiments this SNP 
resulted in reduced expression of the gene product, osteopontin. Osteopontin is upregulated in DMD 
muscle (Chen et al., 2000), where it is involved in the inflammatory response and promotes fibrosis. 
Deletion of osteopontin reduces fibrosis and improves muscle function in mdx mice (Vetrone et al., 
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2009). Hence, it follows that a reduction in osteopontin would likely decrease fibrosis and improve the 
pathology of DMD. However the variant in SPP1 predicted to reduce osteopontin expression 
exacerbated the phenotype of DMD patients, which is the opposite effect to what had been 
demonstrated in mdx mice. 
Further investigation revealed that SNP in SPP1 had no effect on either SPP1 mRNA or osteopontin 
protein expression in DMD patients from one of the cohorts in which the association was observed (Piva 
et al., 2012). SPP1 genotype also had no influence on muscle fibre degeneration or the accumulation of 
fibrotic tissue in patient biopsies, which casts some doubt over the ability of the variant in SPP1 to 
modify the pathology of DMD. Nevertheless the effect of SPP1 genotype has been replicated in two 
separate cohorts of DMD patients, so that further investigation is warranted to uncover the true role of 
osteopontin in the pathogenesis of DMD. 
6.3.2.2 LTBP4 
More recently, the gene encoding latent TGF-β binding protein 4 was associated with disease 
progression in a cohort of DMD patients (Flanigan et al., 2013). A series of 4 SNPs in LTBP4 create a 
number of possible haplotypes, which influence the affinity of the protein for TGF-β. The IAAM 
haplotype displays increased affinity for TGF-β and prolongs ambulation in DMD patients. Elevated TGF-
β has been noted in DMD (Bernasconi et al., 1995) and pharmacological reduction of TGF-β signalling 
ameliorates the phenotype of mdx mice (Nelson et al., 2011a), so the association is consistent with our 
knowledge to date on TGF-β and DMD. 
In the investigation of LTBP4 the investigators use the age at loss of ambulation as an indicator of 
disease progression. This is really a semi-quantitative measure as the decision to use a wheelchair is 
largely dependent on family preference and the patient’s physician who is influenced by clinical 
guidelines on the management of DMD (Bushby et al., 2010b). Further investigation of the influence 
that LTBP4 haplotype has on muscle function is therefore crucial in understanding its role in the 
pathogenesis of DMD. 
6.3.2.3 ACTN3 
In comparison to the aforementioned modifier genes, we have shown ACTN3 genotype to influence 
multiple quantitative assessments of muscle strength and performance in the 10m walk test, an 
indication of overall muscle function in a well characterised cohort of DMD patients. Interestingly, the 
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SPP1 analysis was performed on the same CINRG cohort that we used for our analysis. The authors did 
report observing a significant association between ACTN3 genotype and grip QMT in this cohort, but 
discounted the observation as the same association was not replicated in a second DMD cohort. 
However their chosen replication cohort data includes only qualitative assessments of muscle strength 
(MRC score) for which inter-rater reliability is an issue (Bushby and Connor, 2011). Quantitative muscle 
tests are considerably more reliable as an indicator of muscle strength (Mayhew et al., 2007), and hence 
we consider the consistent associations across multiple QMTs in a single cohort to be stronger evidence 
for ACTN3 as a genetic modifier than replication in a second cohort of poorer data quality. 
Unlike SPP1 and LTBP4, we have also shown that the ACTN3 modifier effect seen in DMD patients 
can be directly modeled by the manipulation of Actn3 in mdx mice, allowing us to investigate the 
biological mechanisms which underlie the modifier effect in vivo. As a result, one can argue that ACTN3 
shows the strongest evidence as a genetic modifier of DMD. 
6.4 α-Actinin-3 Deficiency Ameliorates Disease Progression 
We saw a reduction in branched fibres in aged KO mdx muscle which corresponded to a protective 
effect against stretch-induced damage. Fibre branching accumulates over time as a marker of muscle 
damage (Chan et al., 2007), suggesting an amelioration of disease progression in α-actinin-3 deficient 
muscle. We have evidence to suggest that a shift towards slow fibre metabolism is responsible for the 
reduced rate of dystrophic progression in KO mdx. 
6.4.1 Slow Fibre Metabolism is Protective 
It is well recognized that fast fibres are preferentially lost in DMD, while slow fibres are relatively 
spared from degeneration. Previous studies have suggested that this could be a result of the smaller 
diameter of slow fibres, their increased level of utrophin expression or the increase in aerobic 
metabolism (Ljubicic et al., 2011, Stupka et al., 2008). In the KO mdx model we were able to discount the 
effects of both fibre size and utrophin expression as they showed no difference, highlighting the 
significance of muscle fibre metabolism in the pathology of DMD. 
Mitochondrial oxidation is impaired in dystrophic muscle (Even et al., 1994, Kuznetsov et al., 1998) 
and results in ATP deficits. Because intracellular Ca2+ homeostasis is largely maintained by the ATP 
dependent sarcoplasmic reticulum Ca2+-ATPase (SERCA) pump, the mitochondria play an important role 
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in intracellular [Ca2+] regulation. A rise in resting [Ca2+] is seen in mdx muscle (Head, 1993), which is 
consistent with impaired SERCA pump function. Increased calcium will also have a negative effect on 
mitochondrial function (Brookes et al., 2004), causing further impairment to oxidative metabolism in a 
‘pathogenic loop’ which may contribute to disease progression. 
Give that mitochondrial oxidation is increased in KO mdx, we expect that this may have a positive 
effect on the intracellular calcium homeostasis. As such, future studies in this model will focus on the 
calcium handling properties of KO mdx muscle in an attempt to further characterise the mechanisms by 
which α-actinin-3 deficiency alters the progression of DMD. 
6.4.2 Increased Regeneration in KO mdx? 
We also postulate that the muscle fibre regeneration process may also be involved in the protective 
effect of α-actinin-3 deficiency, as it plays a significant role in the secondary pathology which drives the 
progression of DMD. In addition to its function in fibre type specification, calcineurin has an important 
role in regulating skeletal muscle regeneration and remodelling (Sakuma et al., 2003). Indeed, inhibition 
of calcineurin impairs muscle regeneration in mdx mice, exacerbating the pathology (Stupka et al., 
2004). Because calcineurin activity is increased in KO mdx muscle, it is possible that they display more 
efficient muscle fibre regeneration which may contribute to the protective effect. We have previously 
seen evidence of increased regeneration in Actn3 KO mice at baseline by microarray (Seto et al., 2011), 
suggesting that this hypothesis has merit. 
Future work in this project will involve the use of notexin to induce a controlled degree of myotoxic 
damage to mdx muscle (Plant et al., 2006) and follow the subsequent regeneration process to evaluate 
the influence of α-actinin-3 deficiency. Our collaborator, Stewart Head, has also shown that it is possible 
to induced branched fibre formation by simulating the repeated rounds of damage and regeneration in 
DMD by repeated notexin insults over a period of time (Unpublished Data). We will us this technique to 
more closely assess the role of α-actinin-3 in the formation of branched fibres. 
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6.5 ACTN3: Implications in DMD Moving Forward 
6.5.1 Patient Management and Therapeutic Development 
Much of the focus in DMD has traditionally centred on building muscle strength in patients; 
signalling pathways involving myostatin (Wagner et al., 2002) and IGF-1 (Patel et al., 2005)which induce 
hypertrophy have been targeted for therapeutic intervention. Our findings suggest that reduced force 
may actually be beneficial for DMD patients and that, instead of building muscle mass and strength we 
should focus on increasing the endurance capacity of skeletal muscle. Consistent with this, more recent 
clinical guidelines for patient management in DMD suggest that frequent, low intensity aerobic exercise 
is most beneficial to patients. 
Our study joins a growing list of data which suggest that inducing a shift towards a slow twitch 
muscle phenotype may be of genuine therapeutic development in DMD. Drugs that mimic the effects of 
exercise and cause a shift towards slow fibre properties and increase endurance capacity have displayed 
positive results in mdx mice (Hori et al., 2011, Jahnke et al., 2012, Miura et al., 2009) and represent 
promising therapeutic options in the management of DMD. Future gene therapy approaches are likely to 
restore expression of a truncated dystrophin protein leaving a BMD-like phenotype (Gregorevic et al., 
2004). While this is obviously a massive improvement on the terminal prognosis of DMD, it does suggest 
that symptomatic-based therapeutics like metabolic remodelling agents are likely to have value as 
adjunctive therapies as we move into the age of genetic-based cures for muscle disease. 
6.5.3 Wider Implications 
Mutation in a number of different structural components of muscle can give rise to various forms of 
muscular dystrophy. While these disorders all have different primary causes, there is remarkable 
consistency in the molecular mechanisms which contribute to the progression of muscle weakness 
across the different conditions (Wallace and McNally, 2009). In particular, impaired oxidative 
metabolism is a feature shared by many of the muscular dystrophies  (Chen et al., 2000, Turk et al., 
2006). Hence it is likely that the effect of ACTN3 as a genetic modifier may not be restricted to DMD, but 
may be more broadly applicable to muscular dystrophy in general. We chose DMD as a starting point for 
this project because it is the most common and best characterised of the muscular dystrophies, but 
given our results to date, extending this work into other forms of muscular dystrophy is now a priority 
for our research team.  
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